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Lantibiotics contain post-translational introduced (methyl)lanthionine 
residues, and are a group of peptides diverse in structure. Two distinct classes 
can be identified based on the structural organization of the enzymes introducing 
the characteristic thioether bonds, LanB and LanC in class I and the 
multifunctional enzyme LanM in class II. The antimicrobial activity of lantibiotics 
ranges from cell wall biosynthesis interference to membrane pore formation or a 
combination of these two activities. The main target is lipid II and lantibiotics 
appear in particular resilient to resistance mechanisms. In addition, the presence 
of the lanthionine bonds provide lanthipeptides with thermostability and 
proteolytic resistance. Lantibiotics form interesting candidates as novel 
antimicrobial substances. Here the mechanisms of lantibiotic biosynthesis, their 








Keynote abbreviations and terms 
RiPP: Ribosomally synthesized and post–translationally modified peptide 
Lanthipeptide: Lanthionine-containing RiPP 
Lantibiotic: Lanthionine-containing antibiotic peptide; lanthipeptide possessing 
antimicrobial activity (class I & II lanthipeptides) 
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1. Ribosomally synthesized and post-translationally modified peptides 
Ribosomally synthesized and post–translationally modified peptides (RiPPs) 
(1) are natural products produced throughout the three kingdoms of life. It 
concerns a vastly growing group of peptides. In the recent proposed 
nomenclature by Arnison et al. (1), it is suggested to refer to the biosynthetic 
pathway of RiPPs as Post-Ribosomal Peptide Synthesis (PRPS). 
RiPPs are genome encoded as precursor peptides. They consist of an N-
terminal leader and a C-terminal core peptide (figure 1). A typical example of 
such a precursor peptide structure is found in the group of lanthipeptides. There 
are some exceptions where a leader-like peptide is found at the C-terminus like 
in the case of bottromycins. The precursor peptide can also contain a signal 
sequence at the N-terminus of the leader peptide. This is usually seen with RiPPs 
produced by eukaryotic cells. The signal sequence then directs the peptides to 
different cell-compartments, like the endoplasmic reticulum, where modification 
and secretion takes place. The precursor peptide can also encode an additional 
recognition sequence at the C-terminus, such as motifs that direct peptide 
cyclization as found in cyanobactins and amatoxins (1). The N-terminal leader 
peptide serves as a recognition region for the post-translational modification 
enzymes, and for the export and immunity proteins (1, 2). Although the exact 
mechanism of leader recognition is not known, most leader peptides form an  




Figure 1: Schematic representation of the RiPP precursor peptide, which is post-translationally 
modified and after proteolysis and secretion yields the mature peptide. (Made after the proposed 
nomenclature described by Arnison et al. (1))  




An example of peptides belonging to the category of RiPPs are 
lanthipeptides, lanthionine-containing peptides. Known lanthipeptides display a 
diverse range of activities. They can be morphogenetic (6), antiviral (7), 
antiallodynic (8), or antimicrobial. When lanthipeptides possess antimicrobial 
activity they are called lantibiotics, lanthionine-containing antibiotic peptides (9). 
Lanthipeptides contain unusual meso-lanthionine (Lan) residues, but in addition 
may also contain 3-methyllanthionine (MeLan) residues. These 
(methyl)lanthionine bonds are believed to give lanthipeptides thermostability and 
proteolytic resistance, but they are also critical for their activity. A lanthionine is 
composed of two alanine residues that are cross-linked on their β-carbon via a 
thioether bond. The methyllanthionine structure contains an extra methyl group. 
The Lan and MeLan residues are introduced into the precursor peptide in two 
enzymatic steps. Serine and threonine, respectively, are dehydrated to form 
dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively. Hereafter the 
dehydrated residues are coupled to a cysteine via Michael-type addition, to form 
a thioether crosslink. Based on the modification enzymes that introduce the 
(methyl)lanthionine residues the lanthipeptides can be divided into four different 
classes (10) (figure 2). The well characterized class I and II lanthipeptides, that 
mainly comprise lantibiotics and therefore also known as class I and II 
lantibiotics. And the more recently discovered class III and IV lanthipeptides. 
 
2.1 Class I lanthipeptides 
In class I lanthipeptides/lantibiotics, the (methyl)lanthionine residues are formed 
by two distinct enzymes, a dehydratase (LanB) and a cyclase (LanC). Another 
characteristic of class I lanthipeptides is their elongated and flexible structure 
(figure 3). This secondary structure plays an important role in the antimicrobial 
effect of class I lantibiotics by binding to lipid II and in the pore formation (11, 
12). Peptides belonging to class I lanthipeptides include subtilin, epidermin, Pep5 
and the well-known lantibiotic nisin. Nisin is produced by Lactococcus lactis and 
was discovered in 1927 (13). It is one of the few commercial used lanthipeptides 
and shows activity against bacteria involved in food spoilage, like Bacillus cereus 
and Listeria monocytogenes. Since nisin has a food-grade status it is applied as a 
preservative (E234, Nisaplin®) in the food industry for example in dairy, bakery, 
vegetables, meat and fish products (14). 





Figure 2: Schematic representation of the four lanthipeptide classes based on the lanthionine 
introducing modification enzymes. The dark lines in LanC and LanC-like cyclase domains represent 
the conserved Zn-ligands. (made after the examples from Yu et al. and Zhang et al. (51, 129)) 
 
 
2.2 Class II lanthipeptides 
In class II lanthipeptides/lantibiotics there is a single multifunctional 
lanthionine synthetase (LanM) that carries out both the dehydration and 
cyclization reactions. LanM contains two domains, an N-terminal dehydration 
domain and a C-terminal cyclase domain. The N-terminal dehydration domain 
does not show any homology to LanB of the class I lantibiotics. However, the C-
terminal cyclase domain shows about 25% sequence identity with LanC (10), 
including the conserved zinc-binding residues (15). 
Unlike class I lantibiotics, class II peptides generally have a more globular 
structure. Another characteristic feature of class II lantibiotics is the presence of 
a bifunctional transporter encoded within the gene cluster. This transporter  
 




Figure 3: Representative examples of lanthipeptides belonging to four different classes. This 
includes the elongate structure of class I lanthipeptides and the labionin structures characteristic 
for class III lanthipeptides. The structure of venezuelin, class IV, is putative (21, 45). 
 
 
fulfills a dual role, i.e., transporting the peptide across the membrane and 
removal of the leader peptide from the lanthipeptide through the activity of an N-
terminal peptidase domain. Within the class II lantibiotics there is an additional 
group termed the two-component lantibiotics. These lantibiotics consist of two 
structural peptides that are both necessary for antimicrobial activity. Both are 
modified by individual LanM enzymes, but transported by a single LanT which in 
addition cleaves the leader peptides. An example of such a two–component 
lantibiotic is the well-described lacticin 3147 (16, 17). 
 
2.3 Class III lanthipeptides 
Class III lanthipeptides, e.g. SapB and Labyrinthopeptins, lack antimicrobial 
activity. Instead these peptides have morphogenetic and signaling functions. Like 
class II peptides, class III peptides are modified by a single multifunctional 
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modification enzyme termed LanKC. This enzyme contains three domains: an N-
terminal lyase domain, a central kinase domain and a C-terminal cyclase domain. 
The lyase domain and the kinase domain, carry out the dehydration of serine and 
threonine residues, while the cyclase domain forms the distinct 
(methyl)lanthionine rings. The cyclase domain of LanKC does not contain the 
characteristic zinc-binding motifs found in LanC and LanM. However, it does show 
homology to other cyclase domains (18). In addition to the lanthionine bond, a 
group of the class III enzymes also form the so-called labionin structures (figure 
3), known from labyrinthopeptins (8). The labionin (Lab) structure is formed by 
the addition of a second Dha to an enolate intermediate, formed by the addition 
of a Cys thiol to Dha (19, 20) (figure 6). Besides morphogenic and signaling 
functions, class III peptides may be used as therapeutic agents. The 
labyrinthopeptin A2 peptide is currently under development as an antiallodynic 
drug (8). 
 
2.4 Class IV lanthipeptides 
A fourth class, class IV lanthipeptides, has been assigned recently through the 
discovery of the lanthipeptide venezuelin produced by Streptomyces venezuelae 
(21). While the multifunctional lanthionine synthetase, LanL, resembles the class 
III enzyme, it differs at the C-terminal cyclase domain. The enzyme contains 
three distinct domains, an N-terminal lyase domain, a central kinase domain and 
a C-terminal cyclase domain. While the lyase domain and the kinase domain 
show homology towards the corresponding domains of the enzyme of class III 
peptides, the cyclase domain of LanL is homologous to LanC (21). It contains the 
characteristic zinc-binding motifs absent in the class III lanthionine synthetase. 
 
3. Lantibiotic gene clusters 
Lanthipeptides are encoded in gene clusters. These gene clusters can be 
found on plasmids, conjugative transposable elements or on the chromosome of 
the producing organism (22). The generic locus symbol that has been assigned 
to the genes in the lanthipeptides gene clusters is lan, but to distinguish between 
individual gene clusters of lanthipeptides more specific names are used such as 
for nisin or mersacidin, where nis or mrs is used, respectively. Examples of 
lantibiotic gene clusters are shown in figure 4. These gene clusters contain genes 




Figure 4: Lantibiotic gene clusters involved in the biosynthesis of nisin, subtilin, mersacidin, lacticin 
3147 and mutacin II. Promoters, where known, are indicated by small arrows. 
 
 
for lantibiotic biosynthesis, regulation, self-immunity, transport and processing. 
The gene encoding the precursor peptide is labeled lanA, for instance nisA, 
mutA or for the two-component lantibiotic lacticin 3147, ltnA1 and ltnA2. The 
precursor encoding genes are usually clustered in one operon with the 
modification enzymes designed genes: lanB for the lantibiotic dehydratase, lanC 
for the cyclase or lanM for the bifunctional lanthionine synthase of class II 
lantibiotics. In addition, lantibiotics can undergo further post translational 
modifications as for instance decarboxylation of the C-terminus by LanD, or the 
conversion of L-serine to D-alanine by LanJ. To transport the peptide across the 
cytoplasmic membrane a dedicated transporter is encoded in the gene clusters, 
termed LanT. In class II lantibiotics this transporter contains a peptidase domain, 
which will cleave off the leader peptide during or prior to transport. Since class I 
lantibiotic transporters do not contain this peptidase domain their gene cluster 
generally encodes an extracellular serine protease, LanP. However, not all 
lantibiotic gene clusters encode a dedicated protease, for instance the gene is 
missing in the gene cluster of subtilin. Studies on the maturation of subtilin 
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revealed it was matured by nonspecific extracellular serine proteases produced 
by subtilin producing and non-producing strains (70, 71). Proteins involved in 
lantibiotic biosynthesis, transport and processing will be described in more detail 
in section 4. 
 
3.1 Lantibiotic regulatory genes 
Regulatory genes, lanR and lanK, are also encoded in the lantibiotic gene 
clusters. LanK generally encodes a receptor-histidine kinase and lanR a 
transcriptional response regulator. The best described lantibiotic regulation 
systems are that of nisin and subtilin (23, 24). Their biosynthesis is 
autoregulated by a two-component regulatory mechanism, also described as 
quorum-sensing systems. For example in the biosynthesis of nisin, the presence 
of low concentrations active lantibiotic will be detected by the receptor-histidine 
kinase present at the cell surface. Binding of lantibiotic to NisK will trigger the 
autophosphorylation of a histidine residue, a signal cascade is initiated were the 
phosphoryl group is transferred to a aspartate residue on NisR. Next, NisR will 
bind the nisA and nisF operators, and transcription of nisABTCIP and nisFEG 
operons are initiated. The nisR promotor regulates the nisRK genes, however, its 
regulation is not known (25). The regulation seems to be related to the growth 
stage of the producing strain. Nisin production starts during the mid-exponential 
growth phase and peaks at the transition from log- to stationary-phase (23). 
Regulation of subtilin biosynthesis involves multiple environmental signals before 
production is initiated. As described for nisin, subtilin biosynthesis is dependent 
on the presence of SpaK and SpaR. The transcription of the spaRK genes is 
dependent on the alternative sigma factor, σH, which in turn is inhibited by the 
transition state regulator AbrB (24). From the autoregulatory systems of nisin 
and subtilin heterologous gene expression tools have been constructed, namely 
the well-known nisin-controlled gene expression (NICE) and subtilin-regulated 
gene expression (SURE) systems (26, 27). A typical two-component regulatory 
system is also present in the mersacidin gene cluster, mrsR2 and mrsK2. 
However, these genes only regulate transcription of the immunity genes, 
mrsFGE, when mersacidin is present extracellular. In addition, the gene cluster 
also encodes a second transcriptional response regulator, mrsR1, which is 
necessary for transcription of the mersacidin biosynthesis genes. A corresponding 
receptor-histidine kinase has not been found. MrsR1 does not seem to be 
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autoregulated and it is unknown what triggers the transcription of the mersacidin 
biosynthesis genes (28). These so-called orphan regulators are not uncommon in 
lantibiotic gene clusters. For example, EpiQ of the epidermin gene cluster (29), 
LtnR of the lacticin 3147 gene cluster (30), and MutR of the mutacin II gene 
cluster (31). Biosynthesis is also closely regulated by specific cellular events and 
culture conditions. For example, the sigma factor σH controlling SpaKR in subtilin 
production is only formed during stationary phase (24), or a drop in pH induces 
RcfB which in turn activates lacticin 481 production (32). 
 
3.2 Lantibiotic immunity genes 
Since lantibiotics are produced and act against closely related strains, self-
protection is needed. Therefore, the lantibiotic gene clusters encode self-
protection/immunity proteins. There are two mechanisms that can be employed 
for self-immunity. LanI encodes an immunity protein and lanFE(G) encode a ABC 
transporter. Both LanI and LanFE(G) can function on their own as immunity 
mechanisms or the proteins can co-operate to mediate immunity. The immunity 
ABC transporters consists of two or three subunits. LanF is the ATPase domain 
and LanE and LanG are integral membrane domains. Lantibiotics that have 
reached the cytoplasmic membrane, before or during pore formation, are 
excreted into the environment by such ABC transporters. Especially, the gene 
clusters of lipid II targeting lantibiotics contain genes encoding the immunity ABC 
transporter (33). 
LanI proteins show little similarity towards each other, suggesting diverse 
immunity mechanisms. LanI can bind the produced lantibiotic prohibiting it from 
binding to the target or it may shield the membrane target from the lantibiotic. 
NisI is a hydrophilic lipoprotein with an N-terminal lipid moiety that anchors the 
protein to the cell membrane and interacts with nisin. However, not all NisI 
contains this lipid membrane anchor and a fraction of the protein is secreted 
from the cell. Extracellular NisI will aggregate nisin (34) and thereby inactivate 
the lantibiotic. Although NisI and NisFEG provide two immunity mechanisms, 
complete immunity is only provided when all nisin immunity genes are 
expressed. The subtilin gene cluster also contains both immunity mechanisms. 
SpaFEG functions like NisFEG in lantibiotic excretion. However, SpaI seems to 
employ a different method compared to NisI. SpaI is mostly a hydrophilic protein 
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with an N-terminal lipid anchor. SpaI sequesters subtilin in the cytoplasmic 
membrane preventing co-localization and pore formation by the peptides (35). 
The gene cluster of Pep5 contains the immunity protein, PepI, but lacks an 
immunity ABC transporter. PepI is relatively small with a hydrophobic N-terminus 
and a hydrophilic C-terminus. PepI is located at the membrane-cell wall interface 
and thought to shield the targets, possibly teichoic or lipoteichoic acids, from 
Pep5 thereby preventing pore formation (36). Another example of a LanI peptide 
is that of lacticin 3147. LtnI contains three predicted hydrophobic regions of 
about 20 amino acids suggesting a transmembrane localization. In addition, it 
contains a leucine zipper motif at the C-terminus through which dimerization is 
possible (37). LtnI binds and aggregates lacticin 3147, in that way, it prevents 
membrane insertion and pore formation. In addition, it may also shield lipid II as 
target of lacticin 3147. 
A third gene, lanH, has been identified to play a role in the immunity 
systems. LanH is an accessory factor which is involved in the assembly of the 
immunity ABC transporter, e.g. EpiH of epidermin. A second example of a LanH 
is that of NukH, of the nukacin ISK-1 gene cluster. The structure of NukH 
resembles that of LtnI, with three membrane spanning domains (38), and it was 
proposed to bind nukacin ISK-1 and thereby inactivate the lantibiotic (39). 
Moreover, the nukacin ISK-1 gene cluster also contains the immunity ABC 
transporter. Expression studies proposed a cooperative action between NukH and 
NukFEG, which would be more in line with the accessory function in assembly 
(38). 
Summarizing, different immunity mechanisms have been proposed for 
LanI, LanFE(G) and LanH. The LanFE(G) proteins seem to be more conserved in 
structure and proposed mechanism of immunity throughout lantibiotics. For LanI, 
different mechanisms have been proposed that are specific for the lantibiotic 
produced. Interestingly, although also some cases of cross-immunity have been 
reported, e.g. NukHFEG against the closely related lacticin 481, most lantibiotic 
producers have their own specific immunity mechanisms. It should be 
emphasized that due to the presence of immunity mechanisms, there is a 
potential risk that immunity is acquired through horizontal gene transfer where 
bacteria that are currently sensitive to specific lantibiotics gain resistance. 
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4. Lantibiotic biosynthesis enzymes 
4.1 Structural peptides (LanA) 
The LanA precursor peptide consist of an N-terminal leader peptide and a 
C-terminal core peptide (figure 1). The N-terminal leader peptide is generally 
between 23 and 59 amino acids long, and although it can contain serine and 
threonine residues it does not contain cysteine residues. The precise mechanism 
by which the leader peptide acts is not yet fully understood (2). However, it 
plays a significant role in targeting the peptide to the biosynthesis and transport 
proteins. Importantly, the lantibiotic remains inactive until the leader peptide is 
removed and thus provides intrinsic protection to the producer cell. 
The leader peptides of the two main lantibiotic classes have their own 
characteristics. Class I leader peptides usually are about 25 amino acids long and 
rich in aspartate residues. Sequence alignment (2, 40) suggests a distinct motif, 
the FxLD motif, around positions -20 till -15. At position -2, there is usually a 
proline residue (figure 5). Class II leader peptides are rich in aspartate and 
glutamate residues and also contain a conserved motif, ELxxBx (B = V, L or I) at 
position -8 till -3 (2). This motif is usually followed by a double glycine motif, GG, 
GA, GS or GT, marking the proteolytic cleavage site that is recognized by the 
class II lantibiotic associated transporters (figure 5). Remarkably, the leader 
peptides of the two-component lantibiotics do not contain the ELxxBxx motif but 
do have the double glycine motif. In vitro studies on lacticin 481 suggest that the 
leader peptide plays a role in efficient modification of the core peptide, but it is 
not necessary for modification per se. When the core peptide of lacticin 481 was 
in vitro offered alone or in trans with the leader peptide, modification occurred 
although with a lesser efficiency (5, 41). Besides LctM, EpiD which is an oxidative 
decarboxylase providing a further modification of the lantibiotics, was able to 
modify substrates even in the absence of the leader peptide (42). These results 
seem to contradict a critical role of the leader peptide in recognition by the 
modification enzymes. Furthermore, leader peptides of class II bacteriocins that 
are not post-translationally modified also contain the characteristic double 
glycine motif in addition to an E(L/B)xxBx motif (2). Site-directed mutagenesis 
studies have shown that the double glycine motif is not essential for modification 
of the core peptide (5). However, the double glycine motif is important for 
proteolytic processing by the peptidase C39 domain of the bifunctional 
transporters (43, 44). On the other hand, some class II lantibiotics including 







ent of leader and core peptides of subclasses w
ithin class I and class II lantibiotics. C
lass I leader peptides contain the conserved FxLD
 
m




odified residues of the core peptides are highlighted by grey boxes and the residues involved in (m
ethyl)lanthionine bridges are 
connected by black lines. The black arrow
 underneath the lichenicidin A
2 peptide indicates the cleavage site behind the double glycine m
otif leaving the 
6 am
ino acids that require an extra proteolysis step to a m
ature peptide. 
Chapter 1: Introduction 
19 
 
mersacidin-like and cinamycin-like peptides, contain relatively long leader 
peptides that do not comprise the ELxxBxGG motif. Taken together it could very 
well be that non-conserved amino acids and/or the structure of the leader 
peptides play a role in the recognition by the specific modification enzymes. 
The C-terminal core peptide of the precursor peptide is post-translationally 
modified and after leader peptide removal the mature lantibiotic is released. Most 
lantibiotics are between 19-38 amino acids long. Class I lantibiotics are generally 
more elongated while class II peptides are more globular. Within these two 
classes, peptides can be further grouped based on their structure and similarity 
(45) (figure 5). For a complete list of lanthipeptides identified up to 2013 see the 
review by Dischinger et al. (45). Some distinct groups in class I lantibiotics are 
the nisin-, epidermin- and Pep5-like peptides. The nisin-like peptides include 
nisin A and its variants Q, U, Z, F as well as subtilin, entianin and others. These 
peptides have an overall elongated conformation with two amphipathic screw-
shaped domains, one N-terminal domain formed by rings A, B and C and a 
second C-terminal domain formed by rings D and E. The two domains are 
connected by a flexible hinge region. The epidermin-like peptides include in 
addition to epidermin its natural variant gallidermin and the closely related 
mutacin peptides. This group has a conserved lanthionine ring at position 3 till 7 
that is also found in the nisin-like group and that has been shown to play a role 
in activity (46, 47). Pep5-like peptides include Pep5, two variants of epilancin 
and epicidin 280. Pep5 contains eight positive charged residues rendering this 
peptide highly basic. 
Since class II lantibiotics represent the largest group at present, they 
possess diverse structures. One of these subgroups are the lacticin 481-like 
peptides, containing among others lacticin 481, variacin, nukacin ISK-1 and 
mutacin II (48). The members share high sequence homology and are equipped 
with a similar ring formation pattern. They are all hydrophobic and bear no net 
charge at pH 7. The N-terminus of the mature peptide is usually linear while the 
C-terminus is globular due to the three overlapping (Me)Lan bridges. Mersacidin-
like peptides are among the smaller lantibiotics with an average number of 20 
amino acids and a compact globular structure. The cinnamycin-like group is 
composed of cinnamycin, duramycin, duramycin B and C and ancovenin. All 
cinnamycin-like lantibiotics are 19 amino acids long and produced by 
Streptomyces spp. They share a similar amino acid sequence and (Me)Lan ring 
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structure. Also characteristic for this group is the presence of a conserved 
lysinoalanine ring and, except for ancovenin, a hydroxyaspartate. In the group of 
the two-component peptides reside among others lacticin 3147, staphylococcin 
C55, plantaricin W, haloduracin and cytolysin. Except for cytolysin, the α-
peptides (LanA1) resemble mersacidin while the β-peptides (LanA2) are long and 
screw-shaped (49). Structural data of lacticin 3147 (49) and haloduracin (50) in 
combination with bioinformatics studies suggest that the three rings of the α-
peptides are conserved. The same holds for the last two C-terminal (Me)Lan 
rings in the β-peptides. In addition, the N-terminal methyllanthionine ring in 
HalA2 is conserved but not present in LtnA2. 
 
4.2 (Methyl)lanthionine introducing modification enzymes 
In class I lanthipeptides (methyl)lanthionine formation is performed by 
LanB and LanC. LanB enzymes are about 120 kDa in size and do not show any 
homology to other characterized proteins in the databases (51). A study from 
Garg et al. (52) on NisB, the dehydratase of nisin, showed that NisB requires 
ATP, glutamate and an unknown macromolecule to dehydrate threonine and 
serine residues in the nisin precursor peptide. A recent follow-up study (53) 
suggested that a nucleic acid in the form of a glutamyl-tRNAGlu is present 
constituting the unknown macromolecule. During dehydration, the hydroxyl 
groups of serine and threonine are converted to glutamyl esters. The glutamyl 
esters are then removed and as a result the carbon-carbon double bonds are 
formed in the dehydroalanine or dehydrobutarine residue (52) (figure 6A). A co-
crystal structure of NisB and NisA (53) suggests that NisB forms a dimer with a 
bifurcated cleft-like structure in the center. In addition, crystallization and 
alanine substitution data show that the N-terminal region of NisB, about 700 
residues, is responsible for the glutamylation and that a 300 residue C-terminal 
part of NisB is responsible for the glutamate elimination step (52, 53). Since 
LanB enzymes do not show any homology towards other known proteins, but are 
homologous among each other suggest that these enzymes catalyze the 
dehydration in the same manner. However, it has not yet been determined if all 
LanB enzymes dehydrate serine and threonine residues via glutamylation. 
The cyclase enzymes (LanC) catalyze the thiol addition of a free cysteine 
to a dehydroalanine or dehydrobutyrine residues (figure 6B). Although LanC 
 




Figure 6: The dehydration (A) and cyclization (B) steps during the formation of (methyl)lanthionine 
and labionin residues. During dehydration the side chain hydroxyl group of Ser and Thr are 
activated to form dehydroamino acids (blue), dehydroalanine and dehydrobutyrine, respectively. 
Based on NisB studies it is believed class I enzymes dehydrated the amino acids via glutamylation 
(magenta) while the enzymes of class II-IV use phosphorylation (orange). In the cyclizations step 
in class I, II and IV the cysteine residue (red) is activated in a zinc dependent manner while for 
class III the cyclization step is zinc independent, via a currently unknown mechanism. Also class III 
enzymes can form labionin structures. These labionin structures are formed from one Cys (red) and 
two dehydroalanines (blue and green) connected via a carbon–carbon crosslink (8). 
Dha, dehydroalanines; Dhb, dehydrobutyrine; Abu, 2‐aminobutyric acid; Lab, labionin. 
Adapted by permission from John Wiley & Sons: Insights into the evolution of lanthipeptide 




enzymes do not show sequence homology to known characterized peptides, they 
do show structural similarities with the β subunit of mammalian farnesyl 
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transferases (54). The crystal structure of NisC reveals two layers of α-barrels 
folded in a toroid and a connecting extended domain. The center of the toroid 
contains the zinc ion and the conserved zinc-ligands, His331, Cys284 and 
Cys330. This active site of LanC enzymes, with a Zn2+ ion, activates the thiol in 
the cysteine. The residues His212, Arg280, Asp141 and Tyr285 are also 
conserved throughout the LanC proteins. These four residues are thought to play 
a role in deprotonation of the cysteine residue and the protonation of the 
enolate. However, mutagenesis studies on Arg280 and Tyr285 of NisC (15), and 
corresponding residues in SpaC (55), show that these residues are not essential 
for cyclization. In addition, residues His212 and Asp141 are critical for correct 
cyclization of nisin, the His212 residue is even conserved in the LanC-like cyclase 
domains of LanM proteins supporting the importance of the amino acid. A study 
by Li et al. (54) showed that NisC requires the leader peptide for the cyclization 
reaction, since a leader-less dehydrated prenisin is not converted to mature 
nisin. The study also showed that adenosine triphosphate (ATP) is not required 
for the cyclization reaction. Furthermore, dehydrated prenisin was converted into 
nisin by SpaC, the cyclase enzyme involved in the biosynthesis of subtilin. This 
suggest that dehydration and cyclization in class I lantibiotics occur 
independently. 
Class II lantibiotics contain one multifunctional modification enzyme, 
LanM, that performs both the dehydration and cyclization reaction. LanM 
enzymes are about 110-120 kDa in size and contain two domains. The N-
terminal dehydratase domain does not show any significant sequence identity 
with LanB (56), but only shows sequence homology to other LanM enzymes (51). 
It is believed that class II LanM enzymes first phosphorylate the serine or 
threonine residues, after which the phosphate is removed to generate a 
dehydroalanine or dehydrobutarine, respectively (57) (figure 6A). The C-terminal 
part of LanM shows homology to LanC enzymes including the conserved zinc-
ligands. Therefore it is believed that the cyclization in class II lantibiotics is 
catalyzed in the same zinc dependent manner as in class I cyclization (figure 
6B). 
 
4.3 Other post-translational modification enzymes 
Lantibiotics can undergo further post-translational modifications. Fifteen 
different post-translational modifications have been reported (58). It is believed 
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that these extra modifications increase the peptide stability and activity. One of 
these extra modifications is the formation of an S-aminovinyl-D-cysteine 
(AviCys) amino acid. The enzyme responsible for this oxidative decarboxylation 
at the C-terminus of the lantibiotic is generically termed LanD. The formation of 
such an AviCys residue protects the peptide from carboxypeptidases (59, 60). A 
extensively studied LanD protein is EpiD from Staphylococcus epidermidis. EpiD 
belongs to the homooligomeric flavin-containing Cys decarboxylase (HFCD) 
family (22). The consensus sequence of the C-terminal amino acids for the 
recognition by EpiD is [V/I/L/F/W/Y/(M)]-[A/S/V/T/C/(I/L)]-C (42). Another 
example is MrsD that forms the S-aminovinyl-3-methyl-D-cysteine (AviMeCys) 
amino acid in its substrate mersacidin. MrsD is a flavin adenine dinucleotide 
(FAD)-containing enzyme. The crystal structures of EpiD (61) and MrsD (62) 
revealed a conserved Rossman fold typically found in flavodoxin binding proteins. 
GdmD which belongs to the gallidermin biosynthetic gene cluster of 
Staphylococcus gallinarum was shown to modify also other lanthipeptides than 
gallidermin, namely a nisin variant when co-expressed in Lactococcus lactis (63). 
Spontaneously hydrolysis of N-terminally exposed dehydroalanine and 
dehydrobutyrine residues can occur. These residues become exposed after leader 
peptide removal and are subsequently hydrolyzed to 2-oxopropionyl (OPr) and 2-
oxobutyryl (OBu) groups (64). Moreover, LanJ can convert L-serine to D-alanine. 
Until now only two lanthipeptides contain D-alanine residues, lactocin S and both 
peptides of the two-component lantibiotic lacticin 3147, i.e., LtnA1 contains one 
and LtnA2 holds two D-alanine residues. The LtnJ enzyme involved in this 
process shows homology to zinc-dependent alcohol dehydrogenases and 
NAD(P)H-dependent quinone oxidoreductases of the zinc-containing alcohol 
dehydrogenase superfamily (65). The first step in generating a D-alanine is the 
dehydration of a serine to form a Dha residue by LtnM1 or LtnM2 (65). Next, the 
stereospecific hydrogenation of Dha occurs resulting in the formation of D-
alanine (66). 
 
4.4 Lantibiotic transport and processing 
Lantibiotics are excreted from the cell by dedicated ATP-binding cassette 
(ABC) transporters (figure 7). ABC transporters associated with class I 
lantibiotics, named NisT-type transporters, are about 550 to 600 residues in size. 
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These transporters contain 3 domains, an N-terminal hydrophobic domain, a six-
helix membrane spanning permease domain and a C-terminal ATP-binding 
domain. For both nisin and subtilin a multimeric complex between the 
transporter and the modification enzymes can be formed (67, 68). However, 
complex formation is not a requirement for transport as without NisC, 
dehydrated NisA could be secreted. In addition, NisT alone is able to export 
unmodified nisin or non-related peptides fused behind the nisin leader peptide 
(69). These findings show that NisT is equipped with a low substrate specificity. 
To obtain the mature and active lantibiotic, the N-terminal leader peptide 
needs to be removed. In class I lantibiotics a dedicated subtilisin-like serine 
protease, generally termed LanP, removes the leader peptide commonly at the 
extracellular face of the membrane. These LanP proteases can vary in size 
depending if they contain an N-terminal signal sequence and a C-terminal cell 
wall anchor sequence (22). Serine proteases contain conserved residues in their 
catalytic site. This concerns an aspartate, histidine and serine residues as well as 
a conserved asparagine residue at the oxyanion hole. Generally LanP is a 
extracellular protease and either membrane anchored, e.g. NisP, or soluble 
extracellular, like EpiP. However, PepP and ElkP are two examples of serine 
proteinases that lack a signal sequence and that have been suggested to localize 
in the cytoplasm.  
Transporters associated with class II lantibiotics belong to the family of ABC 
transporter maturation and secretion (AMS) proteins, also known as SunT-type 
transporters, named after the characterized member SunT (72). These 
transporters are about 700 amino acids long and contain an N-terminal peptidase 
domain belonging to the peptidase C39 family, a central transmembrane domain 
and a C-terminal ATP-binding domain (figure 7). LcnC is a bacteriocin transporter 
that belongs to the SunT-type transporters, and for which a cytosolic localization 
of the N-terminal protease domain was demonstrated (73). A similar result was 
obtained for NukT, the lantibiotic nukacin ISK-1 transporter (74). Six 
transmembrane helices in the central permease domain of the transporter were 
suggested, and typically in such ABC transporters, this domain homodimerizes 
with another copy of the ABC transporter. Some of these proteins consist of two 
individual subunits that heterodimerize. The ATP binding domain and the 
peptidase domain seem to function cooperatively, as mutations in either domain 
 




Figure 7: Schematic representation of lantibiotic transport and processing enzymes. With a 
separate ABC-transporter and serine protease for class I lantibiotics (A) and a multifunctional ABC 
transporter maturation and secretion (AMS) protein for class II lantibiotics (B). 
 
 
of the NukT transporter abolish the capability to transport and cleave the leader 
peptide (74). The crystal structure of ComA, an AMS protein (4) showed that the 
peptidase domain corresponds to the structure of papain-like cysteine proteases. 
These cysteine proteases contain conserved glutamine, cysteine, histidine and 
aspartate/asparagine residues that when mutated cause the loss of the peptidase 
activity (44, 75, 76). Many of these transporters are involved in the export of 
bacteriocins (non-lantibiotic and lantibiotic), and the corresponding substrates 
are processed at the so called double glycine site (GG/GA/GS/GT) at the C-
terminus of the leader peptide. The conserved cysteine and histidine residues are 
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part of the catalytic site, while the conserved glutamine is believed to be 
associated with an oxyanion hole (76). 
In addition to the double glycine motif, the α-helical structure of the leader 
peptide seems to be important for recognition by the peptidase C39 domain (44). 
In addition it was proposed that the peptidase domain contains a hydrophobic 
patch that interacts with the hydrophobic surface of the α-helix of the leader 
peptide (3). The peptides of cytolysin require a second proteolytic step by an 
extracellular serine protease, CylA. This protease removes a six amino acid long 
sequence from the N-terminus of, CylLL and CylLS, to yield the active cytolysin 
components (77). The β-peptides of plantaricin W, haloduracin and lichenicidin 
also seems to require an extra round of proteolysis. However, the responsible 
proteases have not yet been identified (50, 78, 79). 
 
5. Lantibiotic mode of action 
Many lantibiotics are antimicrobial agents, but their exact mode of action 
has been studied only for a few lantibiotics. It is believed that the antimicrobial 
activity is mainly based on the inhibition of cell wall biosynthesis, disruption of 
membrane integrity by forming transmembrane pores, or a combination of both 
(10). Lantibiotics act mostly against Gram-positive bacteria. Gram-negative 
bacteria are usually not affected since they have an outer membrane that forms 
a barrier to the entering lantibiotic. 
The mode of action of nisin has extensively been studied and two 
mechanisms appear to be operational, namely pore formation and the inhibition 
of cell wall biosynthesis. Nisin uses lipid II, an amphipathic peptidoglycan 
precursor of cell wall biosynthesis as a docking molecule. Clinically used 
antibiotics, like vancomycin, also target lipid II and bind the D-ala-D-alanyl 
group of lipid II. Lantibiotics bind a different site. For example, the N-terminal A 
and B rings of nisin form a cage that binds the pyrophosphate moiety of lipid II 
(11, 80). The A and B rings are conserved in nisin- and epidermin-like peptides 
(figure 5) and thus the same binding motif can be found in these lantibiotics (81, 
82). Binding of the lantibiotic to lipid II causes inhibition of the cell wall 
biosynthesis. A recent study (82) showed that nisin and mutacin 1140 disrupt 
the functional localization of the lipid II. Following lipid II binding, complexes of 
nisin and lipid II cluster together and the C-terminus of nisin inserts into the 
membrane to form pores. The pores are 2-2.5 nm in diameter and consist of 
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eight nisin and four lipid II molecules (83, 84). In addition, Nisin and subtilin also 
inhibit spore outgrowth. Pep5 also acts by pore formation, but little is known 
about the membrane interaction (85). 
Class II lacticin 481-like peptides are closely related in sequence and 
predicted structure. Moreover, they share a similar self-immunity mechanism 
that removes the peptide from the membrane. Streptococcin A-FF22 has been 
shown to form unstable membrane pores thereby disrupting the membrane 
potential and impairing ATP production (86). Therefore, it is believed that lacticin 
481-like peptides target the membrane by forming pores (48). Indeed, lacticin 
481 (87) and nukacin ISK-1 (88) interact with artificial lipid monolayers, while 
mutacin II (89) causes a depletion of the intracellular ATP pool. However, the 
exact mechanism of pore formation by these lantibiotics has not yet been 
determined. 
Lipid II is also the target for mersacidin, that inhibits peptidoglycan 
biosynthesis at the level of transglycosylation (90). Mersacidin does, however, 
not form pores in the membrane. The C-ring and the glutamic acid in this ring 
are essential for lipid II binding and the peptide changes its conformation upon 
binding (91, 92). The ring is conserved also in the lacticin 481-like peptides and 
the α-peptides of the two-component peptides, suggesting a similar mode of 
action for these lantibiotics. 
Two-component lantibiotics also use a dual mode of action. The individual 
peptides display no or only a weak antimicrobial activity, but strong activity is 
observed when both peptides are present. Except for cytolysin, the α-peptides of 
the two-component lantibiotics usually resemble the structure of mersacidin. 
Since the three C-terminal rings have the same topology as in mersacidin it is 
assumed that these peptides target lipid II. The β-peptides have a more 
elongated structure, and it has been suggested that they are involved in the pore 
forming activity. With the two-component lantibiotic lacticin 3147, both peptides 
work synergistically in a ratio of 1:1 (93, 94). LtnA1 forms a complex with lipid II 
thereby inhibiting cell wall biosynthesis, while LtnA2 then binds to this complex 
and forms a pore in the membrane (95). 
Other activities reported for lantibiotics include a cytolytic effect on 
erythrocytes and polymorphonuclear leukocytes by cytolysin (77). Among the 
group of cinnamycin-like peptides, some inhibit phospholipase A2 by 
sequestering the phosphatidylethanolamine (PE) substrate (96).  
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6. Engineering and applications of lantibiotics 
Lantibiotics are gene encoded and ribosomally synthesized and therefore 
they can be more readily engineered than non-ribosomal or polyketide antibiotics 
(97). Lantibiotic engineering has mainly been employed for structure-function 
studies and to identify essential amino acid residues. Nisin is one of the best 
studied lantibiotics because of a very efficient expression system. Expression 
systems have also been created for other lantibiotics like subtilin, Pep5, 
epidermin, gallidermin, mutacin II, lacticin 481, lacticin 3147 and mersacidin 
(17, 98-102). Most of these systems use homologous or closely related Gram-
positive bacteria as a host strain. However, lantibiotics are naturally expressed 
by and demonstrate activity towards Gram-positive bacteria, and thus there is an 
inherent risk that the engineered lanthipeptide is active against the production 
host. As an alternative, expression in the Gram-negative Escherichia coli has 
been attempted where the peptide is made intracellular in its inactive, leader 
peptide containing form. Examples of lanthipeptides that are heterologous 
expressed are nukacin ISK-1 (103), nisin, prochlorosins and haloduracin (104), 
cinnamycin (105) and lichenicidin (106). By genome-mining, lantibiotic and 
associating genes are readily identified, and vast numbers of such peptides 
appear to be produced by bacteria. However, expressing such lantibiotics by the 
natural host is complex as often they emerge from non-cultivatable bacteria. 
Therefore, the heterologous expression in E. coli may be employed to increase 
concentrations and produce such putative lantibiotics. 
Although lantibiotics contain their own specific export systems, the 
possibility to employ the general Sec or Tat export systems to export lantibiotics 
has been investigated. Kuipers et al. (107) showed that when the Tat or Sec 
signal sequence is fused to the nisin leader peptide in a strain lacking NisT, the 
dehydrated nisin was secreted. However, a fully modified nisin also containing 
(methyl)lanthionine-bridges could not be transported. 
Engineering can also be used to increase the activity of lantibiotics or 
make them more suitable for applications. For example, nisin variants with 
higher activity and enhanced solubility were created (108). In addition, 
mutagenesis of ring A of nisin resulted in two peptides with higher antimicrobial 
activity (109). For mersacidin, new variants have been patented (110, 111). In 
addition, introduction of a commercial protease recognition site replacing the 
native cleavage site (40, 104), has been shown to be advantageous for the 
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production of an inactive lantibiotic that post-production can be activated 
through the use of a specific protease. 
The lantibiotic biosynthesis enzymes can also be used to engineer peptides 
that normally do not contain such modifications. This might provide native 
peptides with an altered biological activity, different specificity or increased 
resistance to proteolysis. LtnM2T (112) of lacticin 3147 and NisBTC (113) of nisin 
have been shown to be able to introduce the characteristic modifications into 
non-lanthionine peptides that were fused behind the appropriate leader peptides. 
Also, Kluskens at al. (114) demonstrated that NisBTC successfully dehydrates 
and secretes non-lantibiotic peptides like vasopressin, angiotensin, and 
enkephalin. These findings represent a promising application of the lantibiotic 
modifying enzymes, and suggest that these enzymes are equipped with a low 
substrate specificity. This could be exploited for the bioengineering of a wide 
range of peptides. 
Lantibiotic regulation genes are widely used to control gene expression. 
Well-known examples are the nisin-controlled gene expression (NICE) and 
subtilin-regulated gene expression (SURE) systems (26, 27). These systems are 
broadly used to express non-lantibiotic related genes in L. lactis and B. subtilis. 
On the other hand they can also be used to express biosynthetic genes of 
lantibiotics for the heterologous production of lanthipeptides or analysis of 
lantibiotic biosynthetic enzymes. Examples are the production of nukacin ISK-1 
in L. lactis using the NICE system (115) and the study of enzyme complexes 
involved in the biosynthesis of lacticin 3147 and nisin (112). 
A further application is the use of lantibiotic synthetase enzymes in vitro. 
This has the advantage to introduce (methyl)lanthionine-rings in peptides in the 
absence of the cellular quality control mechanisms. In addition, it overcomes the 
potential secretion problem and adverse effects of the bioactivity of the 
lantibiotic towards the producing host strain. The first in vitro application was the 
lantibiotic synthetase of lacticin 481 (LctM) (116). Both LctM and lctA where 
separately and heterologously expressed in E. coli, purified and combined in 
vitro. The system was used to test the substrate specificity of LctM. Also, HalM 
(50), NisB (52) and NisC (54) have been used in vitro. 
An example of successful commercial application of a lantibiotic is nisin. It 
is already for over 50 years used as a food preservative without significant 
development of microbial resistance. Lantibiotics are also interesting peptides to 
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be used as antimicrobials because of the target (lipid II) and the low probability 
to generate resistance. Lantibiotics have shown a broad activity towards Gram-
positive pathogens, for example mersacidin exhibits activity against methicillin-
resistant Staphylococcus aureus in a murine model (117) and against 
vancomycin resistant enterococci (90). In addition, the presence of a 
(methyl)lanthionine residue is believed to increase the biostability and resistance 
against proteolytic degradation (118, 119) making them excellent candidates for 
the creation of novel antibiotic structures. A limitation, however, is that these 
lantibiotics are not active against Gram-negative bacteria limiting the use as 
narrow spectrum antibiotics. In addition, most lantibiotics are not stable at a 
neutral or basic pH, resulting in oxidation of the (methyl)lanthionine bridges and 
loss of activity (120, 121). This potentially interferes with a medical application 
of lanthipeptides. An example of a lanthipeptide used for medical applications is 
microbisporicin that is active against nosocomial infections (122). An analog of 
actagardine can be employed for the treatment of Clostridium difficile infections 
(123). Duramycin has potential for the treatment of cystic fibrosis since it 
increases the chloride secretion in lung epithelium (124, 125). Mutacin 1140 is in 
preclinical development as treatment against Gram-positive bacterial infections 
(126). Nisin and nisin variants show anti-tumor activity in head and neck cancer 
(130). Since cytolysin can also act as a virulence factor, lantibiotics could also 
play a role in other therapeutic applications. Because of issues with penetration 
and solubility, most current medical applications concern surface application that 
require formulations such as in skin creams. 
Lantibiotics not only have potential in human healthcare but may also be 
used in veterinary healthcare (127). Another application is in molecular imaging. 
Zhao et al. (128) described the possibility to use duramycin as a molecular 
imaging probe, since it exhibits a high affinity for phosphatidylethanolamine an 
abundant phospholipid in cell membranes of mammalian cells. 
 
7. concluding remarks 
Lanthipeptides constitute a large group of ribosomally synthesized and 
post–translationally modified peptides. Lately, research on these lanthipeptides 
has accelerated at a high speed. More and more lanthipeptide associated genes 
have been discovered through metagenome searches and new classes, e.g. class 
IV, and posttranslational enzymes have been identified. The group of lantibiotics 
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specify antimicrobial activity, they are structurally diverse and modified by 
separate dehydratase and cyclase enzymes (class I) or multifunctional enzymes 
(class II). Although many of the intimate details on lantibiotic biosynthesis have 
been elucidated, more insight is needed on the precise mechanisms of 
modification, substrate recognition, and the function of the actual leader 
peptides. Bioengineering of known and novel lanthipeptides using in vitro and in 
vivo techniques exploiting the promiscuity of the lantibiotic biosynthesis enzymes 
is an emerging field that will allow the development of novel agents that can be 
applied as therapeutics. 
 
8. Scope of thesis 
The research described in this thesis focuses on the development of an 
expression system for lanthipeptides that belong to class II. The envisioned 
production system contains a known lantibiotic modification enzyme and possibly 
the associated transporter. The first half of the thesis embarks on the 
development of a class II lanthipeptide production system in Lactococcus lactis 
employing the modification enzymes LtnM1 or LtnM2 and the transporter LtnT of 
lacticin 3147. While the second half will investigate Escherichia coli as a 
heterologous host for such a production system. 
Chapter 1 provides an overview of our current understanding of the 
biosynthesis of the diverse classes of lanthipeptides, their activities and mode of 
action as well as their potential for applications. 
Chapter 2 investigates the function of LtnT. The catalytic cysteine of the N-
terminal peptidase C39 domain was mutated and the domain was deleted, after 
which the ability of these variants to transport the associated substrates was 
evaluated. The data suggest that LtnT requires an active peptidase C39 domain 
for transport. 
Chapter 3 examines whether the modification enzymes, LtnM1 and LtnM2, 
in combination with LtnT modify, process and secrete their cognate substrates 
LtnA1 and LtnA2, respectively. Modified and processed peptides were detected 
and an active lacticin 3147 could be produced. 
Chapter 4 further evaluates the substrate specificity of the LtnM1T and 
LtnM2T systems. Variants of LtnA1 and LtnA2 were created including a swap of 
the respective leader peptides, an all cysteine to alanine mutation to prevent 
thioether bridge formation and the introduction of a factor Xa protease site in the 
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leader peptide cleavage region of LtnA1. This work revealed a high specificity of 
the LtnM1 and LtnM2 enzymes towards their cognate substrates, which limits a 
more general application of these enzymes. 
Chapter 5 describes the construction of a production system in E. coli 
using the modification enzymes of lacticin 3147 (LtnM2) and mutacin II (MutM). 
Both enzymes were found to be active in E. coli producing fully dehydrated MutA 
and LtnA2, respectively. Also, the modification enzymes were found to be 
capable of dehydrating a diverse range of peptides. 
In chapter 6, a putative lanthionine synthetase and its associated 
structural peptide from Streptococcus pneumoniae Spain 23F-1 were expressed 
in E. coli. LanM-SPN23F was shown to be active, producing a 7 till 8 times 
dehydrated novel lanthipeptide. In addition, GdmD (LanD) was co-expressed and 





1. PG Arnison, MJ Bibb, G Bierbaum, AA Bowers, TS Bugni, G Bulaj, JA Camarero, DJ 
Campopiano, GL Challis, J Clardy, PD Cotter, DJ Craik, M Dawson, E Dittmann, S 
Donadio, PC Dorrestein, K Entian, MA Fischbach, JS Garavelli, U Goransson, CW 
Gruber, DH Haft, TK Hemscheidt, C Hertweck, C Hill, AR Horswill, M Jaspars, WL 
Kelly, JP Klinman, OP Kuipers, AJ Link, W Liu, MA Marahiel, DA Mitchell, GN Moll, BS 
Moore, R Muller, SK Nair, IF Nes, GE Norris, BM Olivera, H Onaka, ML Patchett, J Piel, 
MJT Reaney, S Rebuffat, RP Ross, H Sahl, EW Schmidt, ME Selsted, K Severinov, B 
Shen, K Sivonen, L Smith, T Stein, RD Sussmuth, JR Tagg, G Tang, AW Truman, JC 
Vederas, CT Walsh, JD Walton, SC Wenzel, JM Willey, WA van der Donk. 2013. 
Ribosomally synthesized and post-translationally modified peptide natural products: overview 
and recommendations for a universal nomenclature. Nat. Prod. Rep. 30:108-160. 
2. TJ Oman, WA van der Donk. 2010. Follow the leader: the use of leader peptides to guide 
natural product biosynthesis. Nature Chemical Biology. 6:9-18. 
3. Y Kotake, S Ishii, T Yano, Y Katsuoka, H Hayashi. 2008. Substrate recognition 
mechanism of the peptidase domain of the quorum-sensing-signal-producing ABC transporter 
ComA from Streptococcus. Biochemistry (N. Y. ). 47:2531-2538. 
4. S Ishii, T Yano, A Ebihara, A Okamoto, M Manzoku, H Hayashi. 2010. Crystal structure 
of the peptidase domain of Streptococcus ComA, a bifunctional ATP-binding cassette 
transporter involved in the quorum-sensing pathway. J. Biol. Chem. 285:10777-10785. 
5. GC Patton, M Paul, LE Cooper, C Chatterjee, WA van der Donk. 2008. The Importance of 
the Leader Sequence for Directing Lanthionine Formation in Lacticin 481†. Biochemistry (N. 
Y.). 47:7342-7351. 
6. JM Willey, AA Gaskell. 2010. Morphogenetic signaling molecules of the streptomycetes. 
Chem. Rev. 111:174-187. 
Chapter 1: Introduction 
33 
 
7. G Férir, MI Petrova, G Andrei, D Huskens, B Hoorelbeke, R Snoeck, J Vanderleyden, J 
Balzarini, S Bartoschek, M Brönstrup. 2013. The lantibiotic peptide labyrinthopeptin A1 
demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications. 
PloS One. 8:e64010. 
8. K Meindl, T Schmiederer, K Schneider, A Reicke, D Butz, S Keller, H Gühring, L 
Vértesy, J Wink, H Hoffmann. 2010. Labyrinthopeptins: a new class of carbacyclic 
lantibiotics. Angewandte Chemie International Edition. 49:1151-1154. 
9. N Schnell, K Entian, U Schneider, F Götz, H Zähner, R Kellner, G Jung. 1988. Prepeptide 
sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. Nature. 
333:276-278. 
10. PJ Knerr, WA van der Donk. 2012. Discovery, biosynthesis, and engineering of 
lantipeptides. Annu. Rev. Biochem. 81:479-505. 
11. E Breukink, I Wiedemann, C van Kraaij, OP Kuipers, HG Sahl, B de Kruijff. 1999. Use 
of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science. 286:2361-
2364. 
12. H Brötz, M Josten, I Wiedemann, U Schneider, F Götz, G Bierbaum, H Sahl. 1998. Role 
of lipid‐bound peptidoglycan precursors in the formation of pores by nisin, epidermin and 
other lantibiotics. Mol. Microbiol. 30:317-327. 
13. LA Rogers. 1928. The Inhibiting Effect of Streptococcus Lactis on Lactobacillus Bulgaricus. J. 
Bacteriol. 16:321-325. 
14. J Delves-Broughton, P Blackburn, R Evans, J Hugenholtz. 1996. Applications of the 
bacteriocin, nisin. Antonie Van Leeuwenhoek. 69:193-202. 
15. B Li, WA van der Donk. 2007. Identification of essential catalytic residues of the cyclase 
NisC involved in the biosynthesis of nisin. J. Biol. Chem. 282:21169-21175. 
16. O McAuliffe, C Hill, RP Ross. 2000. Each peptide of the two-component lantibiotic lacticin 
3147 requires a separate modification enzyme for activity. Microbiology. 146:2147-2154. 
17. PD Cotter, LH Deegan, EM Lawton, LA Draper, PM O'Connor, C Hill, RP Ross. 2006. 
Complete alanine scanning of the two‐component lantibiotic lacticin 3147: generating a 
blueprint for rational drug design. Mol. Microbiol. 62:735-747. 
18. S Kodani, ME Hudson, MC Durrant, MJ Buttner, JR Nodwell, JM Willey. 2004. The SapB 
morphogen is a lantibiotic-like peptide derived from the product of the developmental gene 
ramS in Streptomyces coelicolor. Proc. Natl. Acad. Sci. U. S. A. 101:11448-11453. 
19. WM Müller, T Schmiederer, P Ensle, RD Süssmuth. 2010. In Vitro Biosynthesis of the 
Prepeptide of Type‐III Lantibiotic Labyrinthopeptin A2 Including Formation of a C C Bond as 
a Post‐Translational Modification. Angewandte Chemie International Edition. 49:2436-2440. 
20. H Wang, WA van der Donk. 2012. Biosynthesis of the class III lantipeptide catenulipeptin. 
ACS Chemical Biology. 7:1529-1535. 
21. Y Goto, B Li, J Claesen, Y Shi, MJ Bibb, WA van der Donk. 2010. Discovery of unique 
lanthionine synthetases reveals new mechanistic and evolutionary insights. PLoS Biology. 
8:e1000339. 
22. C Chatterjee, M Paul, L Xie, WA van der Donk. 2005. Biosynthesis and Mode of Action of 
Lantibiotics. Chem. Rev. 105:633-684. 
Chapter 1: Introduction 
34 
 
23. OP Kuipers, MM Beerthuyzen, PG de Ruyter, EJ Luesink, WM de Vos. 1995. 
Autoregulation of nisin biosynthesis in Lactococcus lactis by signal transduction. J. Biol. Chem. 
270:27299-27304. 
24. T Stein, S Borchert, P Kiesau, S Heinzmann, S Klöss, C Klein, M Helfrich, K Entian. 
2002. Dual control of subtilin biosynthesis and immunity in Bacillus subtilis. Mol. Microbiol. 
44:403-416. 
25. PG de Ruyter, OP Kuipers, MM Beerthuyzen, I van Alen-Boerrigter, WM de Vos. 1996. 
Functional analysis of promoters in the nisin gene cluster of Lactococcus lactis. J. Bacteriol. 
178:3434-3439. 
26. OP Kuipers, G Bierbaum, B Ottenwälder, HM Dodd, N Horn, J Metzger, T Kupke, V 
Gnau, R Bongers, P van den Bogaard. 1996. Protein engineering of lantibiotics. Antonie 
Van Leeuwenhoek. 69:161-170. 
27. RS Bongers, JW Veening, M Van Wieringen, OP Kuipers, M Kleerebezem. 2005. 
Development and characterization of a subtilin-regulated expression system in Bacillus 
subtilis: strict control of gene expression by addition of subtilin. Appl. Environ. Microbiol. 
71:8818-8824. 
28. A Guder, T Schmitter, I Wiedemann, HG Sahl, G Bierbaum. 2002. Role of the single 
regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of mersacidin 
production and immunity. Appl. Environ. Microbiol. 68:106-113. 
29. A Peschel, J Augustin, T Kupke, S Stevanovic, F Götz. 1993. Regulation of epidermin 
biosynthetic genes by EpiQ. Mol. Microbiol. 9:31-39. 
30. O McAuliffe, T O'Keeffe, C Hill, RP Ross. 2001. Regulation of immunity to the two‐
component lantibiotic, lacticin 3147, by the transcriptional repressor LtnR. Mol. Microbiol. 
39:982-993. 
31. P Chen, F Qi, J Novak, PW Caufield. 1999. The specific genes for lantibiotic mutacin II 
biosynthesis in Streptococcus mutans T8 are clustered and can be transferred en bloc. Appl. 
Environ. Microbiol. 65:1356-1360. 
32. SM Madsen, T Hindré, J Le Pennec, H Israelsen, A Dufour. 2005. Two acid‐inducible 
promoters from Lactococcus lactis require the cis‐acting ACiD‐box and the transcription 
regulator RcfB. Mol. Microbiol. 56:735-746. 
33. LA Draper, RP Ross, C Hill, PD Cotter. 2008. Lantibiotic immunity. Curr. Protein Pept. Sci. 
9:39-49. 
34. O Koponen, TM Takala, U Saarela, M Qiao, PE Saris. 2004. Distribution of the NisI 
immunity protein and enhancement of nisin activity by the lipid-free NisI. FEMS Microbiol. 
Lett. 231:85-90. 
35. T Stein, S Heinzmann, S Dusterhus, S Borchert, KD Entian. 2005. Expression and 
functional analysis of the subtilin immunity genes spaIFEG in the subtilin-sensitive host 
Bacillus subtilis MO1099. J. Bacteriol. 187:822-828. 
36. A Hoffmann, T Schneider, U Pag, HG Sahl. 2004. Localization and functional analysis of 
PepI, the immunity peptide of Pep5-producing Staphylococcus epidermidis strain 5. Appl. 
Environ. Microbiol. 70:3263-3271. 
37. O McAuliffe, C Hill, RP Ross. 2000. Identification and overexpression of ltnl, a novel gene 
which confers immunity to the two-component lantibiotic lacticin 3147. Microbiology. 146 (Pt 
1):129-138. 
Chapter 1: Introduction 
35 
 
38. Y Aso, K Okuda, J Nagao, Y Kanemasa, N Thi Bich Phuong, H Koga, K Shioya, T 
Sashihara, J Nakayama, K Sonomoto. 2005. A novel type of immunity protein, NukH, for 
the lantibiotic nukacin ISK-1 produced by Staphylococcus warneri ISK-1. Biosci. Biotechnol. 
Biochem. 69:1403-1410. 
39. K Okuda, Y Aso, J Nagao, K Shioya, Y Kanemasa, J Nakayama, K Sonomoto. 2005. 
Characterization of functional domains of lantibiotic-binding immunity protein, NukH, from 
Staphylococcus warneri ISK-1. FEMS Microbiol. Lett. 250:19-25. 
40. A Plat, LD Kluskens, A Kuipers, R Rink, GN Moll. 2011. Requirements of the engineered 
leader peptide of nisin for inducing modification, export, and cleavage. Appl. Environ. 
Microbiol. 77:604-611. 
41. MR Levengood, GC Patton, WA van der Donk. 2007. The leader peptide is not required for 
post-translational modification by lacticin 481 synthetase. J. Am. Chem. Soc. 129:10314-
10315. 
42. T Kupke, C Kempter, G Jung, F Gotz. 1995. Oxidative decarboxylation of peptides 
catalyzed by flavoprotein EpiD. Determination of substrate specificity using peptide libraries 
and neutral loss mass spectrometry. J. Biol. Chem. 270:11282-11289. 
43. P Chen, F Qi, J Novak, RE Krull, PW Caufield. 2001. Effect of amino acid substitutions in 
conserved residues in the leader peptide on biosynthesis of the lantibiotic mutacin II. FEMS 
Microbiol. Lett. 195:139-144. 
44. LA Furgerson Ihnken, C Chatterjee, WA van der Donk. 2008. In Vitro Reconstitution and 
Substrate Specificity of a Lantibiotic Protease†. Biochemistry (N. Y.). 47:7352-7363. 
45. J Dischinger, S Basi Chipalu, G Bierbaum. 2014. Lantibiotics: Promising candidates for 
future applications in health care. International Journal of Medical Microbiology. 304:51-62. 
46. WC Chan, HM Dodd, N Horn, K Maclean, LY Lian, BW Bycroft, MJ Gasson, GC Roberts. 
1996. Structure-activity relationships in the peptide antibiotic nisin: role of dehydroalanine 5. 
Appl. Environ. Microbiol. 62:2966-2969. 
47. W Liu, JN Hansen. 1993. The antimicrobial effect of a structural variant of subtilin against 
outgrowing Bacillus cereus T spores and vegetative cells occurs by different mechanisms. 
Appl. Environ. Microbiol. 59:648-651. 
48. A Dufour, T Hindré, D Haras, J Le Pennec. 2007. The biology of lantibiotics from the 
lacticin 481 group is coming of age. FEMS Microbiol. Rev. 31:134-167. 
49. NI Martin, T Sprules, MR Carpenter, PD Cotter, C Hill, RP Ross, JC Vederas. 2004. 
Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. 
Biochemistry (N. Y. ). 43:3049-3056. 
50. AL McClerren, LE Cooper, C Quan, PM Thomas, NL Kelleher, WA van der Donk. 2006. 
Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. Proc. Natl. 
Acad. Sci. U. S. A. 103:17243-17248. 
51. Y Yu, Q Zhang, WA van der Donk. 2013. Insights into the evolution of lanthipeptide 
biosynthesis. Protein Science. 22:1478-1489. 
52. N Garg, LM Salazar-Ocampo, WA van der Donk. 2013. In vitro activity of the nisin 
dehydratase NisB. Proc. Natl. Acad. Sci. U. S. A. 110:7258-7263. 
53. MA Ortega, Y Hao, Q Zhang, MC Walker, WA van der Donk, SK Nair. 2014. Structure 
and mechanism of the tRNA-dependent lantibiotic dehydratase NisB. Nature. 
Chapter 1: Introduction 
36 
 
54. B Li, JP Yu, JS Brunzelle, GN Moll, WA van der Donk, SK Nair. 2006. Structure and 
mechanism of the lantibiotic cyclase involved in nisin biosynthesis. Science. 311:1464-1467. 
55. M Helfrich, K Entian, T Stein. 2007. Structure-function relationships of the lanthionine 
cyclase SpaC involved in biosynthesis of the Bacillus subtilis peptide antibiotic subtilin. 
Biochemistry (N. Y.). 46:3224-3233. 
56. RJ Siezen, OP Kuipers, WM de Vos. 1996. Comparison of lantibiotic gene clusters and 
encoded proteins. Antonie Van Leeuwenhoek. 69:171-184. 
57. C Chatterjee, LM Miller, YL Leung, L Xie, M Yi, NL Kelleher, WA van der Donk. 2005. 
Lacticin 481 synthetase phosphorylates its substrate during lantibiotic production. J. Am. 
Chem. Soc. 127:15332-15333. 
58. JM Willey, WA van der Donk. 2007. Lantibiotics: Peptides of Diverse Structure and 
Function. Annu. Rev. Microbiol. 61:477-501. 
59. CS Sit, S Yoganathan, JC Vederas. 2011. Biosynthesis of aminovinyl-cysteine-containing 
peptides and its application in the production of potential drug candidates. Acc. Chem. Res. 
44:261-268. 
60. T Kupke, F Götz. 1997. In vivo reaction of affinity‐tag‐labelled epidermin precursor peptide 
with flavoenzyme EpiD. FEMS Microbiol. Lett. 153:25-32. 
61. M Blaesse, T Kupke, R Huber, S Steinbacher. 2000. Crystal structure of the peptidyl‐
cysteine decarboxylase EpiD complexed with a pentapeptide substrate. EMBO J. 19:6299-
6310. 
62. M Blaesse, T Kupke, R Huber, S Steinbacher. 2003. Structure of MrsD, an FAD-binding 
protein of the HFCD family. Acta Crystallographica Section D: Biological Crystallography. 
59:1414-1421. 
63. AJ van Heel, D Mu, M Montalbán-López, D Hendriks, OP Kuipers. 2013. Designing and 
producing modified, new-to-nature, peptides with antimicrobial activity by use of a 
combination of various lantibiotic modification enzymes. ACS Synth. Biol. 2:397-404. 
64. R Kellner, G Jung, M Josten, C Kaletta, K Entian, H Sahl. 1989. Pep5: structure 
elucidation of a large lantibiotic. Angewandte Chemie International Edition in English. 28:616-
619. 
65. PD Cotter, PM O'Connor, LA Draper, EM Lawton, LH Deegan, C Hill, RP Ross. 2005. 
Posttranslational conversion of L-serines to D-alanines is vital for optimal production and 
activity of the lantibiotic lacticin 3147. Proc. Natl. Acad. Sci. U. S. A. 102:18584-18589. 
66. S Suda, EM Lawton, D Wistuba, PD Cotter, C Hill, RP Ross. 2012. Homologues and 
bioengineered derivatives of LtnJ vary in ability to form D-alanine in the lantibiotic lacticin 
3147. J. Bacteriol. 194:708-714. 
67. K Siegers, S Heinzmann, K Entian. 1996. Biosynthesis of Lantibiotic Nisin 
POSTTRANSLATIONAL MODIFICATION OF ITS PREPEPTIDE OCCURS AT A MULTIMERIC 
MEMBRANE-ASSOCIATED LANTHIONINE SYNTHETASE COMPLEX. J. Biol. Chem. 271:12294-
12301. 
68. P Kiesau, U Eikmanns, Z Gutowski-Eckel, S Weber, M Hammelmann, KD Entian. 1997. 
Evidence for a multimeric subtilin synthetase complex. J. Bacteriol. 179:1475-1481. 
69. A Kuipers, E de Boef, R Rink, S Fekken, LD Kluskens, AJ Driessen, K Leenhouts, OP 
Kuipers, GN Moll. 2004. NisT, the transporter of the lantibiotic nisin, can transport fully 
Chapter 1: Introduction 
37 
 
modified, dehydrated, and unmodified prenisin and fusions of the leader peptide with non-
lantibiotic peptides. J. Biol. Chem. 279:22176-22182. 
70. C Corvey, T Stein, S Düsterhus, M Karas, K Entian. 2003. Activation of subtilin precursors 
by Bacillus subtilis extracellular serine proteases subtilisin (AprE), WprA, and Vpr. Biochem. 
Biophys. Res. Commun. 304:48-54. 
71. T Stein, K Entian. 2002. Maturation of the lantibiotic subtilin: matrix‐assisted laser 
desorption/ionization time‐of‐flight mass spectrometry to monitor precursors and their 
proteolytic processing in crude bacterial cultures. Rapid Communications in Mass 
Spectrometry. 16:103-110. 
72. S Gebhard. 2012. ABC transporters of antimicrobial peptides in Firmicutes bacteria–
phylogeny, function and regulation. Mol. Microbiol. 86:1295-1317. 
73. CM Franke, J Tiemersma, G Venema, J Kok. 1999. Membrane topology of the lactococcal 
bacteriocin ATP-binding cassette transporter protein LcnC. Involvement of LcnC in lactococcin 
a maturation. J. Biol. Chem. 274:8484-8490. 
74. M Nishie, M Sasaki, J Nagao, T Zendo, J Nakayama, K Sonomoto. 2011. Lantibiotic 
transporter requires cooperative functioning of the peptidase domain and the ATP binding 
domain. J. Biol. Chem. 286:11163-11169. 
75. KH Wu, PC Tai. 2004. Cys32 and His105 are the critical residues for the calcium-dependent 
cysteine proteolytic activity of CvaB, an ATP-binding cassette transporter. J. Biol. Chem. 
279:901-909. 
76. S Ishii, T Yano, H Hayashi. 2006. Expression and characterization of the peptidase domain 
of Streptococcus pneumoniae ComA, a bifunctional ATP-binding cassette transporter involved 
in quorum sensing pathway. J. Biol. Chem. 281:4726-4731. 
77. CR Cox, PS Coburn, MS Gilmore. 2005. Enterococcal cytolysin: a novel two component 
peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells. 
Current Protein and Peptide Science. 6:77-84. 
78. H Holo, Z Jeknic, M Daeschel, S Stevanovic, IF Nes. 2001. Plantaricin W from 
Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiology. 
147:643-651. 
79. ZO Shenkarev, EI Finkina, EK Nurmukhamedova, SV Balandin, KS Mineev, KD 
Nadezhdin, ZA Yakimenko, AA Tagaev, YV Temirov, AS Arseniev. 2010. Isolation, 
structure elucidation, and synergistic antibacterial activity of a novel two-component 
lantibiotic lichenicidin from Bacillus licheniformis VK21. Biochemistry (N. Y.). 49:6462-6472. 
80. SD Hsu, E Breukink, E Tischenko, MA Lutters, B de Kruijff, R Kaptein, AM Bonvin, NA 
van Nuland. 2004. The nisin–lipid II complex reveals a pyrophosphate cage that provides a 
blueprint for novel antibiotics. Nature Structural & Molecular Biology. 11:963-967. 
81. RR Bonelli, T Schneider, HG Sahl, I Wiedemann. 2006. Insights into in vivo activities of 
lantibiotics from gallidermin and epidermin mode-of-action studies. Antimicrob. Agents 
Chemother. 50:1449-1457. 
82. HE Hasper, NE Kramer, JL Smith, JD Hillman, C Zachariah, OP Kuipers, B de Kruijff, E 
Breukink. 2006. An alternative bactericidal mechanism of action for lantibiotic peptides that 
target lipid II. Science. 313:1636-1637. 
83. I Wiedemann, R Benz, HG Sahl. 2004. Lipid II-mediated pore formation by the peptide 
antibiotic nisin: a black lipid membrane study. J. Bacteriol. 186:3259-3261. 
Chapter 1: Introduction 
38 
 
84. HE Hasper, B de Kruijff, E Breukink. 2004. Assembly and stability of nisin-lipid II pores. 
Biochemistry (N. Y.). 43:11567-11575. 
85. M Kordel, R Benz, HG Sahl. 1988. Mode of action of the staphylococcinlike peptide Pep 5: 
voltage-dependent depolarization of bacterial and artificial membranes. J. Bacteriol. 170:84-
88. 
86. R Jack, R Benz, J Tagg, H Sahl. 1994. The mode of action of SA‐FF22, a lantibiotic isolated 
from Streptococcus pyogenes strain FF22. European Journal of Biochemistry. 219:699-705. 
87. RA Demel, T Peelen, RJ Siezen, B Kruijff, OP Kuipers. 1996. Nisin Z, mutant nisin Z and 
lacticin 481 interactions with anionic lipids correlate with antimicrobial activity. European 
Journal of Biochemistry. 235:267-274. 
88. SM Asaduzzaman, J Nagao, Y Aso, J Nakayama, K Sonomoto. 2006. Lysine-oriented 
charges trigger the membrane binding and activity of nukacin ISK-1. Appl. Environ. Microbiol. 
72:6012-6017. 
89. ML Chikindas, J Novak, AJ Driessen, WN Konings, KM Schilling, PW Caufield. 1995. 
Mutacin II, a bactericidal antibiotic from Streptococcus mutans. Antimicrob. Agents 
Chemother. 39:2656-2660. 
90. H Brötz, G Bierbaum, PE Reynolds, H Sahl. 1997. The lantibiotic mersacidin inhibits 
peptidoglycan biosynthesis at the level of transglycosylation. European Journal of 
Biochemistry. 246:193-199. 
91. SD Hsu, E Breukink, R Kaptein. 2006. Structural motifs of lipid II-binding lantibiotics as a 
blueprint for novel antibiotics. Anti-Infective Agents in Medicinal Chemistry (Formerly Current 
Medicinal Chemistry-Anti-Infective Agents). 5:245-254. 
92. ST Hsu, E Breukink, G Bierbaum, HG Sahl, B de Kruijff, R Kaptein, NA van Nuland, AM 
Bonvin. 2003. NMR study of mersacidin and lipid II interaction in dodecylphosphocholine 
micelles. Conformational changes are a key to antimicrobial activity. J. Biol. Chem. 
278:13110-13117. 
93. SM Morgan, PM O'connor, PD Cotter, RP Ross, C Hill. 2005. Sequential actions of the two 
component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at 
nanomolar concentrations. Antimicrob. Agents Chemother. 49:2606-2611. 
94. S Suda, PD Cotter, C Hill, RP Ross. 2012. Lacticin 3147-biosynthesis, molecular analysis, 
immunity, bioengineering and applications. Current Protein and Peptide Science. 13:193-204. 
95. I Wiedemann, T Böttiger, RR Bonelli, A Wiese, SO Hagge, T Gutsmann, U Seydel, L 
Deegan, C Hill, RP Ross. 2006. The mode of action of the lantibiotic lacticin 3147–a complex 
mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. 
Mol. Microbiol. 61:285-296. 
96. F Märki, E Hänni, A Fredenhagen, J van Oostrum. 1991. Mode of action of the 
lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as 
indirect inhibitors of phospholipase A 2. Biochem. Pharmacol. 42:2027-2035. 
97. D Field, C Hill, PD Cotter, RP Ross. 2010. The dawning of a ‘Golden era’ in lantibiotic 
bioengineering. Mol. Microbiol. 78:1077-1087. 
98. C Szekat, RW Jack, D Skutlarek, H Farber, G Bierbaum. 2003. Construction of an 
expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl. Environ. 
Microbiol. 69:3777-3783. 
Chapter 1: Introduction 
39 
 
99. B Ottenwalder, T Kupke, S Brecht, V Gnau, J Metzger, G Jung, F Gotz. 1995. Isolation 
and characterization of genetically engineered gallidermin and epidermin analogs. Appl. 
Environ. Microbiol. 61:3894-3903. 
100. G Bierbaum, M Reis, C Szekat, HG Sahl. 1994. Construction of an expression system for 
engineering of the lantibiotic Pep5. Appl. Environ. Microbiol. 60:4332-4338. 
101. W Liu, JN Hansen. 1992. Enhancement of the chemical and antimicrobial properties of 
subtilin by site-directed mutagenesis. J. Biol. Chem. 267:25078-25085. 
102. P Chen, J Novak, M Kirk, S Barnes, F Qi, PW Caufield. 1998. Structure-activity study of 
the lantibiotic mutacin II from Streptococcus mutans T8 by a gene replacement strategy. 
Appl. Environ. Microbiol. 64:2335-2340. 
103. J Nagao, Y Harada, K Shioya, Y Aso, T Zendo, J Nakayama, K Sonomoto. 2005. 
Lanthionine introduction into nukacin ISK-1 prepeptide by co-expression with modification 
enzyme NukM in Escherichia coli. Biochem. Biophys. Res. Commun. 336:507-513. 
104. Y Shi, X Yang, N Garg, WA van der Donk. 2010. Production of lantipeptides in Escherichia 
coli. J. Am. Chem. Soc. 133:2338-2341. 
105. A Ökesli, LE Cooper, EJ Fogle, WA van der Donk. 2011. Nine post-translational 
modifications during the biosynthesis of cinnamycin. J. Am. Chem. Soc. 133:13753-13760. 
106. T Caetano, J Barbosa, E Möesker, RD Suessmuth, S Mendo. 2014. Bioengineering of 
lanthipeptides in Escherichia coli: assessing the specificity of lichenicidin and haloduracin 
biosynthetic machinery. Res. Microbiol. 165:600-604. 
107. A Kuipers, J Wierenga, R Rink, LD Kluskens, AJ Driessen, OP Kuipers, GN Moll. 2006. 
Sec-mediated transport of posttranslationally dehydrated peptides in Lactococcus lactis. Appl. 
Environ. Microbiol. 72:7626-7633. 
108. J Lubelski, R Rink, R Khusainov, GN Moll, OP Kuipers. 2008. Biosynthesis, immunity, 
regulation, mode of action and engineering of the model lantibiotic nisin. Cell. Mol. Life Sci. 
65:455-476. 
109. R Rink, J Wierenga, A Kuipers, LD Kluskens, AJ Driessen, OP Kuipers, GN Moll. 2007. 
Dissection and modulation of the four distinct activities of nisin by mutagenesis of rings A and 
B and by C-terminal truncation. Appl. Environ. Microbiol. 73:5809-5816. 
110. MJ Dawson,  J Cortes Bargallo, NA Appleyard. 2007. WO0703 6706. 
111. G Bierbaum, H Sahl. 2009. Lantibiotics: mode of action, biosynthesis and bioengineering. 
Curr. Pharm. Biotechnol. 10:2-18. 
112. A Kuipers, J Meijer-Wierenga, R Rink, LD Kluskens, GN Moll. 2008. Mechanistic 
dissection of the enzyme complexes involved in biosynthesis of lacticin 3147 and nisin. Appl. 
Environ. Microbiol. 74:6591-6597. 
113. R Rink, A Kuipers, E de Boef, KJ Leenhouts, AJM Driessen, GN Moll, OP Kuipers. 2005. 
Lantibiotic structures as guidelines for the design of peptides that can be modified by 
lantibiotic enzymes. Biochemistry (N. Y.). 44:8873-8882. 
114. LD Kluskens, A Kuipers, R Rink, E de Boef, S Fekken, AJM Driessen, OP Kuipers, GN 
Moll. 2005. Post-translational modification of therapeutic peptides by NisB, the dehydratase of 
the lantibiotic nisin. Biochemistry (N. Y.). 44:12827-12834. 
115. Y Aso, J Nagao, H Koga, K Okuda, Y Kanemasa, T Sashihara, J Nakayama, K 
Sonomoto. 2004. Heterologous expression and functional analysis of the gene cluster for the 
Chapter 1: Introduction 
40 
 
biosynthesis of and immunity to the lantibiotic, nukacin ISK-1. Journal of Bioscience and 
Bioengineering. 98:429-436. 
116. L Xie, LM Miller, C Chatterjee, O Averin, NL Kelleher, WA van der Donk. 2004. Lacticin 
481: in vitro reconstitution of lantibiotic synthetase activity. Science. 303:679-681. 
117. D Kruszewska, HG Sahl, G Bierbaum, U Pag, SO Hynes, A Ljungh. 2004. Mersacidin 
eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. 
Antimicrob. Chemother. 54:648-653. 
118. JR van der Meer, J Polman, MM Beerthuyzen, RJ Siezen, OP Kuipers, WM De Vos. 
1993. Characterization of the Lactococcus lactis nisin A operon genes nisP, encoding a 
subtilisin-like serine protease involved in precursor processing, and nisR, encoding a 
regulatory protein involved in nisin biosynthesis. J. Bacteriol. 175:2578-2588. 
119. G Bierbaum, C Szekat, M Josten, C Heidrich, C Kempter, G Jung, HG Sahl. 1996. 
Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. 
Appl. Environ. Microbiol. 62:385-392. 
120. AC Ross, JC Vederas. 2011. Fundamental functionality: recent developments in 
understanding the structure–activity relationships of lantibiotic peptides. J. Antibiot. 64:27-
34. 
121. S Wilson-Stanford, A Kalli, K Hakansson, J Kastrantas, RS Orugunty, L Smith. 2009. 
Oxidation of lanthionines renders the lantibiotic nisin inactive. Appl. Environ. Microbiol. 
75:1381-1387. 
122. D Jabes, C Brunati, G Candiani, S Riva, G Romano, S Donadio. 2011. Efficacy of the new 
lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive 
pathogens. Antimicrob. Agents Chemother. 55:1671-1676. 
123. S Boakes, T Ayala, M Herman, AN Appleyard, MJ Dawson, J Cortés. 2012. Generation of 
an actagardine A variant library through saturation mutagenesis. Appl. Microbiol. Biotechnol. 
95:1509-1517. 
124. AM Jones, JM Helm. 2009. Emerging treatments in cystic fibrosis. Drugs. 69:1903-1910. 
125. MM Cloutier, L Guernsey, P Mattes, B Koeppen. 1990. Duramycin enhances chloride 
secretion in airway epithelium. Am. J. Physiol. 259:C450-4. 
126. O Ghobrial, H Derendorf, JD Hillman. 2010. Pharmacokinetic and pharmacodynamic 
evaluation of the lantibiotic MU1140. J. Pharm. Sci. 99:2521-2528. 
127. PD Cotter, C Hill, RP Ross. 2005. Bacteriocins: developing innate immunity for food. Nature 
Reviews Microbiology. 3:777-788. 
128. M Zhao, Z Li, S Bugenhagen. 2008. 99mTc-labeled duramycin as a novel 
phosphatidylethanolamine-binding molecular probe. J. Nucl. Med. 49:1345-1352. 
129. Q Zhang, Y Yu, JE Velasquez, WA van der Donk. 2012. Evolution of lanthipeptide 
synthetases. Proc. Natl. Acad. Sci. U. S. A. 109:18361-18366. 
130 P Kamarajan, T Hayami, B Matte, Y Liu, T Danciu, A Ramamoorthy, F Worden, S 
Kapila, Y Kapila. 2015. Nisin ZP, a Bacteriocin and Food Preservative, Inhibits Head and 






The role of the cytosolic peptidase domain of the lantibiotic ABC 
transporter LtnT in the secretion of lacticin 3147 
 
Hannah L. Zwart, Janny G. de Wit & Arnold J. M. Driessen 
Department of Molecular Microbiology, Groningen Biomolecular Sciences and Biotechnology 





LtnT of Lactococcus lactis subsp. lactis DPC3147 belongs to the ABC 
transporter maturation and secretion (AMS) protein family. It mediates the 
secretion of the lanthipeptides LtnA1 and LtnA2, which together constitute the 
two-component class II lantibiotic lacticin 3147. In addition, LtnT processes the 
leader peptide by means of an intracellular N-terminal peptidase C39 domain. In 
contrast, class I lantibiotics depend on a specific extracellular proteinase for 
processing. To investigate the importance of this domain in the transport 
mechanism of LtnT, the catalytic cysteine was mutated and the N-terminal 
peptidase domain was deleted. In both cases, this completely abolished the 
production of LtnA1 or LntA2. These data suggest that LtnT requires an active 









Lantibiotics, lanthionine-containing antibiotic peptides, harbor 
(methyl)lanthionine, dehydroalanine and/or dehydrobutarine residues that are 
post translationally introduced into the peptides. In class I lantibiotics (e.g. nisin) 
the modifications are introduced by two enzymes, LanB a dehydratase and LanC 
a cyclase. In class II lantibiotics (e.g. nukacin ISK-1 or lacticin 3147) the 
modifications are done by a bifunctional modification enzyme, LanM. The 
lantibiotic precursor peptide LanA consist of a N-terminal leader peptide and a C-
terminal core peptide. Only the latter is post-translationally modified by the 
before mentioned enzymes. In order to obtain the mature and active peptide, the 
N-terminal leader peptide needs to be removed. In class I lantibiotics, an 
extracellular serine protease, generally termed LanP, removes the leader peptide 
after transport. In class II lantibiotics, the leader is removed concomitant with, 
or prior to transport by a dedicated bifunctional ATP-Binding Cassette (ABC) 
transporter, LanT (1). 
Transporters associated with class II lantibiotics are ABC transporter 
maturation and secretion (AMS) proteins, also known as SunT-type transporters, 
named after the characterized member SunT (2). These transporters consist of 
approximately 700 amino acids and contain a N-terminal peptidase domain 
belonging to the peptidase C39 family, a central transmembrane domain and a 
C-terminal ATP-binding domain (figure 1A). This peptidase domain is localized at 
the cytoplasmic side of the membrane (3, 4). Therefore, it is assumed that there 
is an even number, namely four or six, transmembrane helices in the central 
domain of the transporter. In addition, the ATP binding and peptidase domain 
appear to function cooperatively (4). Mutations in either domain of the NukT 
transporter abolishes the capability to transport the lanthipeptide and to cleave 
the leader peptide. The crystal structure of ComA, an AMS protein, has been 
solved (5) showing that the peptidase domain has a similar structure as papain-
like cysteine proteases. These cysteine proteases contain a conserved cysteine 
residue and several other conserved residues that when mutated cause the loss 
of peptidase activity (6-8). The substrates of the peptidase domain containing 
ABC transporters are usually bacteriocins (non-lantibiotic and lantibiotic) that are 
processed at a so-called double glycine site (GG/GA/GS/GT) at the C-terminus of  
 




Figure 1: A) schematic representation of the three domains of the lacticin 3147 transporter LtnT. 
C15 indicates the position of the catalytic active cysteine, that was substituted for an alanine in 
LtnT-C15A. The N-terminus including residues 3 to 134 was removed to obtain the truncated trLtnT 
mutant. B) Hydrophobicity plot showing the six transmembrane domains for proteins belonging to 
the ABC transporter maturation and secretion (AMS) protein family which includes LtnT. The 
hydrophobicity plot was generated on 120 proteins homologous to LtnT using MemGen 4.2.0 (14). 
 
 
the leader peptide. In addition to the double glycine motif, the α-helical structure 
of the leader peptide seems to be important for the recognition by the peptidase 
C39 domain (7). Furthermore it was proposed that the peptidase domain 
contains a hydrophobic patch that interacts with the hydrophobic surface of the 
α-helix of the leader peptide (9). The catalytic site of the peptidase domain 
contains a conserved cysteine and histidine residue, whereas a conserved 
glutamine is believed to be associated with the oxyanion hole typically found in 
peptidases that belong to the cysteine protease family (8). 
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The transporter of the two-component lantibiotic lacticin 3147, LtnT, 
functions as a bifunctional transporter catalyzing both the processing and 
transport of these lantibiotics. Although there are some reports on the structure 
and export mechanism of SunT-type transporters (2), little is known about the 
specificity of the lacticin 3147 transporter and the role of its peptidase domain. 
Here LtnT variants with a mutation and deletion in the peptidase domain were 
analyzed for their ability to process and transport substrate peptides to assess 
the role of the peptidase C39 domain in the transport mechanism. 
 
Material and Methods 
 
Bacterial strains, plasmids and growth conditions. Strains and 
plasmids used in this study are listed in table 1. Lactococcus lactis NZ9000 was 
used as a host for the plasmids. All strains were grown at 30°C in Bacto M17 
broth (Becton Dickinson Difco) supplemented with 0.5% glucose. Where needed 
chloramphenicol (5 µg/mL), erythromycin (5 µg/mL) or both antibiotics (3 
µg/mL) were added to the medium. 
 
 
Table 1: Bacterial strains and plasmids used in this study 
Strain or plasmid Characteristic(s) Source or reference 
Strains 
Lactococcus lactis NZ9000 MG1363 derivative; pepN::nisRK+ (17) 
Plasmids 
pIL253 Emr (18) 
pILPltnT-2 pIL253 derived; ltnT-ltnM2 cloned behind 
the Pnis promoter, disruption of ltnM2 by 
BglII digestion; Emr 
(11) 
pILPltnT-2-his pILPltnT-2 derived; containing His-tag at 
C-terminus of LtnT; Emr 
This study 
pILPltnT-C15A pILPltnT-2 derived; mutation of active 
cysteine at position 15 to alanine; Emr 
This study 
pILPltnT-C15A-his pILPltnT-C15A derived; containing His-tag 
at C-terminus of LtnT-C15A; Emr 
This study 
pILPtrltnT-b pILPltnT-2 derived; disruption of C39 
peptidase domain by removing Lys3-
Glu134 of LtnT; Emr 
This study 
pILPtrltnT-b-his pILPtrltnT-b derived; containing His-tag at 





pA24 pNZ8048 derived; ltnA2 cloned behind the 
Pnis promoter; Cmr 
(11) 
pA13 pNZ8048 derived; ltnA1 cloned behind the 
Pnis promoter; Cmr 
Kind gift from Lanthio 
Pharma 
Emr erythromycin resistance marker 
Cmr chloramphenicol resistance marker 
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Plasmid construction. Plasmid construction was carried out using 
standard procedures (10). Phusion High-Fidelity DNA Polymerase for PCR, 
restriction and DNA modifying enzymes were all purchased from Thermo 
Scientific. All sequencing analysis were performed at Macrogen Europe. PCR 
primers used to create the below described constructs can be found in table 2. 
 
 
Table 2: Primers used in this study 
Primer name Primers sequence 
(5’-3’) 
Characteristics 
   
045-fw CTTTAAACAAGCTAGCAGAACGCCC Amplification of LtnT-C15A 
fragment one, NheI restriction site 
046-rv CAGCAAAGTCCAGCTTCAGTTTGTG Amplification of LtnT-C15A 
fragment one, C15A mutation 
047-fw ACAAACTGAAGCTGGACTTTGCTG Amplification of LtnT-C15A 
fragment two, C15A mutation 
048-rv CTGTCGCTGCAGTGACATAGTTATTAG Amplification of LtnT-C15A 
fragment two, PstI restriction site 
159-fw 
 








CATCACCACTAATTTATTATTTTATAAATAAAATAC Primer to introduce His-tag 
154-rv 
 
[Phos]ATGGTGATGCTTAGAAGTATATATTTTC Primer to introduce His-tag 




The pIL253 derived plasmids are based on pILPltnT-2 (11), which was a 
kind gift from Lanthio Pharma. This plasmid was used to create the following 
constructs. To generate a mutant of LtnT with a mutation at its presumed 
catalytic cysteine, plasmid pILPltnT-C15A was generated using overlap extension 
PCR. In de first step two products were generated, from pILPltnT-2, both 
containing the C15A mutation in LtnT and with an overlapping sequence of 24 
bp. In de second step the overlapping products were annealed and extended with 
the outer primers to yield a single product. Subsequently, the DNA fragment was 
treated with NheI and PstI restriction enzymes followed by ligation into the 
NheI/PstI site of pILPltnT-2. The sequence of the resulting plasmid was analyzed 
for the presence of the C15A mutation. Mutagenesis PCR was also executed on 
pILPltnT-2 to delete residue Lys3-Glu134 of LtnT which correspond to the 
peptidase domain. This yielded pILPtrltnT-b. 
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LtnT, LtnT-C15A and trLtnT were fused to a C-terminal hexa histidine-tag 
at the C-terminus of LtnT using mutagenesis PCR. The corresponding transporter 
variants were cloned into respective pILP-plasmids yielding, pILPltnT-2-his, 
pILPltnT-C15A-his and pILPtrltnT-b-his. 
The pNZ8048 derived plasmids (table 1), pA24 (11) and pA13, used in this 
study were a kind gift of Lanthio Pharma. After molecular cloning, L. lactis 
NZ9000 was transformed with the indicated pNZ8048 and pIL253 derived 
plasmids by electrotransformation (12) using a Bio-Rad gene pulser. 
 
Expression of the His-tagged lacticin 3147 transporter. L. lactis 
NZ9000 cells were transformed with pILPltnT-2-His, pILPltnT-C15A-His or 
pILPtrltnT-b-His and grown overnight in GM17. Fresh GM17 was inoculated 1:60 
with an overnight culture of the expression strain, incubated at 30°C till an 
optical density at 600 nm (OD600) of 0.4-0.5 at which point expression was 
induced with nisin (Sigma-Aldrich) at a concentration of 1 ng/mL. After four 
hours of induction, cells were harvested by centrifugation at 16,100 x g for 7 
minutes. The cell pellet was lysed by resuspension in 4 mg/mL Lysozyme 
(Roche) in MilliQ water and incubation for 30 minutes at 55°C. SDS-PAGE, 
Coomassie brilliant blue staining and immunoblotting were used to detect the 
LtnT transporters. Western blotting using an anti-His antibody (5 PRIME) was 
done according to standard protocols. 
 
MALDI-TOF mass spectrometry. Minimal medium was prepared as 
described by Rink et. al. (13) with the vitamin mix replaced by BME Vitamins 
(Sigma-Aldrich). Minimal medium was inoculated 1:50 with an overnight culture 
of an expression strain grown in GM17. After three hours at 30°C, expression 
was induced by adding 1 ng/mL nisin (Sigma-Aldrich), and growth was continued 
for 24 hours. Next cells were removed from the culture by centrifugation (20 
min., 3724 x g). A sample of 1 µL of the supernatant was applied to the MALDI-
TOF target, dried and washed with a drop of MilliQ water. Subsequently, 1 µL of 
matrix, 5 mg/mL α-Cyano-4-hydroxycinnamic acid (Sigma-Aldrich) dissolved in 
50% Acetonitrile and 0,1% trifluoroacetic acid (TFA), was added to the sample 
and dried. 
In addition, peptides were precipitated from the culture supernatant by 
addition of 10% trichloroacetic acid (TCA). After 30 minutes on ice the sample 
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was spun for 30 minutes at 17,000 x g. The pellet was washed with acetone, 
centrifuged (15 min. at 17,000 x g) and dried (5 min. at 42°C). The TCA 
precipitated pellet was dissolved in 10 µL MilliQ water of which 1 µL was applied 
to the MALDI-TOF target, and treated as described above. Spectra were recorded 
with a Voyager DE PRO MALDI-TOF mass spectrometer (Applied Biosystems) and 
analyzed with Data Explorer TM 4.0.0.0 (Applied Biosystems). An external 




Hydrophobicity plot of LtnT homologues. LtnT, the transporter of 
lacticin 3147, belongs to the family of ABC transporter maturation and secretion 
(AMS) proteins. It is 708 amino acids long, containing a N-terminal peptidase 
domain, a central transmembrane domain and a C-terminal cytosolic ATP-binding 
domain (figure 1A). Studies of Franke et al. (3) and Nishie et al. (4) indicate that 
the peptidase domain also localizes at the cytoplasmic side of the membrane. To 
facilitate a cytoplasmic location for both ATPase domain as well as the peptidase 
domain, there must be an even number of transmembrane helices. However it is 
not yet clear if the central transmembrane domain contains four or six helices. 
Therefore, 120 homologues of LtnT (supplementary table 1) where used to 
generate an averaged hydrophobicity plot using MemGen 4.2.0 (14). The 
averaged hydrophobicity plot (figure 1B) clearly shows the presence of six 
transmembrane helices and confirms the previously proposed localization of the 
N- and C-terminal domains. 
 
Multiple sequence alignment of AMS proteins. To assess the role of 
the peptidase domain in transport, a multiple sequence alignment was generated 
to identify conserved residues of the active site. LtnT was aligned against known 
AMS proteins, SunT, NukT, LctT, CvaB and ComA (figure 2). This revealed a 
number of conserved residues, i.e., Gln9, which is part of the assumed oxyanion 
hole, and Cys15, His89 and Asp105 that localize to the predicted catalytic site. 
Based on these alignment results, a variant of LtnT was created by site-directed 
mutagenesis in which the conserved cysteine at position 15 was exchanged for 
an alanine. For a second variant of LtnT, the peptidase C39 encoding sequence 
was removed. BLAST analysis suggests that this domain of LtnT is specified by 
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Figure 2: Multi sequence alignment of the first 152 amino acids of LtnT (NCBI accession number: 
AAC56012.1) against NukT (BAC98761.2), LctT (AAC72259.1), SunT (AAC12993.1), CvaB 
(CAA40744.1) and ComA (AAA69510.1). The conserved residues of the peptidase C39 domain are 
marked with *. 
 
 
amino acids 4 till 129. To ensure the complete removal, residues Lys3 till Glu134 
were deleted. 
 
Expression of LtnT and variants in L. lactis NZ9000. In order to 
determine if the LtnT transporter variants are expressed in L. lactis NZ9000, a 
His-tag sequence was introduced at the C-terminus of the ATP binding domain. 
After expression, cell samples were compared to an empty vector control by 
SDS-PAGE. His-LtnT and His-LtnT-C15A could be detected as an unique protein 
around 75 kDa that was absent when cells were transformed with the control 
plasmid (figure 3A). The truncate His-trLtnT could not be assigned in coomassie 
brilliant blue stained SDS-PAGE. Therefore, samples were also analyzed by 
Western blotting using a His-tag antibody. This allowed for the detection of His-
tagged proteins of about 75 kDa, corresponding to His-LtnT and His-LtnT-C15A, 
and of 60 kDa, which corresponds to the His-trLtnT (figure 3B). The proteins 
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show a faster migration on SDS-PAGE than expected for their calculated masses 
of 80.8 and 65.5 kDa, respectively. This is a typical feature of membrane 
proteins. In addition, some C-terminal degradation products of LtnT were 
observed that were absent in the empty vector control. The data demonstrate 




Figure 3: A) Coomassie stained SDS-PAGE comparing cells of L. lactis strains expressing His-LtnT, 
His-LtnT-C15A, His-trLtnT or the empty vector. The arrow indicates an unique protein at 75 kDa. B) 
Western blot stained with a Tetra-His antibody (Qiagen) showing by an arrow the presence of His-
tagged LtnT and LtnT-C15A at 75 kDa and trLtnT at 60 kDa. 
 
 
Secretion and processing of LtnA1 and LtnA2 by LtnT and variants. 
In order to evaluate if LtnT is active without the presence of the associated 
biosynthesis enzymes of the lacticin 3147 gene cluster, LtnT was co-expressed 
with either LtnA1 or LtnA2. The supernatant of the expressing strains was 
screened via MALDI-TOF mass spectrometry for the presence of processed but 
unmodified LtnA1 and LtnA2. A peak of 3424.59 Da (figure 4A) was observed in 
the supernatant of the strain co-expressing LtnT and LtnA1 that was absent in 
the empty vector controls. The observed mass corresponds to the theoretical 
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mass of 3430.88 Da (15) for the unmodified core peptide of LtnA1. Likewise, co-
expression of LtnA2 and LtnT yielded a peptide with a mass of 2982.85 Da 
(figure 4B). This mass corresponds to the theoretical mass of unmodified 
processed LtnA2, 2986.44 Da (15). Taken together the results show that the 
lacticin 3147 transporter can transport and process its unmodified natural 




Figure 4: MALDI-TOF mass spectra of culture media showing the presence of (A) unmodified core 
peptide LtnA1 of 3424.59 Da after co-expression of LtnA1 and LtnT in L. lactis NZ9000, (B) 




Next, the ability of the LtnT transporter containing the cysteine to alanine 
mutation at position 15, to transport LtnA1 or LtnA2 was analyzed. However, in 
this case, no peptide product could be detected. Also with the second variant of 
LtnT with a truncation of the peptidase C39 domain no peptide product of LtnA1 
or LtnA2 could be detected in the medium fraction. These results suggest that 
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Since LtnT is responsible for both the maturation and the secretion of 
LtnA1 and LtnA2, it plays a key role in the biosynthesis of lacticin 3147. Previous 
reports on NukT (16) showed that NukT is not able to transport unmodified 
peptides. Here it is shown that co-expression of LtnT with either LtnA1 or LtnA2 
does results in the production of unmodified and processed peptides. This 
suggests that LtnT can function without the presence of other enzymes encoded 
in the gene cluster of lacticin 3147, and thus that modification is not an essential 
requirement for LtnT mediated transport and processing. However, it is noted 
that the level of production is low causing a high background in the MALDI-TOF 
mass spectra, thus indicating impaired transport. 
A BLAST analysis revealed that LtnT contains a conserved peptidase 
domain that belongs to the peptidase C39 family. By aligning this domain with 
peptidase domains of other AMS proteins, conserved amino acids were identified 
in LtnT (figure 2). Although various studies (3-9, 16) report work on AMS 
proteins and their peptidase domain, the exact role of the peptidase C39 domain 
in the transport mechanism of the lacticin 3147 transporter is unknown. 
Therefore, two variants of LtnT, LtnT-C15A with an alanine replacement of the 
conserved catalytic cysteine residue, and a truncate of the peptidase domain, 
trLtnT, were assessed for their ability to export LtnA1 and LtnA2. The truncate 
more resembles transporters associated with class I lantibiotics that secrete the 
peptides independently from their processing. However, eliminating the active 
cleavage site either by mutation or deletion completely abolished the production 
and likely the export. This suggests that LtnT requires an active peptidase C39 
domain in order to export peptides. Similar findings were reported for the 
lantibiotic transporter NukT (4), and it was suggested that the transport and 
processing are cooperative events. 
Taken together, this study shows that unmodified substrate peptides can 
be processed and exported by LtnT. In addition, LtnT requires an active 
peptidase C39 domain to transport substrates across the membrane. 
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Supplementary table 1: List of the 120 proteins used to create the hydrophobicity plot for the ABC 
transporter maturation and secretion (AMS) protein family including LtnT. 
Protein name 
in MemGen 4.2.0 
GI number NCBI-definition 
LCGT1755lgar 347522361 ABC transporter ATP binding protein/permease [Lactococcus garvieae 
ATCC 49156] 
MCHL5208mext 218533082 ABC transporter [Methylobacterium extorquens CM4] 
HEL16410shel 257064337 multidrug ABC transporter ATPase and permease [Slackia 
heliotrinireducens DSM 20476] 
BVU0291bavu 150002889 ABC transporter ATP-binding protein [Bacteroides vulgatus ATCC 
8482] 
MTOL0119eoli 408671693 ABC transporter related protein [Emticicia oligotrophica DSM 17448] 
FP1877fpsy 150025919 Probable ABC-type multidrug transport system, ATPase and permease 
components [Flavobacterium psychrophilum JIP02/86] 
63030342cals 428297090 bacteriocin-processing peptidase [Calothrix sp. PCC 6303] 
AVA2398avar 75908614 bacteriocin-processing peptidase [Anabaena variabilis ATCC 29413] 
FJOH1164fjoh 146298925 ABC transporter-like protein [Flavobacterium johnsoniae UW101] 
ACSA3723bsal 324977005 ABC-type bacteriocin transporter [Bacteroides salanitronis DSM 
18170] 
PH214095sspc 326801479 xenobiotic ABC transporter ATPase [Sphingobacterium sp. 21] 
ALHY2553hahy 332664511 xenobiotic-transporting ATPase [Haliscomenobacter hydrossis DSM 
1100] 
DFER4910dfer 255038655 ABC transporter [Dyadobacter fermentans DSM 18053] 
LAGDfaes 436836888 Lactococcin-G-processing and transport ATP-binding protein lagD 
[Fibrella aestuarina BUZ 2] 
BREC0941erec 238923324 transporter, truncation, partial [Eubacterium rectale ATCC 33656] 
OCEL0740ccel 302873642 bacteriocin ABC transporter [Clostridium cellulovorans 743B] 
REBR1063tbre 332297704 bacteriocin ABC transporter [Treponema brennaborense DSM 12168] 
TDE0425tden 42525941 bacteriocin ABC transporter ATP-binding/permease [Treponema 
denticola ATCC 35405] 
SPSE0465stps 386318478 ABC-type bacteriocin transporter family protein [Staphylococcus 
pseudintermedius ED99] 
BALH4659bthu 118480203 ABC-type bacteriocin transporter family protein [Bacillus thuringiensis 
str. Al Hakam] 
CTHE0534rthe 125973053 bacteriocin-processing peptidase [Ruminiclostridium thermocellum 
ATCC 27405] 
CAP0073cace 15004777 ABC ATPase containing transporter [Clostridium acetobutylicum ATCC 
824] 
ALHA1929halh 435854614 ABC-type bacteriocin transporter [Halobacteroides halobius DSM 
5150] 
CSAC0158csac 146295230 ABC-type bacteriocin transporter [Caldicellulosiruptor saccharolyticus 
DSM 8903] 
AMET1032alme 150388859 bacteriocin ABC transporter [Alkaliphilus metalliredigens QYMF] 
62PC0024efae 384519720 bacteriocin ABC transporter [Enterococcus faecalis 62] 
P6700602spne 307126742 transport/processing ATP-binding protein ComA [Streptococcus 
pneumoniae 670-6B] 
LJP0571ljoh 385825511 lactacin F ABC transporter permease component [Lactobacillus 
johnsonii DPC 6026] 
SUNTlegl 289164872 ABC-type bacteriocin/lantibiotic exporters, contain an N-terminal 
double-glycine peptidase domain [Legionella longbeachae NSW150] 
BPRI0803bupr 302670168 bacteriocin ABC transporter ATP-binding protein/permease/protease 
[Butyrivibrio proteoclasticus B316] 
SWOL2230swol 114567738 hypothetical protein Swol_2230 [Syntrophomonas wolfei subsp. wolfei 
str. Goettingen G311] 
ELEN2946elen 257792673 ABC transporter-like protein [Eggerthella lenta DSM 2243] 
YAGR0273cygr 427701593 NHLM bacteriocin system ABC transporter, peptidase/ATP-binding 
protein [Cyanobium gracile PCC 6307] 




in MemGen 4.2.0 
GI number NCBI-definition 
28316118mrad 170745389 ABC transporter [Methylobacterium radiotolerans JCM 2831] 
PUNR1803npun 186682212 ABC transporter [Nostoc punctiforme PCC 73102] 
PUNF5050npun 186685135 ABC transporter [Nostoc punctiforme PCC 73102] 
NACY1965acyl 440681565 NHPM bacteriocin system ABC transporter, peptidase/ATP-binding 
protein [Anabaena cylindrica PCC 7122] 
GMSR0644mgry 568145045 ABC transporter related protein [Magnetospirillum gryphiswaldense 
MSR-1] 
ALHY0667hahy 332662660 NHPM bacteriocin system ABC transporter, peptidase/ATP-binding 
protein [Haliscomenobacter hydrossis DSM 1100] 
SUNTpthe 147678715 bacteriocin/lantibiotic ABC transporter [Pelotomaculum 
thermopropionicum SI] 
PLUT0873clut 78186738 ATPase [Chlorobium luteolum DSM 273] 
XNC14505xnem 300725260 Colicin V secretion/processing ATP-binding protein cvaB [Xenorhabdus 
nematophila ATCC 19061] 
A386B254apas 529230277 ABC transporter related [Acetobacter pasteurianus 386B] 
ARI03623saen 161505465 hypothetical protein SARI_03623 [Salmonella enterica subsp. arizonae 
serovar 62:z4,z23:- str. RSK2980] 
S7000270prst 386741469 hypothetical protein S70_00270 [Providencia stuartii MRSN 2154] 
17580105ypse 153949267 bacteriocin ABC transporter ATP-binding-protein/permease [Yersinia 
pseudotuberculosis IP 31758] 
KVAR4715kvar 288937560 ABC transporter [Klebsiella variicola At-22] 
SWP1032spie 212633897 Toxin secretion ATP-binding protein [Shewanella piezotolerans WP3] 
CJA3604ceja 192361880 putative toxin transporter [Cellvibrio japonicus Ueda107] 
AS122274sers 333927129 peptide-transporting ATPase [Serratia sp. AS12] 
CC0684ccre 16124937 ABC transporter [Caulobacter crescentus CB15] 
ARAD7449arad 222081179 toxin secretion ABC transporter [Agrobacterium radiobacter K84] 
RLEG6343rleg 241554125 ABC transporter [Rhizobium leguminosarum bv. trifolii WSM1325] 
CVABpvag 308185474 type I secretion system atpase [Pantoea vagans C9-1] 
MCHFsply 518650451 putative microcin-H47 secretion/processing ATP-binding protein MchF 
[Serratia plymuthica 4Rx13] 
SDEN0474sden 91791838 ABC transporter related [Shewanella denitrificans OS217] 
RAXB1xalb 285018564 peptide ABC transporter ATPase/permease [Xanthomonas albilineans 
GPE PC73] 
SWOO3807swoo 170728135 ABC transporter-like protein [Shewanella woodyi ATCC 51908] 
SESU1940psuw 319787533 ABC transporter [Pseudoxanthomonas suwonensis 11-1] 
BPRA0247ppro 54307468 toxin transporter [Photobacterium profundum SS9] 
SOA0049sone 24376277 toxin secretion ABC transporter, ATP-binding subunit/permease 
protein, putative [Shewanella oneidensis MR-1] 
SWP4866spie 212637550 Toxin secretion ABC transporter, ATP-binding subunit/permease 
protein, putative [Shewanella piezotolerans WP3] 
BNIB1807vnig 549719946 putative COLICIN V SECRETION ABC TRANSPORTER [Vibrio 
nigripulchritudo] 
PECL1942pecl 381280280 ABC-type bacteriocin transporter [Pediococcus claussenii ATCC BAA-
344] 
ELEN2945elen 257792672 ABC transporter-like protein [Eggerthella lenta DSM 2243] 
ENT29170ents 479181661 ABC-type bacteriocin/lantibiotic exporters, contain an N-terminal 
double-glycine peptidase domain [Enterococcus sp. 7L76] 
73311066rode 311112735 cytolysin B transport protein [Rothia dentocariosa ATCC 17931] 
LKTBrode 311112748 peptide-transporting ATPase [Rothia dentocariosa ATCC 17931] 
GS508715smut 397650480 Toxin RTX-I translocation ATP-binding protein [Streptococcus mutans 
GS-5] 
GTNG2061gthe 138895705 lantibiotic ABC transporter [Geobacillus thermodenitrificans NG80-2] 
BH0451bhal 15613014 lantibiotic mersacidin transporter system [Bacillus halodurans C-125] 
LANTblic 511061028 lantibiotic transport protein LanT [Bacillus licheniformis 9945A] 
ATHE1112cbes 222529104 ABC transporter [Caldicellulosiruptor bescii DSM 6725] 
APXIBcsai 550920830 toxin RTX-I translocation ATP-binding protein [Clostridium 
saccharobutylicum DSM 13864] 
OCEL4224ccel 302877016 peptidase C39 bacteriocin processing [Clostridium cellulovorans 743B] 
OCEL4227ccel 302877019 peptidase C39 bacteriocin processing [Clostridium cellulovorans 743B] 




in MemGen 4.2.0 
GI number NCBI-definition 
GAU3887gaur 226229293 putative bacteriocin processing/transport ATP-binding protein 
[Gemmatimonas aurantiaca T-27] 
L0835646acti 494688062 ABC transporter [Actinoplanes sp. N902-109] 
HAUR1869haur 159898393 ABC transporter-like protein [Herpetosiphon aurantiacus DSM 785] 
HAUR3741haur 159900258 ABC transporter-like protein [Herpetosiphon aurantiacus DSM 785] 
66052216cmin 434386215 ABC-type bacteriocin/lantibiotic exporter with N-terminal double-
glycine peptidase domain [Chamaesiphon minutus PCC 6605] 
E1093122anas 153005977 ABC transporter-like protein [Anaeromyxobacter sp. Fw109-5] 
PAXBcoco 383455645 exotoxin translocation ATP-binding protein PaxB [Corallococcus 
coralloides DSM 2259] 
HOCH5839hoch 262198999 ABC transporter [Haliangium ochraceum DSM 14365] 
MCHFcoco 383457198 putative lantibiotic ABC transporter permease/ATP-binding protein 
[Corallococcus coralloides DSM 2259] 
MXAN2853mxan 108761029 lantibiotic ABC transporter permease/ATP-binding protein [Myxococcus 
xanthus DK 1622] 
TAUR3272stia 310820533 antibiotic ABC transporter permease/ATP-binding protein [Stigmatella 
aurantiaca DW4/3-1] 
20002102pmir 529237769 toxin transporter [Proteus mirabilis BB2000] 
VV20484vvul 27366918 RTX toxin transporter [Vibrio vulnificus CMCP6] 
PLU3127plum 37527015 hypothetical protein plu3127 [Photorhabdus luminescens subsp. 
laumondii TTO1] 
YE1998yent 123442269 RTX family toxin transporter [Yersinia enterocolitica subsp. 
enterocolitica 8081] 
RTXBpasy 253990551 RTX toxin ABC transporter protein [Photorhabdus asymbiotica] 
OCEL2848ccel 302875675 type I secretion system ATPase [Clostridium cellulovorans 743B] 
SSA1100ssan 125717929 hemolysin exporter, ATPase component [Streptococcus sanguinis 
SK36] 
38901580falo 374308022 leukotoxin translocation ATP-binding protein LktB [Filifactor alocis 
ATCC 35896] 
B3811446caho 154147938 leukotoxin translocation ATP-binding protein LktB [Campylobacter 
hominis ATCC BAA-381] 
ULKU1197skuj 313682322 type I secretion system ATPase [Sulfuricurvum kujiense DSM 16994] 
01EI2150eict 238920046 type I secretion system ATPase family protein [Edwardsiella ictaluri 
93-146] 
SMED0884smed 150396107 type I secretion system ATPase [Sinorhizobium medicae WSM419] 
M4463820mspm 170741976 type I secretion system ATPase [Methylobacterium sp. 4-46] 
AFE2693acfe 218665057 type I secretion system ATPase [Acidithiobacillus ferrooxidans ATCC 
23270] 
D7812189smar 440230852 type I secretion system ABC transporter, HlyB family [Serratia 
marcescens FGI94] 
30165030pmuc 379722776 hypothetical protein PM3016_5030 [Paenibacillus mucilaginosus 3016] 
PAJ1258pana 386015850 hypothetical protein PAJ_1258 [Pantoea ananatis AJ13355] 
NMCC1317nmen 161870276 ABC transporter family protein [Neisseria meningitidis 053442] 
PPRO2369pepr 118580783 type I secretion system ATPase [Pelobacter propionicus DSM 2379] 
VEIS2576veis 121609532 type I secretion system ATPase [Verminephrobacter eiseniae EF01-2] 
35231035fcf. 387824618 ABC-type bacteriocin/lantibiotic exporter [Francisella cf. tularensis 
subsp. novicida 3523] 
BPRO1020posp 91786919 Type I secretion system ATPase, HlyB [Polaromonas sp. JS666] 
SVI3379svio 294142150 toxin secretion ABC transporter protein, HlyB family [Shewanella 
violacea DSS12] 
SY112340ffas 479198404 type I secretion system ABC transporter, HlyB family [Fretibacterium 
fastidiosum] 
HLYBspja 294013160 hemolysin secretion protein HlyB [Sphingobium japonicum UT26S] 
ESAL2073dsal 242279543 type I secretion system ATPase [Desulfovibrio salexigens DSM 2638] 
CAUL4165caus 167648124 type I secretion system ATPase [Caulobacter sp. K31] 
ESOP5579mopp 337270029 type I secretion system ATPase [Mesorhizobium opportunistum 
WSM2075] 
MMC11970magn 117925265 type I secretion system ATPase [Magnetococcus marinus MC-1] 
 




in MemGen 4.2.0 
GI number NCBI-definition 
RADO6926brsp 146343683 toxin secretion ABC transporter ATP-binding and membrane protein 
[Bradyrhizobium sp. ORS 278] 
HLYBndef 302038746 type I secretion system AtPase HlyB [Candidatus Nitrospira defluvii] 
RPE1085rpal 115523107 type I secretion system ATPase [Rhodopseudomonas palustris BisA53] 
RADO6201brsp 146343016 toxin secretion ABC transporter ATP-binding and membrane protein 
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Lantibiotics are ribosomal synthesized peptides that contain unusual amino 
acids and that are stabilized by thioether bonds. In class II lantibiotics, these 
post-translational modifications involve a dehydratase and cyclase activity both 
catalyzed by a single bifunctional enzyme, LanM. Production of the two 
component lantibiotic lacticin 3147 depends on the activity of LtnM1 and LtnM2 
lanthionine synthetase enzymes and the transporter LtnT. To examine the 
performance of these enzymes as a generic class II lantibiotic production system, 
the respective genes were co-expressed in Lactococcus lactis NZ9000. LtnM1 and 
LtnM2 in conjunction with LtnT supported the modification, maturation and 
excretion of the cognate substrates LtnA1 and LtnA2, respectively. When mixed, 
LtnA1 and LtnA2 inhibited the growth of an indicator strain demonstrating the 









Figure 1: shorthand notation of mature LtnA1 and LtnA2 of the two-component lantibiotic lacticin 





The two-component lantibiotic lacticin 3147 (figure 1) is produced by 
Lactococcus lactis subsp. lactis DPC3147 (1). Lantibiotics are a subgroup of 
lanthipeptides that display antimicrobial activity. Lanthipeptides are ribosomal 
synthesized and post-translationally modified peptides that contain the unusual 
amino acid meso-lantihionine (Lan) and (2S,3S,6R)-3-methyllanthionine 
(MeLan). These amino acids are formed during the post-translational 
modification of serine and threonine residues that are dehydrated to form 2,3-
dehydroalanine or (Z)-2,3-dehydrobutyrine, respectively. Dehydroalanine or 
dehydrobutyrine residues are then coupled to cysteine via a thioether bond to 
form the lanthionine or methyllanthionine ring, respectively. Based on the 
modification enzymes that introduces the (methyl)lanthionine residues, 
lanthipeptides can be divided into four classes (2). Class I and II lanthipeptides 
are mainly comprised of the more well-known lantibiotics, lanthionine-containing 
antibiotic peptides. In class I lanthipeptides, or lantibiotics, the formation of a 
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lanthionine ring is catalyzed by separate dehydratase (LanB) and cyclase (LanC) 
enzymes, whereas in class II lantibiotics both reactions are catalyzed by a single 
bifunctional enzyme, LanM. LanM enzymes typically contain a N-terminal 
dehydratase domain which does not show any homology to LanB. The C-terminal 
domain of LanM contains a cyclase domain which shows ~25% sequence identity 
to LanC (2), including the conserved zinc-binding residues that are required for 
catalysis (3). Class III and IV lanthipeptides also contain a single multifunctional 
modification enzymes to install the (methyl)lanthionine rings, LanKC and LanL, 
respectively (4, 5). Both enzymes contain three domains, a N-terminal lyase 
domain, a central kinase domain and a C-terminal cyclase domain. The difference 
between the LanKC and LanL enzyme lies within the cyclase domain. The cyclase 
domain of LanL enzymes is homologous to LanC while the cyclase domain of 
LanKC appears unique. In addition, some LanKC enzymes are also able to form a 
so-called labionin structure in which a second dehydroalanine is added to the 
enolate intermediate, formed by the addition of a cysteine to a dehydroalanine 
residue (6). 
The genes involved in lantibiotic biosynthesis are usually found in clusters. 
These clusters encode genes for the modification enzymes (LanBC or LanM). In 
addition to the (methyl)lantihonine residue forming enzymes, lantibiotics can 
undergo further post-translational modifications like decarboxylation (LanD) or in 
the case of lacticin 3147 conversion of L-serine to D-alanine catalyzed by LtnJ. 
Furthermore, the clusters also contain genes encoding an ATP-binding cassette 
(ABC) transporter (lanT) to transport the peptide into the environment. In class 
II lantibiotics these transporters contain a proteolytic domain to remove the 
leader peptide, however class I lantibiotic transporters do not contain such a 
domain instead encode a protease that cleaves the leader sequence (lanP) from 
the secreted precursor peptide. The gene cluster furthermore contains genes 
encoding proteins involved in self-protection/immunity (lanIFEG) and regulation 
of lantibiotic production (lanKR). The lanA gene encodes the linear precursor 
peptide. Lacticin 3147 is a two-component lantibiotic and its functional 
lanthipeptide is formed by two peptides encoded in the gene cluster as two 
precursor peptides, ltnA1 and ltnA2. Both precursor peptides depend on a 
dedicated modification enzyme, LtnM1 and LtnM2, respectively (7). The 
lantibiotic precursor peptide contains at its N-terminus a leader peptide that is 
recognized by the modification enzymes and transporter. The C-terminal core 
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peptide is modified and after leader peptide removal, it is released into the 
medium as a mature lantibiotic. In class II lantibiotics, the leader sequence 
contains a double glycine motif, GG, GA, GS or GT, which is recognized by the N-
terminal peptidase C39 domain of the bifunctional transporter typically found in 
class II lantibiotics. 
Antibiotic resistance is currently a serious threat in the treatment of 
infectious diseases. Therefore, novel antibiotics based on new core structures are 
urgently needed to counteract this resistance. Lantibiotics are an interesting 
group of molecules with the potential to act as antimicrobial agents. So far no 
known resistance mechanism exists against lantibiotics other than the immunity 
proteins found in the producing strains. For instance, the lantibiotic nisin is used 
for over 50 years as a food preservative without the significant development of 
microbial resistance. The antimicrobial activity of a few lantibiotics has been 
studied in detail, and these peptides act by inhibiting cell wall biosynthesis by 
binding lipid II, disrupting membrane integrity by forming pores, or a 
combination of the two mechanisms (2). With the two-component lacticin 3147, 
both peptides need to be present at an equimolar concentration (9, 10) to yield 
the active unit. LtnA1 forms a complex with lipid II thereby inhibiting cell wall 
biosynthesis. LtnA2 will then bind this complex and the complex will then form 
pores in the membrane (11). 
A large arsenal of lanthipeptides producing gene clusters has been found in 
microbial genomes and these reflect a so far untapped source of bioactivity. To 
produce these lanthipeptides in the natural host is not a simple task as often the 
conditions for production and growth are not known, nor has the host been 
isolated or cultivated. The development of a heterologous expression system to 
produce so far uncharacterized lanthipeptides might provide a generic solution to 
this problem. Such a system has been developed for class I lanthipeptides based 
on the nisin gene cluster employing the modification enzymes (NisBC) and the 
transporter (NisT) of nisin (12-16). However, for class II lanthipeptides, a 
generic production system does not yet exist. In a previous study it was shown 
that LtnM2 and LtnT can modify, process and transport LtnA2 and unrelated 
peptides, containing nisin and angiotensin variants fused behind the leader 
peptide of lacticin A2 (17). Interestingly, for LtnM1 and LtnT it is unclear if they 
are able to modify, process and transport LtnA1 separate from remaining 
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enzymes encoded in the lacticin 3147 gene cluster. Therefore, the potential of 
LtnM1 and LtnT to produce functionally active LtnA1 was examined in this study. 
 
Materials and methods 
 
Bacterial strains, plasmids and growth conditions. Strains and 
plasmids used in this study are listed in table 1. Lactococcus lactis NZ9000 was 
used as a host for the plasmids. All strains were grown at 30°C in Bacto M17 
broth (Becton Dickinson Difco) supplemented with 0.5% glucose. Where needed 
chloramphenicol (5 µg/mL), erythromycin (5 µg/mL) or both antibiotics (3 
µg/mL) were added to the medium. 
To create the expression strains the plasmids pA13 or pA24 were 
transformed to L. lactis NZ9000 in combination with pILPM1T or pILPTM2, 
respectively, by means of electrotransformation as described previously by Holo 
et al. (18) using a Bio-Rad gene pulser. 
 
 
Table 1: Bacterial strains and plasmids used in this study 
Strain or plasmid Characteristic(s) Source or reference 
strains   
Lactococcus lactis NZ9000 
 
MG1363 derivative; pepN::nisRK+ (19) 
L. lactis LL108 (pORI 208) 
 
Emr Cmr (19, 20) 
L. lactis IFPL105 
 
pBAC105, lacticin 3147 producing 
strain 
(25) 
L. lactis subsp. lactis IL1403 
 
  




pILPTM2 pIL253 derived; ltnT-ltnM2 cloned 
behind the Pnis promoter; Emr 
(17) Kind gift from 
Lanthio Pharma 
pILPM1T pIL253 derived; ltnM1-ltnT cloned 
behind the Pnis promoter; Emr 





pA24 pNZ8048 derived; ltnA2 cloned 
behind the Pnis promoter; Cmr 
(17) Kind gift from 
Lanthio Pharma 
pA13 pNZ8048 derived; ltnA1 cloned 
behind the Pnis promoter; Cmr 
Kind gift from Lanthio 
Pharma 
Emr erythromycin resistance marker 
Cmr chloramphenicol resistance marker 
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SDS-PAGE analysis of LtnM1 and LtnM2. L. lactis NZ9000 cells were 
transformed with pILPM1T & pA13 or pILPTM2 & pA24 and grown overnight in 
GM17. Fresh GM17 was inoculated 1:60 with an overnight culture of the 
expression strain, incubated for 3 hours at 30°C (optical density at 600 nm 
(OD600) between 0.4-0.5) till expression was induced by adding nisin (Sigma-
Aldrich) with an end concentration of 1 ng/mL. After 4 hours of induction cells 
were harvested by centrifugation (16,100 x g for 8 minutes) and cell pellets were 
kept at -20°C. Before the sample was applied to SDS-PAGE the cell pellet was 
lysed by resuspension in 4 mg/mL Lysozyme (Roche) in MilliQ water and 
incubation for 25 min. at 55°C. By means of SDS-PAGE and Coomassie brilliant 
blue staining expression of the lacticin 3147 modification enzymes was assessed. 
 
MALDI-TOF mass spectrometry. L. lactis expression strains were grown 
overnight in GM17 and diluted 50-fold in minimal medium (14). Cultures were 
grown for 3 hours at 30°C before expression was induced by adding nisin 
(Sigma-Aldrich) to an end concentration of 1 ng/mL. After 4 (and 24) hours of 
incubation, the supernatant was collected by centrifugation (20 min. at 3724 x 
g). Peptides were precipitated from the supernatant by the addition of 10% 
trichloroacetic acid (TCA) and incubation on ice for 30 min. Next, the sample was 
spun for 30 min. at 17,000 x g and the pellet was washed with acetone. To 
remove the acetone, the sample was spun 15 min. at 17,000 x g and dried for 5 
min. at 42°C. TCA precipitated material was dissolved in 10 µL MilliQ water, and 
1 µL of the sample was applied to the MALDI-TOF target, dried and washed with 
a drop of MilliQ water. Subsequently, 1 µL of matrix, 5 mg/mL α-Cyano-4-
hydroxycinnamic acid (Sigma-Aldrich) dissolved in 50% acetonitrile and 0,1% 
trifluoroacetic acid (TFA), was added to the sample and dried. MALDI-TOF mass 
spectrometry spectra were recorded with a Voyager DE PRO MALDI-TOF mass 
spectrometer (Applied Biosystems) and analyzed with Data Explorer TM 4.0.0.0 
(Applied Biosystems). 
 
Antimicrobial activity assays. L. lactis expression strains overnight 
grown in GM17 were diluted 60-fold in fresh GM17 medium and incubated at 
30°C until it reached an optical density at 600 nm (OD600) between 0.4-0.6. The 
expression was induced by adding nisin (Sigma-Aldrich) to an end concentration 
of 1 ng/mL. After 4 hours of incubation the cells were removed from the 
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supernatant by centrifugation (20 min. at 3724 x g). The sample was used for 
TCA precipitation as described above. The TCA precipitated material was 
dissolved in GM17, with appropriate antibiotics, to create a 1-time or 4-times 
concentrated sample. 
For the activity assay the 1-time concentrated TCA precipitated samples 
were used to create a two-fold diluted series in a microtiter-plate. These samples 
were overlaid in an one to one ratio with an indicator strain. After 5 hours of 
incubation at 30°C the growth inhibition was measured by measuring the OD600. 
The indicator strains, L. lactis LL108(pORI 280) (19, 20) and L. lactis subsp. 
lactis IL1403, were prepared as followed; an overnight culture of the indicator 
strain was diluted 100-fold in fresh medium and grown at 30°C until OD600 
reached 0.2-0.3 before added to the lanthipeptide samples. 
In addition, the bioactivity was assessed by the use of a well-diffusion 
assay. An overnight culture of the indicator strains was diluted 800-times in 
warm (45°C) 0.7% GM17-agar (with appropriate antibiotics). This was used to 
pour a top layer of 16 mL onto plates containing a layer of 10 mL 1.5% GM17-
agar (with appropriate antibiotics). Wells of 8 mm were formed and a volume of 
50 µL 4-times concentrated TCA precipitated lanthipeptides was dispensed in the 
wells. After one hour incubation at room temperature the plates were placed 





Co-expression of LtnM1, LtnT and LtnA1 in Lactococcus lactis. The 
lantibiotic lacticin 3147 is a so called two-component lantibiotic. It is composed 
out of two structural entities LtnA1 and LtnA2. Both components are modified by 
a dedicated modification enzyme, LtnM1 and LtnM2, respectively, but are 
processed and exported by a single transporter, LtnT. Previously, it was shown 
that the transporter could be expressed in L. lactis NZ9000 and retained its 
export and process function while expressed without the remaining lacticin 3147 
enzymes (Chapter 2). To assess the ability of the enzymes LtnM1 and LtnT to 
modify, process and transport class II lanthipeptides as a generic production 
system, the respective genes were co-expressed with the LtnA1 encoding gene, 
as substrate under control of the nisin promoter, in L. lactis NZ9000. First the 
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expression of LtnM1 in L. lactis NZ9000 by means of SDS-PAGE was assessed. 
cells co-expressing LtnM1, LtnT and its substrate were examined on a Coomassie 
brilliant blue stained SDS-PAGE. The theoretical mass of LtnM1 is 111,749 Da, 
however no protein band suggesting the presence of LtnM1 was seen on SDS-
PAGE (figure 2). When supernatant of the culture was collected, subjected to 
TCA precipitation and analyzed by MALDI-TOF mass spectrometry a product of 
3301.62 Da was yielded (figure 3A) not found with the control strain transformed 
with an empty expression plasmid (data not shown). The unique mass 
corresponds to the theoretical mass of LtnA1 that is seven times dehydrated, 
i.e., 3304.74 Da (21). The absence of detectable LtnM1 on SDS-PAGE indicates a 
low expression level but the MALDI-TOF mass spectrometry data suggest that 
dehydrated and processed LtnA1 was produced when LtnA1, LtnM1 and LtnT are 




Figure 2: Coomassie stained SDS-PAGE comparing cells of L. lactis NZ9000 strains co-expressing 
LtnM1 or LtnM2 with LtnT and the corresponding substrate in comparison to a strain baring empty 
vectors. The arrow indicates the extra protein, LtnM2, just below 100 kDa. 
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Co-expression of LtnM2, LtnT and LtnA2 was described previously by 
Kuipers et al. (17). Plasmids, pILPTM2 and pA24, were used that expresses the 
aforementioned genes in L. lactis NZ9000. Analysis of the cells, co-expressing 
LtnM2, LtnT and LtnA2, on SDS-PAGE showed a clear extra protein just below 
100 kDa (figure 2) not visible in the sample expressing empty vectors. The 
theoretical mass of LtnM2 is 106,377 Da suggesting this extra band is LtnM2. 
The protein runs slightly lower than its calculated mass, this can be explained by 
incomplete denaturation of the protein. Analysis of the culture supernatant by 
means of MALDI-TOF mass spectrometry yielded a peptide with a mass of 
2844.24 Da (figure 3B), not found with the control strain. This mass corresponds 
to the theoretical mass of eight times dehydrated LtnA2, i.e., 2842.28 Da (21), 
suggesting dehydrated and processed LtnA2 was produced. These findings are in 




Figure 3: MALDI-TOF mass spectra of culture media showing the presence of (A) seven times 
dehydrated LtnA1 core peptide at 3301.62 Da (theoretical mass 3304.74 Da) after co-expression of 
LtnA1, LtnM1 and LtnT in L. lactis NZ9000, (B) eight times dehydrated LtnA2 core peptide at 
2844.24 Da (theoretical mass 2842.28 Da) after co-expression of LtnA2, LtnM2 and LtnT in L. lactis 
NZ9000. 
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Activity of separately produced LtnA1 and LtnA2. Since lacticin 3147 
is a two-component lantibiotic, antimicrobial activity is only observed when LtnA1 
and LtnA2 are combined. To further assess if the separately produced LtnA1 and 
LtnA2 yield an active two-component lantibiotic, the individual supernatant 
fractions were concentrated by TCA precipitation and resuspended in MilliQ 
water. A dilution series of LtnA1 and LtnA2 was made using the 96-wells format 
and the antimicrobial activity was tested against two indicator strains, L. lactis 
LL108(pORI 280) and L. lactis subsp. lactis IL1403. As expected, the individual 
LtnA1 or LtnA2 peptide containing fractions did not show any activity (figure 4) 
as the relative growth was at the same level as the negative controls. When the 
LtnA1 and LtnA2 fractions were combined substantial activity against both 
indicator strains was observed (figure 4) consistent with the strict requirement 
for both peptides for bioactivity (21). When the sample is diluted up to 8-times 
the growth of the indicator strains is strongly inhibited and stayed below zero. 
After diluting the sample 16-times the indicator strains slightly regain their ability 
to grow, after 32-times diluting the sample the growth is still mildly inhibited 
compared to the negative controls, while after 64-times diluting the sample the 
concentration of the peptides is too low to inhibit growth. The individually 
produced LtnA1 and LtnA2 are about four times less active compared to natively 
produced lacticin 3147, that can be diluted up to 64-times before the indicator 
strains regain their ability to grow. In addition to the microtiter-plate assay the 
bioactivity was also tested in a well-diffusion assay. Concentrated TCA 
precipitated supernatant samples were added to a well in a plate containing the 
indicator strains. When LtnA1 or LtnA2 were tested alone no inhibition zone was 
seen, whereas combining both samples, a clear inhibition zone was evident 
(figure 5). These findings demonstrate that the separately produced LtnA1 and 




This study explored the potential of LtnM1 and LtnT for the production of 
class II lanthipeptides. These enzymes are normally involved in the modification, 
transport and maturation of LtnA1, which is a subunit of the two-component 
lanthipeptide lacticin 3147. LtnA1 resembles the globular shape of mersacidin, a 
typical class II lantibiotic (21). First it was examined if this system can be used  




Figure 4: Microtiter plate activity assay of the activity of LtnA1 and LtnA2 against Lactococcus lactis 
LL108(pORI 280) (A) and L. lactis subsp. lactis IL1403 (B). The indicator strain was incubated for 
five hours with TCA precipitated supernatant of strains expressing, LtnA1, LtnM1 and LtnT (closed 
squares), LtnA2, LtnM2 and LtnT (closed triangle) or an 1:1 ratio of the two peptide containing 
samples (closed dot). The graph clearly shows that the sample containing both peptides inhibits 
growth of the indicator strains. As a comparison TCA precipitated supernatant of a lacticin 3147 
expressing strain L. lactis IFPL105 (open diamond) was also included. As negative controls TCA 
precipitated supernatant of a strain expressing empty vectors (closed diamond) and TCA 
precipitated growth medium (open squares) was included.  
A
B
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to produce bioactive LtnA1 when expressed in a L. lactis host strain that normally 
does not produce this peptide. The first step in the formation of a 
(methyl)lanthionine bond is the dehydration of serine and threonine, since each 
dehydration reaction causes a weight loss of 18.02 Da, due to the removal of a 
water molecule, MALDI-TOF mass spectrometry can easily be used to make a 
distinction between dehydrated and non-dehydrated peptides. In addition, 
MALDI-TOF mass spectrometry was used to detect if the leader peptide was 
removed by the lantibiotic transporter. Indeed by mass spectrometry, the fully 
dehydrated and processed LtnA1 peptide could be detected in the culture 
supernatant of the expressing strain suggesting that LtnM1 and LtnT are indeed 
able to modify, process and transport LtnA1. 
Since the second step in the (methyl)lanthionine formation, the cyclisation 
via a thioether bond with a free cysteine, does not cause any changes in mass, 




Figure 5: Activity assay of LtnA1 and LtnA2 against Lactococcus lactis LL108(pORI 280) (A) and  
L. lactis subsp. lactis IL1403 (B). The indicator strain was incubated with 4x concentrated TCA 
precipitated supernatant of strains expressing, LtnA1, LtnM1 and LtnT (2), LtnA2, LtnM2 and LtnT 
(3) or an 1:1 ratio of the two peptide containing samples (4). The halo formed at the sample 
containing both peptides clearly shows that LtnA1 and LtnA2 inhibit growth of the indicator strains. 
As a comparison 4x concentrated TCA precipitated supernatant of the lacticin 3147 expressing 
strain L. lactis IFPL105 (5) was also included. As negative controls 4x concentrated TCA 
precipitated supernatant of a strain expressing empty vectors (1) and TCA precipitated growth 
medium (6) was included.   
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solely without further modification and fragmentation. Without the full 
modification, dehydration and cyclization, the lantibiotic is not active, therefor 
the activity assays were used to determine if the separately produced LtnA1 and 
LtnA2 were fully modified and thereby active. The results show that combining 
LtnA1 and LtnA2 they are able to inhibit growth, concluding that they are active 
and the (methyl)lanthionine rings are formed. Interestingly, activity was 
obtained despite the fact that the additional modification, the conversion of L-
serine to D-alanine, by LtnJ was not present. It was previously reported that in 
the absence of LtnJ, a major reduction in activity is observed (22). Figure 4 
shows that the activity of the two separate produced peptides is about four times 
lower than the activity of the wild type produced lacticin 3147. This phenomenon 
could be due to a low production level and/or the absence of the LtnJ 
modification. 
As described before for other lantibiotic modifying enzymes like LtnM2 
(17), NukM (23) and ProcM (24), LtnM1 is able to modify its natural substrate 
without the presence of other lantibiotic enzymes encoded in the lantibiotic gene 
cluster. Therefore LtnM1 and LtnM2 could form interesting targets to be used in 
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Class II lantibiotics are post-translationally modified by a multifunctional 
enzyme, LanM, that catalyzes the dehydration of serine and threonine residues 
as well as thioether bridge formation between these residues and cysteine. To 
examine the promiscuity of the LanM enzyme and the associated transporter 
LanT for the production of class II lantibiotics, the two-component lantibiotic 
lacticin 3147 was studied. The active lantibiotic consists of two structural 
lanthipeptides, LtnA1 and LtnA2 that are modified by LtnM1 and LtnM2, 
respectively. A set of variants of LtnA1 and LtnA2 were created that include 
swapped leader peptides, cysteine to alanine mutants to prevent thioether bridge 
formation and the introduction of factor Xa protease site in LtnA1. The data 
suggest a high specificity of the LtnM1 and LtnM2 systems for their cognate 
substrates, however LtnM2 also allowed production of a Cys-less variant of LtnA1 












Resistance is currently a serious threat during treatment of infectious 
disease. For many of the currently used antibiotics, resistance mechanisms have 
developed that spread among microbes. Therefore, there is an urgent need for a 
new generation of antibiotics based on different chemical structures than those 
that have been employed so far. Lantibiotics are an interesting group of 
antimicrobial peptides with a potential use as antibiotics. Lantibiotics belong to a 
larger group of peptides called lanthipeptides. Lanthipeptides are ribosomal 
synthesized peptides that contain the unusual amino acids meso-lantihionine 
(Lan) and (2S,3S,6R)-3-methyllanthionine (MeLan). These amino acids are 
formed during post-translational modification in which serine and threonine 
residues are dehydrated to form a 2,3-dehydroalanine or (Z)-2,3-
dehydrobutyrine, respectively. The formed dehydroalanine or dehydrobutyrine 
residues are then coupled to a cysteine via a thioether bond to form the 
lanthionine or methyllanthionine rings, respectively. Based on the modification 
enzymes that introduce the (methyl)lanthionine residues, lanthipeptides can be 
divided into four classes (1). Class I and II lanthipeptides are mainly comprised 
of the lantibiotics, lanthionine-containing antibiotics. In class I 
lanthipeptides/lantibiotics, the formation of a lanthionine ring is catalyzed by a 
dehydratase (LanB) and a cyclase (LanC), whereas in class II lantibiotics both 
reactions are catalyzed by a single bifunctional enzyme, LanM. LanM enzymes 
typically contain a N-terminal dehydratase domain, which does not show any 
homology to LanB. The C-terminal domain of LanM contains a cyclase domain 
which has ~25% sequence identity to LanC (1), including the conserved zinc-
binding residues that are necessary for NisC catalysis (2). Class III lanthipeptides 
are modified by a multifunctional synthetase (LanKC) containing a N-terminal 
lyase domain, a central kinase domain and a putative cyclase domain at the C-
terminus (3). Class IV lanthipeptides are also modified by a trifunctional enzyme 
(LanL), with a similar domain organization as found for class III lanthipeptides 
except that the cyclase domain is homologous to LanC (4). Besides the difference 
in the C-terminal cyclase domain, LanKC enzymes can also generate labionin 
structures, formed from two dehydroalanines and a cysteine residue, while LanL 
enzymes only generate lanthionine rings. 
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The genes involved in lantibiotic biosynthesis are usually found in a cluster 
that harbors the gene for the structural peptide (LanA) and the modification 
enzymes (e.g. LanBCM). Lantibiotics may undergo further post-translational 
modifications like decarboxylation (LanD) or the conversion of a L-serine into a 
D-alanine (LanJ). In addition, the clusters encode genes specifying for an ATP-
binding cassette (ABC) transporter (LanT) to excrete the peptide over the 
membrane, a protease to cleave of the leader sequence (LanP), genes encoding 
proteins for self-protection/immunity (LanIFEG) and genes encoding the 
regulation of lantibiotic production (LanKR). The gene, lanA, encodes the linear 
precursor peptide. The N-terminal part of LanA contains a leader peptide that is 
recognized by the modification enzymes and transporter, the C-terminus of LanA 
encodes the core peptide. The core peptide is modified and matures in its final 
active form after leader peptide removal. With class I lantibiotics, maturation 
occurs extracellular by the protease LanP. However with class II lantibiotics a 
bifunctional transporter is responsible for both the maturation and secretion. This 
transporter harbors an intracellular protease domain, thus maturation likely 
precedes excretion. The leader peptide of class II lantibiotics contains an ELxxBx 
motif (B=V, L, I) which usually ends in the double glycine motif, GG, GA or GS/T, 
which distinguishes it from the leader peptide of class I lantibiotics and it is 
believed that this double glycine motif is recognized by the N-terminal peptidase 
C39 domain of the bifunctional transporter. The ELxxBx motif is generally not 
found in the two-component lantibiotics like lacticin 3147, nonetheless they do 
contain the distinctive double glycine motif (5). 
Lantibiotics form an interesting group of peptides that may be used as 
potential new antibiotics. Since lantibiotics are gene encoded and ribosomally 
synthesized they form an advantage over non-ribosomal or polyketide antibiotics 
in bioengineering applications (6). Moreover, until now no known resistance 
against lantibiotics is reported, an example is the lantibiotic nisin that is already 
for over 50 years used as a food preservative without significant development of 
microbial resistance. The antimicrobial activity of only a few lantibiotics has been 
studied extensively, and believed to emerge from inhibiting cell wall biosynthesis, 
disruption of the membrane integrity by forming pores, or by a combination of 
the two mechanisms (1). Lantibiotics are only active against Gram-positive 
bacteria as these peptides cannot pass the outer membrane of Gram-negative 
bacteria. A less desirable property of some lantibiotics is that they can be 
Chapter 4: Specificity of LtnM enzymes and LtnT transporter 
78 
 
susceptible to proteolytic degradation (8) and their solubility can also be limited 
(9). In addition, the presence of dehydrolanines can render the peptide unstable 
unless the pH is low. However this property can be reversed in many cases by 
removing dehydroalanines by mutagenesis without the loss of activity. 
Lanthipeptides are mainly produced by Gram-positive bacteria like, 
Lactococcus, Bacillus, Staphylococcus, Streptococcus, and by some Streptomyces 
species (10, 11). By genome-mining, many genes associated with lanthipeptides 
have been identified. This has expanded the distribution of lanthipeptides also to 
other firmicutes, actionomycetes, bacteroidetes, chlamydiae, proteobacteria and 
cyanobacteria (4, 12-14). The production of these lanthipeptides by their natural 
host is complicated as many of these organisms have not been cultured nor 
genetically characterized while also the expressing conditions are unknown. A 
potential solution for this problem is the development of a heterologous 
expression system to produce new/putative lanthipeptides. Such a system has 
been described for class I lanthipeptides based on the modification enzymes 
(NisBC) and transporter (NisT) of nisin (15-19). These enzymes turned out to be 
sufficiently relaxed in their substrate specificity to also modify and secrete 
unrelated lanthipeptides. However, such a generic system has not yet been 
reported for class II lanthipeptides. 
It was shown before that LtnM2 and LtnT, that specify the modifying 
enzyme and transporter of one of the structural lanthipeptides of the two-
component lantibiotic lacticin 3147 (figure 1), can modify, process and transport 
LtnA2 and unrelated peptides such as nisin and angiotensin variants that are 
fused behind the lacticin A2 leader (20). Also, LtnM1 and LtnM2 when individually 
co-expressed with the transporter LtnT have been shown to modify, process and 
secrete their natural substrates, LtnA1 and LtnA2, respectively (Chapter 3). 
When the individually produced LtnA1 and LtnA2 are combined, an active lacticin 
3147 can be reconstituted. These findings suggest the biosynthesis enzymes of 
lacticin 3147 have the potential to form the basis of a heterologous expression 
system for class II lanthipeptides. This study has examined the specificity of 
LtnM1 and LtnM2 towards potential substrates and explored the possibility to use 
these enzymes for the development of such a generic class II lanthipeptide 
production system.  




Figure 1: Shorthand notation of mature LtnA1 and LtnA2 of the two-component lantibiotic lacticin 
3147 (after the example from Cotter et al. (34)). The modified residues are marked in gray. 
 
 
Material and Methods 
 
Bacterial strains, plasmids and growth conditions. Strains and 
plasmids used in this study are listed in table 1. Lactococcus lactis NZ9000 was 
used as a host for the plasmids. All strains were grown at 30°C in Bacto M17 
broth (Becton Dickinson Difco) supplemented with 0.5% glucose. Where needed 
chloramphenicol (5 µg/mL), erythromycin (5 µg/mL) or both antibiotics (3 
µg/mL) were added to the medium. Escherichia coli was cultured at 37°C in LB 
Broth (Lennox) (Carl Roth) and supplemented with ampicillin (50 µg/mL). 
 
Molecular cloning and plasmid construction. Plasmid construction was 
carried out using standard genetic methods (21). For PCR, Phusion High-Fidelity 
DNA Polymerase was used and all restriction and DNA modifying enzymes were 
purchased from Thermo Scientific. All constructs were validated by sequence 
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analysis performed at Macrogen Europe. PCR primers used in this study are listed 
in table 2. 
 
 
Table 1: Bacterial strains and plasmids used in this study 
Strain or plasmid Characteristic(s) Source or reference 
Strains 
Lactococcus lactis NZ9000 MG1363 derivative; pepN::nisRK+ (23) 
Escherichia coli DH5α   
L. lactis LL108 (pORI 208) Emr Cmr (23, 24) 
L. lactis IFPL105 pBAC105, lacticin 3147 producing strain (32) 
L. lactis subsp. lactis IL1403   
Plasmids 
pIL253 Emr (33) 
pILPltnT-2 pIL253 derived; ltnT-ltnM2 cloned behind the 
Pnis promoter, disruption of ltnM2 by BglII 
digestion; Emr 
Kind gift from Lanthio 
Pharma. (20) 
pILPM1T pIL253 derived; ltnM1-ltnT cloned behind the 
Pnis promoter; Emr 
Kind gift from Lanthio 
Pharma 
pILPTM2 pIL253 derived; ltnT-ltnM2 cloned behind the 
Pnis promoter; Emr 
Kind gift from Lanthio 
Pharma. (20) 
pNZ8048 Cmr (23) 
pA13 pNZ8048 derived; ltnA1 cloned behind the 
Pnis promoter; Cmr 
Kind gift from Lanthio 
Pharma 
pA24 pNZ8048 derived; ltnA2 cloned behind the 
Pnis promoter; Cmr 
(20) 
pMA38 Plasmid containing synthetic DNA of leader 
peptide LtnA1(-29 to -1)::LtnA2(1 to 29) 
behind the Pnis promoter, BglII and HindIII 
restriction sites, Ampr 
Mr. Gene GmbH 
pMA39 Plasmid containing synthetic DNA of leader 
peptide LtnA2(-36 to -1)::LtnA1(1 to 30) 
behind the Pnis promoter, BglII and HindIII 
restriction sites, Ampr  
Mr. Gene GmbH 
pA38 pNZ8048 derived; leader peptide LtnA1(-29 
to -1)::LtnA2(1 to 29) behind the Pnis 
promoter; Cmr 
This study 
pA39 pNZ8048 derived; leader peptide LtnA2(-36 
to -1)::LtnA1(1 to 30) behind the Pnis 
promoter; Cmr 
This study 
pA13-xa1 pNZ8048 derived; leader peptide LtnA1(-29 
to -5)::IDGR::LtnA1(1 to 30) behind the Pnis 
promoter; Cmr 
This study 
pA13-xa2 pNZ8048 derived; leader peptide LtnA1(-29 
to -1)::IDGR::LtnA1(1 to 30) behind the Pnis 
promoter; Cmr 
This study 
pNZ-A62 pNZ8048 derived; LtnA1(C-less) behind the 
Pnis promoter; Cmr 
This study 
pNZ-A72 pNZ8048 derived; LtnA2(C-less) behind the 
Pnis promoter; Cmr 
This study 
pNZ-A82 pNZ8048 derived; leader peptide LtnA1(-29 
to -1)::LtnA2(1 to 29)(C-less) behind the 
Pnis promoter; Cmr 
This study 
pNZ-A92 pNZ8048 derived; leader peptide LtnA2(-36 
to -1)::LtnA1(1 to 30)(C-less) behind the 
Pnis promoter; Cmr 
This study 
Emr erythromycin resistance marker 
Cmr chloramphenicol resistance marker 
Ampr ampicilin resistance marker 
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Plasmid pA13 (kind gift form Lanthio Pharma) is derived from pNZ8048 
and contains the ltnA1 gene cloned behind the Pnis promoter. This plasmid was 
used to create pA13-xa by mutagenesis PCR wherein the last four amino acids 
(VFGA) of the LtnA1 leader sequence were replaced with the factor Xa protease 
site (IDGR). Likewise, pA13-xa2 was generated by a mutagenesis PCR inserting 
the factor Xa protease site in between the LtnA1 leader sequence and core 
peptide. To determine if the factor Xa protease site encoding sequence was 
inserted correct a sequence analysis was performed by Macrogen Europe. 
pA38 and pA39 were created by replacing the Pnis promotor and the LtnA1 
encoding sequence of pA13 using the BglII and HindIII restriction sites by the 
chimeric products containing the Pnis promoter followed by LtnA1(-29 to 
-1)::LtnA2(1 to 28) or LtnA2(-36 to -1)::LtnA1(1 to 30) using synthetic 
fragments of DNA that were obtained from Mr. Gene GmbH. 
For the creation of pNZ-A62, pNZ-A72, pNZ-A82 and pNZ-A92, that harbor 
cysteine less core peptide encoding sequences, synthetic constructs were 
ordered at GeneArt (Life Technologies). The plasmid DNA supplied by GeneArt 
was used in a PCR to amplify the region containing the Cys-less peptides. The 
PCR-products were digested using HindIII and NcoI and subsequently ligated into 
HindIII and NcoI digested pNZ8048. The resulting plasmid was subjected to 
mutagenesis PCR to remove the extra start codon from the NcoI restriction site. 
All constructs were verified by DNA sequence analysis by Macrogen Europe. 
Constructs were transformed to L. lactis NZ9000 in combination with 
pILPltnT-2 (20), pILPM1T (kind gift form Lanthio Pharma) or pILPTM2 (20) by 
means of electrotransformation as described previously by Holo et. al. (22) using 
a Bio-Rad gene pulser. 
 
MALDI-TOF mass spectrometry. L. lactis expression strains were grown 
overnight in GM17 and diluted 50-fold in minimal medium, this medium was 
prepared as described by Rink et al. (19) or else the vitamin mix was replaced by 
BME Vitamins (Sigma). Cultures were grown for 3 hours at 30°C before 
expression was induced by adding 1 ng/mL nisin (Sigma-Aldrich). After 24 (and 
4) hours of incubation, the supernatant was collected by centrifugation (20 
minutes at 3724 x g). A sample of 1 µL of the supernatant was applied to the 
MALDI-TOF target, dried and washed with a drop of MilliQ water. Subsequently 1 
µL of matrix, 5 mg/mL α-Cyano-4-hydroxycinnamic acid (Sigma-Aldrich) 
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dissolved in 50% Acetonitrile and 0,1% trifluoroacetic acid (TFA), was added to 
the sample and dried. 
In addition, peptides were precipitated from the supernatant by the 
addition of 10% trichloroacetic acid (TCA) and incubation on ice for 30 min. Next, 
the sample was spun for 30 min. at 17,000 x g and the pellet was washed with 
acetone. To remove the acetone, the sample was spun 15 min. at 17,000 x g and 
dried for 5 min. at 42°C. TCA precipitated material was dissolved in 10 µL MilliQ 
water, and 1 µL of the sample was applied to the MALDI-TOF target, dried, 
washed and treated as described above. 
MALDI-TOF mass spectrometry spectra were recorded with a Voyager DE 
PRO MALDI-TOF mass spectrometer (Applied Biosystems). The recorded spectra 
were analyzed with Data Explorer TM 4.0.0.0 (Applied Biosystems). An external 
calibration was used to correct the resulting spectra. 
 
 
Table 2: Primers used in this study 
Primer name Primers sequence 
(5’-3’) 
Characteristics 
   
001-fw ATTGACGGCCGTTGTAGTACTAACACATTCTCGCTCAGTG Phosphorylated 5’-end, encoding 
factor Xa protease site 
002-rv ATCTTCATCAAAATTTTGATCAGATACTTCTT Phosphorylated 5’-end, reversed 
primer for factor Xa protease 
site introduction 
022-rv CGCACCAAATACATCTTCATC reversed primer for factor Xa 
protease site introduction 
019-fw TAATACGACTCACTATAGGGC Forward primer for amplifying 
Cys-less lantibiotic gene from 
synthetic construct supplied by 
GeneArt 
020-rv GACAGGTTTCCCGACTGGAAAG reversed primer for amplifying 
Cys-less lantibiotic gene from 
synthetic construct supplied by 
GeneArt 
170-rv GGTGAGTGCCTCCTTATAATTTATTTTG Phosphorylated 5’-end, reversed 
primer for removing extra start 
codon in Cys-Less constructs 
171-fw ATGAACAAAAATGAAATTGAAACACAAC forward primer for removing 
extra start codon in Cys-Less 
constructs encoding Ltn1 leader 
peptide 
172-fw ATGAAAGAAAAAAATATGAAAAAGAATG forward primer for removing 
extra start codon in Cys-Less 
constructs encoding Ltn2 leader 
peptide 
ATCG sequence encoding factor Xa protease site. 
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Antimicrobial activity assay. L. lactis expression strains overnight 
grown in GM17 were diluted 60-fold in fresh GM17 medium and incubated at 
30°C until it reached an optical density at 600 nm (OD600) between 0.4-0.6. The 
expression was induced by adding nisin (Sigma-Aldrich) to an end concentration 
of 1 ng/mL. After 4 or 24 hours of incubation the cells were removed from the 
supernatant by centrifugation (20 min. at 3724 x g). The supernatant was 
subjected to TCA precipitation as described above, and the pellet was dissolved 
in GM17, with appropriate antibiotics, as a one-fold concentrated sample. 
The concentrated TCA precipitated samples were used to create two-fold 
diluted series in a microtiter-plate. These samples were overlaid in an one to one 
ratio with an indicator strain. After 5 hours of incubation at 30°C the growth 
inhibition was measured by measuring the OD600. The indicator strains, L. lactis 
LL108(pORI 280) (23, 24) and L. lactis subsp. lactis IL1403, were prepared as 
followed; an overnight culture of the indicator strain was diluted 100-fold in fresh 





Substrate promiscuity of the LtnM1 and LtnM2 systems. The 
secondary structure of the two individual entities of the two-component 
lantibiotic lacticin 3147 differ. The mature LtnA1 resembles the globular shape of 
mersacidin, a typical class II lantibiotic, while LtnA2 resembles the elongated 
shape of nisin, a class I lantibiotic (25). Previously, it was shown that co-
expression of LtnM1 and LtnT in L. lactis NZ9000, results in the complete 
modification and export of LtnA1. In addition, co-expression of LtnM2 and LtnT 
support the modification and export of LtnA2. When these two peptides are 
combined, an active antimicrobial lacticin 3147 is obtained (Chapter 3). However, 
it is unknown if LtnM1 can modify LtnA2 or reversely, if LtnM2 can modify LtnA1. 
For this purpose LtnA2 was co-expressed with LtnM1/LtnT in L. lactis NZ9000, 
and the supernatant of the expressing strain was analyzed by MALDI-TOF mass 
spectrometry for the presence of mature LtnA2. Compared to a control bearing 
the empty vectors, no masses could be found that can be attributed to LtnA2. 
Likewise, when LtnA1 was co-expressed with LtnM2/LtnT, no production of LtnA1  
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could be demonstrated. This suggests that LtnM1 and LtnM2 are equipped with a 
high degree of substrate specificity. 
Possibly, the apparent substrate specificity arises from a defective in the 
targeting of the structural peptides to the LtnM modifying enzymes as the leader 
peptides of LtnA1 and LtnA2 differ in amino acid sequence (table 3). Both leader 
peptides are typical for class II lanthipeptides as they contain the double glycine 
motif. Therefore, the leader peptides of LtnA1 and LtnA2 were swapped creating 
peptides containing the LtnA2 core peptide fused behind the LtnA1 leader peptide 
(LtnA1-A2) and a peptide containing the LtnA1 core peptide fused behind the 
LtnA2 leader peptide (LtnA2-A1) (for peptide sequence see table 3). The fusion 
peptides were co-expressed with LtnM1/LtnT and LtnM2/LtnT, and concentrated 
supernatant of the expression cultures was analyzed by MALDI-TOF mass 
spectrometry for the presence of the unprocessed and/or mature peptides. In 
none of the combinations peptides could be detected. Also, bioactivity assays did 
not reveal the presence of active peptides. This further suggests a high substrate 
specificity of LtnM1 and LtnM2 being active towards their own structural 
lanthipeptide only. 
 
Substrate promiscuity of the LtnT transporter. The lacticin 3147 
transporter, LtnT, transports both LtnA1 and LtnA2 across the membrane. This 
implies a less stringent substrate specificity as compared to the modifying 
enzymes. To test if LtnT can process and transport the fusion peptides, they 
were co-expressed in L. lactis NZ9000 without the cognate LtnM enzymes. This 
yielded no peptide products suggesting that LtnT may only secrete the modified 
peptides or that there might be a functional link between LtnT and the modifying 
enzymes. To examine this phenomenon in more detail, the expression studies 
were performed in the presence of the respective LtnM enzymes but to prevent 
full modification, all cysteine residues in the core peptides of LtnA1 and LtnA2 
were replaced by alanine residues, LtnA1(C-less) and LtnA2(C-less) (table 3). 
Thus, in these peptides it is no longer possible to introduce thioether bridges 
albeit dehydration can still occur. First it was examined if LtnT is able to export 
the Cys-less LtnA1 and LtnA2 by co-expression in L. lactis NZ9000. However, no 
peptide products could be detected by MALDI-TOF mass spectrometry in the case 
of Cys-less LtnA2, while with Cys-less LtnA1, a specific mass was detected at 
 





Figure 2: MALDI-TOF mass spectra of culture media showing the presence of (A) unmodified Cys-
less LtnA1 core peptide at 3299.30 Da after co-expression of LtnA1(C-less) and LtnT in L. lactis 
NZ9000, (B) unmodified Cys-less LtnA1 core peptide at 3298.99 Da after co-expression of fusion 
peptide LtnA2-A1(C-less) and LtnT in L. lactis NZ9000, (C) unmodified Cys-less LtnA1 core peptide 
at 3293.36 Da after co-expression of LtnA2-A1(C-less), LtnM2 and LtnT in L. lactis NZ9000. 
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3299.30 Da (figure 2A) that was not present in the supernatant of the control 
strain that bears the empty vectors. This mass corresponds closely to that of the 
unmodified but processed Cys-less LtnA1 with a predicted mass of 3301.50 Da. 
In addition, in the supernatant of a strain co-expressing LtnT and the chimeric 
Cys-less LtnA1-A2, no peptides were found. Although, in the supernatant of a 
strain co-expressing LtnT and the chimeric Cys-less LtnA2-A1, a mass of 3298.99 
Da was detected (figure 2B) that corresponds to unmodified and processed Cys-
less LtnA1 core peptide. These results suggest that LtnT is able to transport and 
process Cys-less LtnA1 even when fused behind the leader peptide of LtnA2, and 
that there is no functional link with LtnM1 per se. 
Next, the supernatant of L. lactis NZ9000 strains co-expressing 
LtnM1/LtnT in combination with LtnA1(C-less) and LtnA1-A2(C-less) were 
analyzed by MALDI-TOF mass spectrometry. None of these conditions yielded 
any of the expected peptides. Also, co-expression of LtnM2/LtnT with LtnA2(C-
less), did not give rise to produced peptides whereas LtnA2-A1(C-less) 
expression yielded a product with a unique mass of 3293.36 Da (Figure 2C), 
which matches the theoretical mass of non-dehydrated but processed Cys-less 
LtnA1, 3301.50 Da as described above. These results indicate that LtnM2/LtnT is 
not able to modify Cys-less LtnA1 but that it is able to process and transport the 
Cys-less peptide behind the leader peptide of LtnA2. Apparently, part of the 
specificity of LtnM2 is leader peptide dependent. 
 
Modification of the LtnA1 leader peptide. The above system allows for 
the production of an active and maturated lantibiotic as LtnT removes the leader 
peptide during transport. However, for the production of uncharacterized 
lanthipeptides it will be necessary to generate an inactive form that in a further 
processing step can be activated to the mature lanthipeptide as otherwise growth 
of the production strain might be inhibited. A possible strategy to achieve this 
goal is to replace the double glycine motif of the leader peptide with a specific 
protease site so the leader peptide can be removed in vitro. With nisin, a factor 
Xa site could be introduced in between the leader and core peptide without 
disturbing modification by NisB/NisC and transport by NisT (26). Therefore, a 
factor Xa protease site (IDGR) was placed between the leader and core peptide 
of LtnA1 and in another approach, the last four amino acids of the leader peptide 
were replace by the same cleavage site (for peptide sequence see table 3). The 
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plasmids encoding the cleavage site containing peptides were co-expressed with 
LtnM1/LtnT. When the supernatant was screened with MALDI-TOF MS no 
peptides were detected nor could antimicrobial activity be detected in a 
bioactivity assay where the supernatant fraction was combined with LtnA2. These 
results suggest that the LtnM1/LtnT system cannot accommodate the production 
of cleavage site modified LtnA1 peptides. 
To assess if LtnT alone is able to export the cleavage site modified LtnA1 
peptides, LtnT was co-expressed with either LtnA1-xa1 or LtnA1-xa2 in L. lactis 
NZ9000. After co-expression supernatant of the expression cultures was 
examined by MALDI-TOF mass spectrometry for the presence of unprocessed 
LtnA1-xa1 or LtnA1-xa2. However, no peptides were detected. These results 
suggest that the presence of the double glycine motif in the leader peptide is 




Novel antibiotic substances are necessary in the battle against multi drug 
resistances. For many antibiotics of biological origin, it is difficult to modify them 
as their production usually is a multi-enzymatic processes. Lantibiotics are 
ribosomal synthesized and gene-encoded and therefore more susceptible to 
bioengineering. Bioengineering with biosynthesis enzymes of lantibiotics could 
give rise to a novel antibiotic peptide. For that reason, lanthipeptide modification 
enzymes with broad substrate specificity need to be found. Previously, it was 
shown that LtnT is able to process and translocate LtnA1 and LtnA2 (Chapter 2). 
When introducing LtnM1 or LtnM2 to the production system, modified processed 
and active LtnA1 or LtnA2 is produced, respectively (Chapter 3). In this study, 
the focus was on determining if LtnM1, LtnM2 and LtnT can be possible 
candidates to be used in a generic class II lanthipeptide production system. The 
next question was to determine if LtnA1 and LtnA2 could be modified by their 
counterparts modification enzyme since lacticin 3147 has two distinct 
modification enzymes for each of these substrates (27). However, no peptides 
related to LtnA1 or LtnA2 were observed by MALDI-TOF mass spectrometry 
analysis. These findings suggest that the modification enzymes are highly 
specific, but alternatively, this specificity may relate only to the targeting or 
activation of LtnM as the two peptides bear different leader peptides. In addition, 
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the absence of peptides in the supernatant suggests that the presence of the 
modification enzymes prevent the export of the peptides since previous results 
show that the transporter is able to export and process the unmodified peptides 
(Chapter 2). Furthermore, these data suggest a functional link between the 
modification enzymes and the transporter. 
To investigate the substrate specificity of LtnM1 and LtnM2 system further, 
the leader peptides of LtnA1 and LtnA2 were swapped and tested for production. 
However, in this case no peptides could be detected. This suggests a high 
specificity of the LtnM1 and LtnM2 enzymes. Previously, it was shown that LtnM2 
is able to modify LtnA2 unrelated peptides when fused behind the LtnA2 leader 
peptide (20). LtnA1 resembles the globular structure of mersacidin and LtnA2 
resembles the elongated structure of nisin (25). Possibly, the respective LtnM 
enzymes can only handle core peptides with a similar overall structure. To 
examine this phenomenon in further detail, we also expressed variants of LtnA1 
and LtnA2 lacking all cysteine residues. Such peptides can still be dehydrated but 
thioether linkages can no longer be formed. Thus, such peptides are essentially 
unstructured. Also, this did not lead to the production of (high levels) of peptide 
except when LtnT or LtnM2/LtnT was co-expressed with a LtnA2-A1(C-less). This 
yielded a processed but unmodified Cys-less variant of LtnA1. This observation is 
in line with the results of Kuipers et.al. (20) who showed that LtnM2 is able to 
modify LtnA2 unrelated peptides when fused to the LtnA2 leader peptide. 
However, it is unclear why LtnM2/LtnT did not produce the Cys-Less LtnA2 fused 
to its native leader peptide. In addition co-expression of LtnT with Cys-less LtnA1 
revealed the presence of the processed Cys-less LtnA1 core peptide. The fact 
that not all dehydrated residues in the wild type lacticin 3147, namely Thr3 and 
Thr5 of LtnA1 and Thr2 and Thr5 of LtnA2 (figure 1), are used in a next 
modification suggest that the modification enzymes are also able to only 
dehydrate residues. Since LtnT was able to process and export Cys-less LtnA1, 
with LtnM1 a processed and at least two times dehydrated Cys-less LtnA1 would 
be expected. However no peptide was detected, suggesting that the presence of 
LtnM1 restricts the peptide production. This phenomenon was also observed by 
Cotter et al. (28), who was unable to detect alanine-substituted peptides, such 
as LtnA1C29A, LtnA2C20A, LtnA2C25A and LtnA2C29A. It is unclear if the lack of 
peptide production is due to an deficiency in modification or blockage of 
exportation. 
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Lantibiotics are active only after the removal of the leader peptide. In class 
II Lantibiotics, processing involves a N-terminal peptidase domain that is present 
in the LanT transporter. When the lanthipeptide modifying system is introduced 
in a heterologous host for the production of unrelated and uncharacterized 
lantibiotics, it is not desirable that the putative lantibiotic is produced in an active 
form as this may kill the production strain. To overcome this problem with the 
class I lantibiotics production system based on the NisBC and NisT system, a 
protease site has been introduced into the leader peptide sequence that can be 
specifically cleaved by a protease using a post-production processing step. This 
was successful with the factor Xa processing site, which is a short and specific 
amino acid sequence recognized by the factor Xa protease (26). Using the same 
approach for the production of unprocessed LtnA1 failed. Either the introduction 
of the factor Xa protease site in between the leader and the core peptide or 
replacing the last four amino acids of the leader peptide by the specific IDGR 
sequence completely blocked the production of LtnA1. Unfortunately, in this 
experimental setup it is not possible to determine at which stage production was 
stopped. It could well be that there is intracellular accumulation of the 
dehydrated peptide because transport is blocked or modification is not taking 
place due to substrate specificity of LtnM1. The leader peptide of LtnA1 contains 
the double glycine motif (i.e., Gly-Ala) at its C-terminus. Site-directed 
mutagenesis studies showed that the presence of the double glycine motif is 
essential for the proteolytic removal of the leader peptide by LanT (29, 30), but 
such modifications did not interfere with the post-translational modifications of 
the core peptide (31). It seems that the LtnM1/LtnT system is highly specific and 
disruption of the double glycine motif or modification of the C-terminal region of 
the leader peptide, interferes with production and maturation and this severely 
limits the use of LtnM1/LtnT as a generic production system of class II 
lantibiotics. 
Overall it can be concluded that the modification enzymes and the 
transporter are relatively specific, and that modifications in the substrate peptide 
readily result in a loss of production. Therefore, LtnM1, LtnM2 and LtnT are not 
suitable candidates to be used in bioengineering and the development of a class 
II lanthipeptide production system. Further insight is needed in the mechanism 
LanM enzymes employ to introduce (methyl)lanthionine residues and the 
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substrate recognition by these enzymes before they could be used for the 
bioengineering of lantibiotics. 
 
 
Table 4: Schematic overview of detected peptides, by means of MALDI-TOF mass spectrometry, in 
supernatant of L. lactis NZ9000 co-expressing LtnT, LtnM1/LtnT or LtnM2/LtnT in combination with 
the indicated substrate variants. 
 
 ltnT LtnM1/LtnT LtnM2/LtnT 
 
Wild type peptides 
 
LtnA1 3424.59 Da * 3301.62 Da * X 
 




LtnA1-A2 X X X 
 
LtnA2-A1 X X X 
 
Cysteine less peptides 
 
LtnA1(C-less) 3299.30 Da X N/A 
 
LtnA2(C-less) X N/A X 
 
LtnA1-A2(C-less) X X N/A 
 
LtnA2-A1(C-less) 3298.99 Da N/A 3293.36 Da 
 
Factor Xa containing peptides 
 
LtnA1-xa1 X X N/A 
 
LtnA1-xa2 X X N/A 
1234.56 Da monoisotopic mass (M+H)+ of detected the peptides 
X no peptide detected by MALDI-TOF MS. 
N/A not applicable/not determined 
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Lantibiotics contain the unusual amino acids lanthionine or 
methyllanthionine, which are introduced post-translationally by lantibiotic 
synthetases. Many of these peptides act as antimicrobial agents. In class II 
lantibiotics the synthetase, LanM, is a bifunctional enzyme that performs both 
the dehydration of serine and threonine residues as well as the cyclization 
reaction that connects the dehydrated residue to a cysteine forming the thioether 
rings. To examine the potential of these modification enzymes in bioengineering 
of peptides, two such synthetase enzymes, MutM and LtnM2, were 
heterologously expressed in E. coli and their substrate specificity was explored. 
In the presence of MutM and LtnM2, fully dehydrated MutA and LtnA2 could be 
detected. When the native leader peptide of LtnA1, NisA, or LtnA2 was replaced 
by the leader peptide of MutA or LtnA2, MutM and LtnM2 supported various 
degrees of dehydration. These results suggest that the modification enzymes 












Lanthipeptides are ribosomally synthesized and post-translationally 
modified peptides (RiPPs) that contain lanthionine or methyllanthionine residues. 
Lantibiotics, lanthionine-containing antibiotic peptides (1), are a subclass of 
lanthipeptides that exhibit antimicrobial activity. The production of lantibiotics is 
specified by gene clusters that can be found on plasmids, conjugative 
transposable elements or on the chromosome of the producing organism (2). The 
precursor peptide, encoded by lanA, can be divided in two parts, the N-terminal 
leader peptide and the C-terminal core peptide that is post-translationally 
modified. The biosynthetic gene cluster also contains genes encoding the 
modification enzymes, e.g. lanB, lanC, lanM lanD and lanJ, a transporter, lanT, a 
protease, lanP, proteins for immunity, e.g. lanI, lanH, lanEFG, and regulatory 
genes, lanR, lanK. 
A lanthionine or methyllanthionine residue is formed by the dehydration of 
serine and threonine residues. The resulting dehydroalanine (Dha) and 
dehydrobutyrine (Dhb) residues, respectively, are then coupled to a cysteine via 
a thioether bond. Based on the modification enzymes that introduce these 
modifications, lantibiotics can be divide in two classes (3, 4). In class I, including 
nisin as the paradigm, the dehydration is performed by the dehydratase LanB 
and the cyclization is catalyzed by a cyclase termed LanC. In class II lantibiotics, 
like mutacin II, there is a bifunctional modification enzyme, LanM, that performs 
both the dehydration and cyclization reaction. The cyclase domain of LanM shows 
homology to the LanC cyclase enzymes. However the N-terminal dehydratase 
domain does not show significant sequence identity with LanB (5). 
Class I and II lantibiotics further differ in the mechanisms by which 
transport and processing of the precursor peptide occurs. In class I lantibiotics, 
the modified precursor peptides are transported across the membrane and 
thereafter processed by an extracellular protease (LanP) releasing the mature 
peptide. With class II lantibiotics, export and processing is done by a bifuntional 
transporter (LanT). The transporter contains an N-terminal intercellular C39 
peptidase domain that removes the leader peptide concomitant with transport 
across the membrane. The leader peptides of class II lantibiotics contains a 
double glycine motif, GG, GA, GS or GT, at position -2 and -1 from the cleavage 
site, which is recognized by the C39 peptidase domain. 
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Lantibiotics exhibit antimicrobial activity mostly against Gram-positive 
bacteria. Gram-negative bacteria are usually not affected as the lantibiotics 
cannot permeate the outer membrane. Lantibiotics interfere with cell wall 
biosynthesis via binding to lipid II and/or disrupt the membrane integrity by pore 
formation. Since lipid II is the target, which is an essential intermediate in cell 
wall biosynthesis, there is only a low probability of generating resistance. In 
addition, (methyl)lanthionine residues are believed to increase the biostability 
and resistance against proteolytic degradation (6, 7), making them an interesting 
substance as antimicrobial agents. 
The lantibiotic biosynthesis genes may be used for bioengineering in order 
to design new antimicrobial peptides or by providing existing peptides with a 
novel activity or biostability. Multiple studies showed that lantibiotic modification 
enzymes can be used for this purpose when expressed in L. lactis, e.g. NisB, 
NisC and NisT (8), LtnM2 and LtnT (9), LtnM1 and LtnT (Chapter 2) or nukacin 
ISK-1 (10). A heterologous expression system in E. coli could be an advantage 
over a production system such as L. lactis using the versatility of the genetic 
systems, the potential for high throughput applications as well as the 
insensitivity towards the expressing strain. Some examples of lanthipeptides that 
are heterologous expressed in E. coli are nukacin ISK-1 (11), nisin, prochlorosins 
and haloduracin (12). Here, mutacin II and the β-peptide of lacticin 3147 were 
co-expressed with their corresponding modification enzymes in E. coli to examine 
if these class II lantibiotics can be produced in this heterologous host. In 
addition, the substrate specificity of the modification enzymes, MutM and LtnM2 
was studied. 
 
Material and methods 
 
Bacterial strains and growth conditions. Strains and plasmids used 
are listed in table 1. Escherichia coli DH5α was used for cloning and maintenance 
of plasmids. E. coli BL21 (DE3) was used as an expression host. Cells were 
cultured in Luria Broth (LB), and depending on the plasmid, supplemented with 
kanamycin (30 µg/ml) and/or ampicillin (50 µg/ml). Streptococcus mutans T8 
(Kind gift from Department of Microbial Genomic, Université Laval, Québec QC 
Canada) was grown in trypton soya broth (Oxoid) at 37°C. 
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Table 1: List of strains and plasmids used in this study 
 Characteristics reference 
Strains   
E. coli DH5α Used for cloning and plasmid 
maintenance 
 
E. coli BL21 (DE3) 
 
Used for protein expression  
Streptococcus mutans T8 Strain containing mutacin II gene 
cluster 
Kind gift from the Department of 
Microbial Genomic, Université 
Laval, Québec QC Canada 
Plasmids   
pETDuet-1 Ampr; contains two multiple 
cloning sites (MCS) under control 
of T7lac promoter 
Novagen 
pETD-LtnM2a Ampr; pETDuet-1 derived; ltnM2 
cloned in MCS2 
This study 
pETD-MutM Ampr; pETDuet-1 derived; mutM 
cloned in MCS2 
This study 
pRSFDuet-1 Kanr; contains two multiple 
cloning sites (MCS) under control 
of T7lac promoter 
Novagen 
pRSFD-ltnA2-M2a Kanr; pRSFDuet-1 derived; ltnA2 
cloned in MCS1, ltnM2 cloned in 
MCS2 
This study 




pRSFD-mutA-M Kanr; pRSFDuet-1 derived; mutA 
cloned in MCS1, mutM cloned in 
MCS2 
This study 
pRSFD-mut-LtnA1-b Kanr; pRSFDuet-1 derived; 
mutA(1-26)::LtnA1(30-59) 
cloned in MCS1 
This study 




pRSFD-mut-LtnA2 Kanr; pRSFDuet-1 derived; 
mutA(1-26)::LtnA2(37-65) 
cloned in MCS1 
This study 
Kanr: kanamycin resistance gene 
Ampr: ampicillin resistance gene 
 
 
Construction of plasmids. Molecular cloning was performed using 
standard procedures (13). Phusion High-Fidelity DNA Polymerase for PCR, 
restriction and DNA modifying enzymes were all purchased from Thermo 
Scientific. Primer sequences for the PCR reactions are listed in table 2 and 
supplementary table 2. 
To create pRSFD-mutA-M, genes encoding mutA and mutM from S. 
mutans T8 were amplified by PCR and cloned into the multiple cloning sites 
(MSC) 1 and 2 of pRSFDuet-1 (Novagen), respectively (for details see 
supplementary information). To create pETD-mutM the PCR product of mutM was 
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cloned into EcoRV and XhoI digested pETDuet-1 (Novagen) (see supplementary 
information). 
To create pRSFD-mut-LtnA1-b and pRSFD-mut-NisA-b synthetic constructs 
containing MutA(-26 to -1)::LtnA1(1 to 30) or MutA(-26 to -1)::NisA(1 to 34) 
with a BamHI restriction site 5’-end and a HindIII restriction site 3’-end were 
ordered from GeneArt (Life Technologies). The synthetic DNA was used as 
template in a PCR, the PCR product was treated with BamHI and HindIII and 
placed in MCS 1 of pRSFDuet-1. Subsequently the resulting plasmids were 
subjected in mutagenesis PCR to place the fusion gene in frame behind the six 
histidine tag sequence. To create pRSFD-mut-ltnA2 a synthetic construct was 
ordered from GeneArt (Life Technologies) containing MutA(-26 to -
1)::IDGR::LtnA2(1 to 29) with a BamHI restriction site 5’-end and a HindIII 
restriction site 3’-end of the fusion gene. The gene was amplified by PCR and 
cloned in MCS 1 of pRSFDuet-1. The resulting plasmid was used in mutagenesis 
PCR to remove the factor Xa protease site (IDGR). All the clones were analyzed 
by DNA sequence analysis at Macrogen Corporation. 
 
Table 2: Primers used in this study 
Primer Sequence (5’-3’) Characteristics 
   
19-fw 
 








CAGCCAGGATCCGATGAATAAACTG Placing fusion gene, mut-
ltnA1 and mut-nisA in frame 
behind His6-tag 
152-mut-ltna1-rv CAGTTTATTCATCGGATCCTGGCTG Placing fusion gene, mut-
ltnA1 and mut-nisA in frame 
behind His6-tag 
149-mut-ltna2-rv ACCACCCAGAATGGTATCCAG Phosphorylated 5’-end, 




ACCACTCCGGCAACACC primer to remove factor Xa-
site 
063-pA24-fw AGCTGGATCCGATGAAAGAAAAAAATATGAAAAAGAATG introduction BamHI site 5’-
end of ltnA2 
064-pnz-3-rv CTTATGGGATTTATCGAAAGCTTG introduction HindIII site 3’-











introduction XhoI site 3’-end 
of ltnM2 
146-ltna2-muta-rv ACCACCATGGCTTTCATCAC Phosphorylated 5’-end, 
forward primer to remove 
factor Xa-site 
148-ltna2-nisa-fw ATTACCAGCATTAGCCTGTGTAC Reverse primer to remove 
factor Xa-site 
ATCG marking the sequence of the corresponding restriction site. 
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For the construction of pRSFD-LtnA2-M2, pA24 (chapter 2, kind gift from 
Lanthio Pharma (9)) harboring the gene ltnA2 was used as a template to amplify 
ltnA2 with a BamHI restriction site 5’-end and HindIII restriction site 3’-end. The 
PCR product was cloned in the MCS 1 of pRSFDuet-1. pILPTM2-2 (chapter 2, kind 
gift from Lanthio Pharma (9)) was used as template to amplify ltnM2 with NdeI 
restriction site 5’-end and a XhoI restriction site 3’-end. Subsequently, the gene 
was cloned in the MSC 2 of pRSFD-LtnA2. In order to create pETD-ltnM2a the 
PCR product of ltnM2 was ligated in MCS 2 of pETDuet-1. 
To generate pRSFD-ltnA2-nisA, a synthetic construct was ordered from 
GeneArt (Life Technologies) containing LtnA2(-1 to -36)::IDGR::NisA(1 to 34) 
with a BamHI restriction site 5’-end and a HindIII restriction site 3’-end of the 
gene. The gene was amplified by PCR and cloned in MCS 1 of pRSFDuet-1. The 
resulting plasmid was then used in mutagenesis PCR to remove the factor Xa 
protease site (IDGR). The clones were analyzed by DNA sequence analysis at 
Macrogen Corporation. 
 
Overexpression and purification of His-tagged lanthipeptides. E. 
coli BL21 (DE3) cells were transformed with pRSFDuet-1 or co-transformed with 
pRSFDuet-1 and pETDuet-1 derived plasmids containing a specific lanA and lanM 
gene (see table 1 and 3). Cells were plated on LB agar containing 50 µg/mL 
ampicillin and/or 30 µg/mL kanamycin depending on the plasmids used and 
overnight incubated at 37°C. Colonies of the resulting plate were resuspended in 
1 mL LB, and used to inoculate 100 mL LB supplemented with appropriate 
antibiotics. Cells were grown at 37°C until the optical density at 600 nm (OD600) 
was between 0.5 and 0.7. The culture was then induced with 0.5 mM isopropyl-
β-D-thiogalactopyranoside (IPTG) and grown for two hours at 37°C (cells 
expressing LtnM2) or overnight at 20°C (cells expressing MutM). Cells were 
harvested by centrifugation at 2851 x g for 20 minutes (4°C), and stored as 
pellets at -20°C. Cell pellets were resuspended in 10 ml start buffer (20 mM Tris-
HCl, 0.5 M NaCl, pH 7.5) and lysed through sonication. Cell debris was removed 
by centrifugation (50 min. at 444,000 x g), and peptides were purified from the 
supernatant by immobilized metal affinity chromatography (IMAC) using a 
HisTrap™ HP column (GE Healthcare) with elution buffer (start buffer containing 
250 mM imidazole). Fractions were analyzed by 15% Tris-tricine SDS-PAGE and 
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Coomassie brilliant blue staining, and by Western blotting using an anti-His 
antibody (5 PRIME) following standard protocols. 
 
HPLC purification and mass spectrometry analysis. After IMAC-
purification trifluor acidic acid (TFA) was added to the peptide containing fraction 
until pH 4 and further purified/desalted by reversed phase HPLC using a Jupiter 
Proteo C12 column (4 μm; 90 Å; 250 mm x 4.6 mm). The following solvents 
were used for RP-HPLC, solvent A (0.1% TFA in MilliQ water) and solvent B 
(0.1% TFA in acetonitrile). The HPLC purified peptide fractions were analyzed by 
matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry. A sample of 1 μL of the HPLC fractions was spotted on the MALDI-
TOF target and directly covered by 1 μL of matrix (5 mg/mL α-cyano-4-
hydroxycinnamic acid dissolved in 50% acetonitrile in 0.1% TFA in MilliQ water). 
The spots were allowed to dry before spectra were recorded with a Voyager DE 
PRO MALDI-TOF mass spectrometer (Applied Biosystems). An external calibration 
was used to correct the resulting spectra. 
 
Protease treatment of purified peptides. HPLC fractions containing the 
peptide were vacuum-dried using a Concentrator plus (Eppendorf). The pelleted 
samples, containing His6-MutA or His6-Mut-NisA, were resuspended in 500 µL 0.1 
M Tris-HCl pH 8 containing 100 µg/mL trypsin (Sigma-Aldrich). The pelleted 
samples, containing His6-LtnA2, His6-Mut-LtnA1 or His6-Mut-LtnA2, were 
resuspended in 500 µL 0.1 M ammonium acetate pH 4 containing 50 µg/mL 
endoproteinase Glu-C from Staphylococcus aureus V8 (Sigma-Aldrich). Samples 
were incubated three hours till overnight at 37°C. After protease treatment TFA 
(0.1%) was added and the peptide fragments were separated by HPLC and 




Heterologous co-expression of Streptococcus mutans MutM and 
MutA in E. coli. To explore the use of the modification enzyme of mutacin II for 
the heterologous production of class II lantibiotics in E. coli, the genes of the 
modification enzyme, mutM, and its natural substrate, mutA, were cloned in 
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a pRSFDuet-1 vector. MutA was fused at its N-terminus to a six histidine-tag 
encoding sequence creating His6-MutA. After co-expression in E. coli BL21 (DE3), 
cells of the expressing strain were analyzed for the presence of His6-MutA. 
Herein, the cell free extract was passed over an immobilized metal affinity 
chromatography (IMAC) column and analyzed by Tris-tricine SDS-PAGE and 
Coomassie brilliant blue staining. This showed the presence of a protein (~10 
kDa) that was absent in the empty vector control (figure 1A). The protein was 
stained by Western blotting using a Tetra-His antibody (5 prime), confirming the 
presence of His-tagged MutA (figure 1B). 
The IMAC fraction that contained the peptide was applied on RP-HPLC for 
further purification. HPLC fractions were collected and analyzed by MALDI-TOF 
mass spectrometry for the presence of His6-MutA. The HPLC fraction around 24 
min. retention time contained a peak of 7421.13 Da (figure 2A/table 4). This 
mass may indicate the presence of a four times dehydrated His6-MutA with a 
theoretical mass of 7430.1649 Da. Since the observed and calculated mass differ 
around 9 Da, the fraction containing the peptide was digested with trypsin, 
herewith confirming the presence of His6-MutA and to get more insight in the 
precise number of dehydrations. After digestion and RP-HPLC, fractions were 
analyzed by MALDI-TOF mass spectrometry. One of the HPLC fractions contained 
peaks that could be assigned to amino acids Leu18-Arg42 and Trp43-Cys67 from 
His6-MutA (figure 3A/table 4). The core peptide of mutacin II, corresponding to 
Asn41-Cys67 in His6-MutA (table 3), contains four Ser and Thr residues that are 
all dehydrated. The calculated mass of the peptide fragment Trp43-Cys67 is 
3046.3261 Da, and a peak corresponding to the four times dehydrated fragment 
was present (figure 3A/table 4). In addition to the fully dehydrated peptide, also 
incomplete dehydration was observed ranging from none to three times 
dehydration. The results suggest that MutM is expressed and active in E. coli 
yielding dehydrated MutA. 
 
MutA chimeric peptides are expressed and dehydrated in E. coli. In 
order to validate if MutM is also capable to dehydrate unrelated peptides a set of 
chimeric peptides was generated (table 3). The chimeric peptides consist of the 
leader peptide of MutA fused to the core peptides of LtnA1, LtnA2 or NisA. The 
respective genes were co-expressed as his-tagged chimeric peptides together  
  




Figure 1: Expression of LanM enzymes and production of LanA products in E. coli. Tris-tricine 
Coomassie stained SDS-PAGE comparing elution fractions after IMAC purification of E. coli strains 
expressing His6-MutA and MutM, His6-Mut-LtnA1 and MutM, His6-Mut-NisA and MutM, His6-Mut-
LtnA2 and MutM or empty vectors (A). Western blot stained with a Tetra-His antibody (Qiagen) 
showing the presence of his-tagged proteins (~9 and ~10 kDa) in the elution fractions after IMAC 
purification (B). Tris-tricine Coomassie stained SDS-PAGE comparing elution fractions after IMAC 
purification of E. coli strains expressing His6-LtnA2 and LtnM2, His6-LtnA2-NisA and LtnM2 or empty 
vectors (C). Western blot stained with a Tetra-His antibody (Qiagen) showing the presence of his-
tagged proteins (~12 kDa) in the elution fractions after IMAC purification (D).  
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with the modification enzyme, MutM. After co-expression in E. coli BL21 (DE3), 
cell free extract was passed over an IMAC column to isolate the His-tagged 
peptides and analyzed by Tris-tricine SDS-PAGE and Coomassie staining. The 
elution fractions contained an extra protein (~10 kDa) compared to the empty 
vector control (figure 1A), that stained with an Tetra-His antibody (figure 1B). 
These data indicate the production of His6-mut-LtnA1, His6-mut-LtnA2 and His6-
mut-NisA. The peptide containing fractions were further purified over RP-HPLC, 
and subjected to MALDI-TOF mass spectrometry. This yielded unique masses of 
7573.67 Da and 7545.19 Da for His6-Mut-LtnA1 (figure 2B/table 4) that likely 
correspond to two and four times dehydrated His6-Mut-LtnA1 which has a 
theoretical mass of 7615.2836 Da when unmodified. The theoretical mass of 
unmodified His6-Mut-NisA is 7682.6631 Da, and mass analysis revealed a peak at 
7607.31 Da which likely corresponds to four times dehydrated peptide (figure 
2C/table 4). With His6-Mut-ltnA2 a peak at 7129.20 Da (figure 2D/table 4) was 
found that likely corresponds to a two-fold dehydrated peptide that unmodified 
has a predicted mass of 7171.9137 Da. 
To determine the degree of dehydration more accurate, the peptides were 
digested by Glu-C or trypsin and analyzed by RP-HPLC and MALDI-TOF mass 
spectrometry. Digestion of His6-Mut-LtnA1 with Glu-C yielded peaks 
corresponding to two, three and four times dehydrated peptide fragment Leu34-
Lys70 (figure 3C/table 4). His6-Mut-NisA was digested with trypsin, yielding a 
NisA fragment (Thr53-Lys74) that was dehydrated once (figure 3D/table 4). His6-
Mut-LtnA2 digested with Glu-C yielded the fragment of Leu34-Gly69 with the two 
masses of 3530.90 Da and 3511.80 Da corresponding to seven and eight times 
dehydrated peptide (figure 3E/table 4). These results suggest that MutM is able 
to modify unrelated peptide substrates when expressed as a chimeric peptide 
with the mutacin II leader peptide. 
 
Heterologous co-expression of lacticin 3147 LtnM2 and its natural 
substrate in E. coli. In addition to MutM, the modification enzyme LtnM2 of the 
two-component class II lantibiotic lacticin 3147, was explored for heterologous 
expression in E. coli. The genes encoding the modification enzyme, LtnM2, and a 
hexa-his tag variant of the natural substrate, LtnA2, were cloned and expressed 
in E. coli BL21 (DE3). Analysis of the cell free extract after IMAC column 
chromatography yielded a unique 12 kDa protein band on Coomassie stained 
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Tris-tricine SDS-PAGE that is absent in the empty vector control (figure 1C). This 
band was also stained with a Tetra-His antibody, confirming the presence of His-
tagged LtnA2 (figure 1D). The peptide was purified using a IMAC column and RP-
HPLC, thereafter analyzed by MALDI-TOF mass spectrometry for the presence of 
His6-LtnA2. One of the fractions contained a peak at 8451.35 Da (figure 2E/table 
4) corresponding to one time dehydrated His6-LtnA2 with a theoretical mass of 
8562.5054 Da when unmodified. The fraction was digested with Endoproteinase 
Glu-C to reveal more exact the number of dehydrations resulting in the following 
peptide fractions: Leu41-Cys79, Gly44-Cys79 and Ser47-Cys79. The calculated 
masses of these peptides are 3938.8574, 3625.6936 and 3324.6026 Da, 
respectively. The observed masses 3822.36, 3479.01 and 3179.87 Da (figure 
3B/table 4) likely correspond to peptide fragments that are eight times 
dehydrated which is identical to the number of dehydrations found in the native 
LtnA2. In addition peptide fragments with incomplete dehydration, ranging from 
none to seven times, were observed (data not shown). Finding dehydrated His6-
LtnA2 proposes an active LtnM2 when expressed in E. coli. 
 
Expression of His6-LtnA2-NisA chimera peptide in E. coli. To 
investigate the ability of LtnM2 to modify peptides other than its native substrate 
LtnA2, His6-LtnA2-NisA was tested. Again, gel-based analysis revealed a unique 
protein band around 12 kDa, absent in the empty vector control sample (figure 
1C), and immunoreactive with a Tetra-His antibody (figure 1D). RP-HPLC and 
MALDI-TOF mass spectrometry revealed a peak at 9014.12 Da (figure 2F/table 
4) in one of the fractions that correspond to three times dehydrated His6-LtnA2-
NisA (theoretical mass 9073.2547 Da). After Glu-C proteinase digestion, no 
peptide fragment could be recovered, likely because the lower levels of 
expression of the protein. These data however show production and dehydration 




Bacteria produce a large variety of lanthipeptides in nature, peptides that 
vary in amino acid sequence, degree of dehydration and number of thioether 
bonds. Although the basic enzymatic machinery is shared among these 
lanthipeptides, the exact specificity of the modifying enzymes is unknown. 
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Several successes have been reported for class I lantibiotics where the NisBC 
enzymes were used to modify unrelated lanthipeptides as well as small peptide 
hormones (14, 15). In addition, one example has been described suggesting that 
LtnM2, from the class II lantibiotic lacticin 3147, has a tolerance for unrelated 
lanthipeptides (9). However, there are no further reports of a production system 
that depends on the single modifying enzyme, LanM, carrying out both 
dehydration and thioether-link formation. Little is known about the promiscuity 
of these LanM enzymes. On the other hand, such modifying enzymes constitute 
an engineering potential, possibly allowing the production of a vast range of 
lanthipeptides when co-expressed with structural LanA-like peptides. To explore 
this possibility, MutM and LtnM2 were co-expressed with several LanA peptides in 
E. coli, and analyzed on the production of peptides by HPLC and MALDI-TOF 
mass spectrometry. This study could show that MutM fully dehydrates (4-times) 
its cognate substrate MutA, that was co-expressed as a His-tagged protein. 
Similarly, LtnM2 was shown to fully dehydrate (8-times) LtnA2. This shows that 
the modification enzymes are active when expressed in a heterologous host like 
E. coli. In addition LtnM2 and MutM seem to be tolerant to the presence of a N-
terminal His-tag. This was shown before for NukM (11), ProcM, the haloduracin 
and nisin modification enzymes (12). Moreover, the leader peptide of MutA and 
LtnA2 was fused to a set of alternative LanA-like peptides to test the substrate 
promiscuity of LtnM2 and MutM, respectively. Indeed, MutM was shown to 
dehydrate His6-Mut-NisA once, His6-Mut-LtnA1 four times, and His6-Mut-LtnA2 
eight times. On the other hand, His6-LtnA2-NisA was dehydrated three times by 
LtnM2. 
Our work focuses on the development of an expression system for class II 
lanthipeptides. The intended production system should contain a known and 
promiscuous lantibiotic modification enzyme. For LtnM2, both expression in the 
Gram-positive host L. lactis and Gram-negative host E. coli as modifying enzyme 
was evaluated. By the co-expression of LtnM2, the transporter LtnT and various 
substrates in L. lactis, some peptides (LtnA2 and LtnA2-A1(C-less)) could be 
produced, but most attempts failed (Chapter 4). This suggest that LtnM2 in 
conjunction with LtnT is not suitable as a bioengineering enzymes for a class II 
lanthipeptide production system. This study, however, suggests that the 
production loss could be due to the substrate specificity of the transporter and 
might not be solely contributed to LtnM2. Although, different substrate variants 
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could be co-expressed with LtnM2, the enzymes does not seem highly specific. 
From the results described here it can be concluded that MutM and LtnM2 are 
capable of dehydrating unrelated LanA peptides when fused behind an 
appropriate leader peptide. However, the extent of dehydration varies from the 
expected number to under dehydration suggesting that further tuning is 




Table 4: Overview of the observed and theoretical masses of the full peptides and peptide 









His6-MutA + MutM 
His6-MutA 7421.13 7430.16 (4x)* -9.03 
































His6-Mut-NisA + MutM 
His6-Mut-NisA 7607.31 7610.58 (4x)* -3.27 
Thr53-Lys74 2276.93 2275.01 (1x)* +1.92 
His6-Mut-ltnA2 + MutM 







His6-LtnA2 + LtnM2 
His6-LtnA2 8451.35 8454.38 (6x)* -3.03 
Leu41-Cys79 3797.72 3794.69 (8x)** +3.03 
Gly44-Cys79 3483.85 3481.53 (8x)** +2.32 
Ser47-Cys79 3181.09 3180.44 (8x)** +0.65 
His6-LtnA2-NisA + LtnM2 
His6-LtnA2-NisA 9014.12 9019.19 (3x)* -5.07 
    
* The average mass of the protein, (M+H)+, calculated without the initial methionine. 
** The monoisotopic mass of the peptides (M+H)+. 
1x Mass calculated after given amount of dehydrations have been subtracted. One dehydration 
reduces the mass with 18.02 Da. 
∆ The difference in theoretical and observed mass. 
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Construction of plasmid pRSFD-mutA-M. Strains and plasmids used to 
create pRSFD-mutA-M are listed in supplementary table 1. L. lactis NZ9000 was 
used as a host for the pNZ8048 and pIL253 derived plasmids. Strains were 
grown at 30°C in Bacto M17 broth (Becton Dickinson Difco) supplemented with 
0.5% glucose. Where needed chloramphenicol (5 µg/mL) or erythromycin (5 
µg/mL) were added to the medium. Primer sequences for the PCR reactions 
described below are listed in supplementary table 2. 
For the construction of pRSFD-mutA, the gene encoding mutA was 
amplified via colony PCR from S. mutans T8. The resulting PCR product was 
treated with PagI and PstI and ligated in pNZ8048 to yield pNZ-mutA-1. This 
plasmid was used in a follow up PCR reaction amplifying mutA with BamHI and 
HindIII restriction sites. The resulting PCR product was ligated in the multiple 
cloning site (MSC) 1 of pRSFDuet-1 (Novagen). 
To construct pILP-mutM-1, the nisin promotor region was amplified via 
PCR from pNZ8048. The PCR product was treated with BamHI and EcoRI and 
ligated in pIL253, resulting in pIL-pnis. Next, the mutM encoding gene was 
amplified via PCR as described for mutA, treated with BamHI and SacI and 
ligated in pIL-pnis creating pILP-mutM-1. 
For pRSFD-mutA-M, mutM was amplified by PCR from pILP-mutM-1 with a 
XhoI restriction site at the 3’-end and a blunt 5’-end, and ligated in MSC 2 of 
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Supplementary table 1: list of strains and plasmids used in creation of pRSFD-mutA-M 
 Characteristics reference 
Strains   
Escherichia coli DH5α Used for cloning and plasmid 
maintenance 
 
Lactococcus lactis NZ9000 MG1363 derivative; pepN::nisRK+ 
Used for cloning and plasmid 
maintenance 
(1) 
Streptococcus mutans T8 Strain containing mutacin II gene 
cluster 
Kind gift from the 
Department of Microbial 
Genomic, Université Laval, 
Québec QC Canada 




pNZ-mutA-1 Cmr; pNZ8048 derived; mutA 
cloned behind the Pnis promoter 
This study 
pRSFDuet-1 Kanr; contains two multiple cloning 






pIL-pnis Emr; pIL253 derived; containing 
Pnis promoter of pNZ8048 
This study 
pILP-mutM Emr; pIL253 derived; containing 
mutM behind Pnis promoter of 
pNZ8048 
This study 
pRSFD-mutA Kanr; pRSFDuet-1 derived; mutA 
cloned in MCS1, mutM cloned in 
MCS2 
This study 
pRSFD-mutA-M Kanr; pRSFDuet-1 derived; mutA 
cloned in MCS1, mutM cloned in 
MCS2 
This study 
Cmr chloramphenicol resistance marker 
Emr erythromycin resistance marker 
Kanr: kanamycin resistance gene 
 
Supplementary table 2: Primers used in creation of pRSFD-mutA-M 
Primer Sequence (5’-3’) Characteristics 
   
050-mut-a1-fw TAGCTCATGAACAAGTTAAACAGTAACG Introduction PagI site 5’-end of 
mutA 
051-mut-a2-rv TAGCCTGCAGTTAACAGCAAGTGAAAACATG Introduction PstI site 3’-end of 
mutA 
086-muta-fw AGTGAGGATCCCATGAACAAGTTAAACAGTAAC Introduction BamHI site 5’-end 
of mutA 
087-muta-rv AGTACAAGCTTAACAGCAAGTGAAAACATG Introduction HindIII site 3’-end 
of mutA 
027-pnis-2-fw CTTAGGGAATTCTAGTCTTATAACTATACTGAC Introduction EcoRI site 5’-end of 
Pnis promoter 
028-pnis-2-rv CTTACTGGATCCGTGAGTGCCTCCTTATAATTTA Introduction BamHI site 3’-end 
of Pnis promoter 
081-mutm-fw ATTAGGATCCATGAACAACCCGTTATTCCCTG Introduction BamHI site 5’-end 
of mutM 
082-mutm-rv CTACGAGCTCTTAGTAAAATGAAAGATTTAAGACATG Introduction of SacI site 3’-end 
of mutM 
088-mutm-fw CATGAACAACCCGTTATTCC  
 
089-mutm-rv CTAGACTCGAGAGCTCTTAG Introduction of XhoI site 3’-end 
of mutM 
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Lantibiotics are post-translationally modified peptides that function as 
antimicrobial agents. With class II lantibiotics, the bifunctional enzyme LanM 
both catalyzes the dehydration of serine and threonine, as well as the cyclization 
reaction that forms the thioether link between these residues and a cysteine. 
This study explored the ability of a putative LanM enzyme to modify its predicted 
class II lantibiotic substrate from Streptococcus pneumoniae Spain 23F-1 by 
heterologous expression in Escherichia coli. The his-tagged LanA-SPN23F protein 
was co-expressed with LanM-SPN23F in E. coli, and the resulting His6-LanA-
SPN23F was purified and examined by MALDI-TOF mass spectrometry for the 
presence of dehydrated residues. The peptide was found to be completely 
dehydrated, i.e. 7-8 times. Since the LanA-SPN23F peptide contains the Ile-Cys-
Cys consensus sequence for a carboxyl-terminal decarboxylation modification, it 
was co-expressed with GdmD, a decarboxylation enzyme of Staphylococcus 











Lanthipeptides are ribosomally synthesized peptides that undergo post-
translational modifications. They are characterized by the presence of the 
unusual amino acids lanthionine (Lan) and methyllanthionine (MeLan) (1, 2). 
Lanthipeptides can be divided into four classes based on the enzyme(s) that 
catalyze the formation of the lanthionine and methyllanthionine residues (1). 
Class I and II lanthipeptides are also termed lantibiotics, lanthionine-containing 
antibiotic peptides (3), since they possess antimicrobial activity. 
Lanthipeptides are encoded by a gene generically termed, lanA. LanA 
contains a N-terminal leader and the C-terminal core peptide. The C-terminal 
core peptide is modified by distinct modification enzymes to introduce 
(methyl)lanthionine residues. Serine and threonine residues are dehydrated to 
form dehydroalanine (Dha) and dehydrobutrine (Dhb) residues, respectively. 
Subsequently, the dehydrated residues are coupled to a cysteine via a thioether 
bridge to form a lanthionine or a methyllanthionine, respectively. In class I 
lantibiotics the formation of these reactions are performed by two distinct 
enzymes, a dehydratase, LanB, and a cyclase, LanC. In class II lantibiotics the 
reaction is performed by a single bifunctional enzyme, LanM. 
Besides the characteristic (methyl)lanthionine formation a lantibiotic can 
undergo more post-translational modifications (4). One of these extra 
modifications that can occur is the formation of an S-aminovinyl-D-cysteine 
(AviCys) amino acid. The enzyme responsible for the oxidative decarboxylation 
at the C-terminus of the lantibiotic is generically termed LanD. A more 
extensively studied LanD is EpiD from Staphylococcus epidermidis. EpiD belongs 
to the homooligomeric flavin-containing Cys decarboxylase (HFCD) family (5). 
The consensus sequence of the C-terminal amino acids for the recognition by 
EpiD is [V/I/L/F/W/Y/(M)]-[A/S/V/T/C/(I/L)]-C (6). Another example of a LanD 
enzyme is GdmD, which belongs to the gallidermin biosynthetic gene cluster of 
Staphylococcus gallinarum. Recently, this enzyme was shown to modify another 
lanthipeptide than gallidermin, namely a nisin variant, when co-expressed in 
Lactococcus lactis (7). 
LanA peptides contain an N-terminal leader peptide. The precise function 
of this leader peptide is unknown (8), but it appears to play a significant role in 
targeting the peptide to the modification enzymes, export and self-immunity 
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systems. Lantibiotics belonging to class II contain the so-called double glycine 
motif (GG, GA, GS or GT) at the C-terminus of their leader peptide. This motif is 
recognized by the bifunctional transporter, LanT, typical for class II lantibiotics 
(9). This transporter contains a N-terminal peptidase C39 domain that is 
responsible for the cleavage of the leader peptide at the cytoplasmic side of the 
membrane whereupon the peptide is exported (9). It was previously shown that 
NukT requires ATP hydrolysis for leader cleavage activity to occur in vivo (10), 
though in vitro, the C39 peptidase domain of LctT can function as an 
independent protease (11). 
Since multidrug resistance is a major problem in the treatment of 
infectious diseases, there is an urgent need for new antimicrobial substances 
based on unique structures. Lantibiotics possess antimicrobial activity and 
resistance against lantibiotics has not yet been reported, making them potential 
alterative candidates for a novel class of antibiotics (12). Thus far, lantibiotics 
are mainly used in food preservation preventing the growth of food pathogens. 
Due to genome-mining and bioinformatics, a multitude of lanthipeptide and 
lantibiotic associated gene clusters have been identified in the DNA databases. 
The bioactivities of these putative lantibiotics are not known. Often the genes are 
identified in metagenomic data and/or bacteria that so far have not been 
cultured. Therefore, expressing such new lantibiotics in their natural host is not 
feasible and ideally production should be realized using an heterologous host. 
Previously, it has been reported that the lantibiotic enzymes NukM (13), ProcM, 
HalM1, HalM2 and NisBC (14), and their substrates can be heterologously 
expressed in Escherichia coli to produce lanthipeptides. Therefore this study 
focuses on the heterologous expression of a putative class II lantibiotic from 
Streptococcus pneumoniae in E. coli. In addition, the substrate was subjected to 
an extra modification that entails a C-terminal decarboxylation. 
 
Material and methods 
 
Bacterial strains and growth conditions. Strains and plasmids used in 
this study are listed in table 1. Escherichia coli DH5α was used for cloning and 
maintenance of the plasmids, E. coli BL21 (DE3) was used as an expression host 
and Luria Broth (LB) was used as culture medium. Depending on the containing 
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Table 1: Strains and plasmids used in this study 
 Characteristics reference 
Strains   
E. coli DH5α 
 
  
E. coli BL21 (DE3) 
 
  
Plasmids   
pETDuet-1 
 
Ampr; contains two multiple cloning sites 









Ampr; pETDuet-1 derived; gdmD cloned in 




Kanr; contains two multiple cloning sites 




Kanr; pRSFDuet-1 derived; lanA-SPN23F 




Kanr; pRSFDuet-1 derived; Leu1-Lys151 of 




Eryr; gdmD cloned behind the Pnis promoter (7) 
Kanr: kanamycin resistance gene 
Ampr: ampicillin resistance gene 
 
 
Construction of the plasmids. Chromosomal DNA isolated from 
Streptococcus pneumoniae Spain 23F-1 (ATCC 700669) was a kind gift from the 
Molecular Genetics department of the University of Groningen, and was used as a 
template to amplify the genes encoding lanA-SPN23F, lanM-SPN23F and the 
protease domain of lanT-SPN23F, LanTc39, using the primers listed in table 2. 
Phusion High-Fidelity DNA Polymerase for PCR, restriction and DNA modifying 
enzymes were all purchased from Thermo Scientific. 
For the construction of pRSFD-LanA and pRSFD-LanTc39 the primers were 
designed such that a BamHI restriction site was added at the 5’-end and a 
HindIII restriction site at the 3’-end of the DNA. The lanA-SPN23F encoding gene 
and the protease domain of LanT-SPN23F were ligated in multiple cloning site 1 
(MCS 1) of pRSFDuet-1 (Novagen), which was treated with the corresponding 
restriction enzymes. Since MCS 1 contains a His-tag, the cloning resulted in the 
addition of a N-terminal six histidine tag in front of the leader peptide of LanA-
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SPN23F and LanTc39. Positive clones containing pRSFD-lanA or pRSFD-lanTc39, 
were analyzed by DNA sequence analysis at Macrogen Corporation. 
For the construction of pETD-LanM the PCR primers for the lanM-SPN23F 
encoding gene introduce a BglII restriction site at the 5’-end of lanM, while at the 
3’-end a natural occurring XhoI restriction site could be used. LanM-SPN23F was 
ligated in multiple cloning site 2 (MCS 2) of pETDuet-1 (Novagen), which was 
treated with corresponding restriction enzymes. pNZE-gdmD (7) was used as a 
template to amplify the gene encoding GdmD using primers that added a NcoI 
restriction site at the 5’-end and a HinDIII restriction site at the 3’-end of the 
gene (table 2). The fragment was cloned in MCS 1 of pETD-lanM (excluding the 
his-tag) to yield pETD-gdmD-lanM. 
 
 
Table 2: Primers sequences used in this study 
Primer Sequence (5’-3’) Characteristics 
   
090-lana-fw 
 




























GATTCAAGCTTAGTCCAAAGGTCTCTTTTCG Introduction HindIII site 3’-end 
of gdmD 
ATCG marking the sequence of the corresponding restriction site. 
 
 
Overexpression and purification of His6-LanA-SPN23F. E. coli BL21 
(DE3) cells were co-transformed with pRSFD-lanA and one of the following 
vectors; pETD-lanM or pETD-gdmD-lanM. After transformation, cells were plated 
on LB agar containing 30 µg/mL kanamycin and 50 µg/mL ampicillin. Colonies 
were resuspended in 1 mL LB and used to inoculate 100 mL LB supplemented 
with kanamycin and ampicillin. Cells were grown at 37°C until the optical density 
at 600 nm (OD600) was between 0.5 and 0.7. The culture was then induced with 
0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and grown for two hours at 
37°C. Cells were harvested by centrifugation at 2851 x g for 20 minutes (4°C) 
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and stored as pellets at -20°C. Cell pellets were resuspended in 10 ml start 
buffer (20 mM Tris-HCl, 0.5 M NaCl, pH 7.5) and lysed through sonication. Cell 
debris was removed by centrifugation (50 min. at 444,000 x g), and the peptides 
were purified from the supernatant by immobilized metal affinity 
chromatography (IMAC) using a HisTrap™ HP column (GE Healthcare) with 
elution buffer (start buffer containing 250 mM imidazole). Fractions were 
analyzed by 15% Tris-tricine SDS-PAGE and Coomassie brilliant blue staining and 
by Western blotting using an anti-His antibody (5 PRIME) following standard 
protocols. 
 
HPLC purification and mass spectrometry analysis of His6-LanA-
SPN23F containing samples. After IMAC-purification trifluor acidic acid (TFA) 
was added to the peptide containing fraction until pH 4, whereupon the samples 
were purified and desalted by reversed phase HPLC using a Jupiter Proteo C12 
column (4 μm; 90 Å; 250 mm x 4.6 mm). The following solvents were used for 
RP-HPLC, solvent A (0.1% TFA in water) and solvent B (0.1% TFA in 
acetonitrile). The HPLC purified peptide fractions were analyzed by matrix 
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry on the presence of the peptide. A sample of 1 μL of the HPLC 
fractions was spotted on the target and directly covered by 1 μL of matrix  
(5 mg/mL α-cyano-4-hydroxycinnamic acid dissolved in 50% acetonitrile in 0.1% 
TFA in MQ). The spots were allowed to dry before spectra were recorded with a 
Voyager DE PRO MALDI-TOF mass spectrometer (Applied Biosystems). An 
external calibration was used to correct the resulting spectra. 
 
Protease treatment of purified peptides. HPLC fractions containing the 
peptide were vacuum-dried using the Concentrator plus (Eppendorf). Pelleted 
samples were resuspended in 100 μL 0.5 M Tris-HCl pH 8 containing 0.5 mg/mL 
trypsin. Samples were incubated overnight at 37°C. After protease treatment 
TFA was added and the peptide fragments were separated by HPLC and analyzed 
by MALDI-TOF MS as described above. 
 
Overexpression and purification of His6-LanTc39. Overexpression of 
His6-LanTc39 was essentially as described for His6-LanA-SPN23F. E. coli BL21 
(DE3) cells were transformed with pRSFD-lanTc39. After transformation the cells 
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were plated on LB agar containing 30 µg/mL kanamycin. Colonies were 
resuspended in 1 mL LB and used to inoculate 100 mL LB supplemented with 
kanamycin. Cells were grown at 37°C until the OD600 was between 0.5 and 0.7. 
After induction with 0.5 mM IPTG, the culture was grown overnight at 20°C. Cells 
were harvested by centrifugation at 2851 x g for 15 min. (4°C). Cell pellets were 
resuspended in 10 mL phosphate start buffer (50 mM Na2HPO4, 0.5 M NaCl, pH 
7.5) (11) and lysed by sonication. Cell debris was removed by centrifugation (50 
min. at 286,000 x g) and the protein was purified from the supernatant using 
gravity-flow chromatography with Ni-NTA Agarose (Qiagen). The protein was 
eluted with the phosphate start buffer containing 250 mM imidazole. Fractions 
were analyzed by 15% SDS-PAGE, Coomassie brilliant blue staining and Western 
blotting using an anti-His antibody (5 PRIME). 
 
Peptidase treatment by LanTc39 on purified peptides. To reduce the 
high imidazole concentration in the purified His6-LanA-SPN23F and His6-LanTc39 
samples, the buffer was replaced by 50 mM Na2HPO4 pH 7.5, 50 mM Na2SO4 (11) 
using Amicon® Ultra Centrifugal Filters (Millipore). The extracted His6-LanA-
SPN23F was purified from an E. coli strain also co-expressing either LanM-
SPN23F or LanM-SPN23F/GdmD. A sample containing His6-LanA-SPN23F (~0.1 
mg/mL) and His6-LanTc39 (~0.2 mg/mL) was incubated for three hours at 25°C 
in 50 mM Na2HPO4 pH 7.5, 50 mM Na2SO4 supplemented with 1 mM DTT (11). 
The reaction was stopped by chilling on ice and subsequently frozen at -20°C 
until further use. To analyze the peptide modification, samples were thawed and 
TFA was added until pH 4 was reached (with a minimum concentration of 0.1% 
TFA). Samples for MALDI-TOF MS analysis were prepared using C18 Zip-tips 
(Millipore) according to manufacturer protocol. MALDI-TOF mass spectrometry 




A putative lantibiotic encoded in the genome of Streptococcus 
pneumoniae ATCC 700669. BActeriocin GEnome mining tooL (BAGEL3) (15, 
16) was used to scan the genome of Streptococcus pneumoniae ATCC 700669, 
and a putative typical class II lantibiotic gene cluster was identified (figure 1A).  
  




Figure 1: Putative class II lanthipeptide gene cluster from Streptococcus pneumoniae ATCC 
700669. BAGEL3 analysis of the predicted class II lanthipeptide gene cluster (A). Alignment of 
mature LanA peptide encoding sequences of lichenicidin VK21 A1 (P86475), haloduracin-alpha 
(Q9KFM5), mersacidin (B4Y535) and the predicted LanA-SPN23F (B8ZK92) shows a conserved 
region for thioether formation (B). 
 
 
The lantibiotic precursor gene was described previously by Croucher et. al. in 
2009 (17) but not studied in detail. The two open reading frames (ORFs) 
downstream were identified as a lantibiotic synthetase (LanM) and a lantibiotic 
transporter (LanT). The three genes upstream of the lantibiotic precursor gene 
likely constitute an ABC transporter that is typically involved in self-immunity 
during lantibiotic production. In addition to the predicted bacteriocin gene 
clusters, BAGEL3 also uses the identified lantibiotic gene to scan it against 
bacteriocin databases. LanA-SPN23F shows homology with haloduracin-alpha 
(Q9KFM5) (18) with 37% identity, lichenicidin VK21 A1 (P86475) (19) with 39% 
identity and mersacidin (B4Y535) (20) with 35% identity. When the core peptide 
sequences of the above mentioned lantibiotics were aligned with the core peptide 
of LanA-SPN23F, a conserved region was found (figure 1B). This region is 
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two-component lantibiotics, suggesting a similar dehydration, including Thr72 
and Thr74, and ring structure for His6-LanA-SPN23F. 
 
Co-expression of Streptococcus pneumoniae LanA-SPN23F and 
LanM-SPN23F in E. coli. In order to characterize the putative lantibiotic from 
Streptococcus pneumoniae Spain 23F-1, a His-tagged variant of LanA-SPN23F, 
His6-LanA-SPN23F, was created. The gene was heterologously co-expressed in E. 
coli Bl21(DE3) cells together with the corresponding modification enzyme, LanM-
SPN23F, using the pRSFDuet and pETDuet vectors. Although the expression was 
not evident on Coomassie stained Tris-tricine SDS-PAGE of whole cell lysates 
(figure 2A), cell free extract passed over an immobilized metal affinity 
chromatography (IMAC) column allowed the specific elution of a protein 
(~11kDa) that was absent in the empty vector control sample (figure 2C). The 
protein band could be detected by Western blotting using a Tetra-His antibody (5 
prime), confirming the presence of a His-tagged LanA-SPN23F (figure 2D). 
 
Analysis of His6-LanA-SPN23F modifications. The purified His6-LanA-
SPN23F was subjected to reversed phase HPLC (RP-HPLC), monitored at a 
wavelength of 214 nm, and compared to an empty vector control sample. As 
shown in figure 3A, the sample containing His6-LanA-SPN23F showed a unique 
peak around 28 minutes likely corresponding to the His6-LanA-SPN23F. Next, 
MALDI-TOF MS analysis was used to validate the identity of the peptide and to 
determine the degree of modification by LanM-SPN23F. Dehydration of serine 
and threonine residues causes a mass loss of 18.02 Da, however, the cyclisation 
reaction that leads to the formation of the Lan or MeLan residues cannot be 
detected by MALDI-TOF as there is no mass change. The theoretical mass of the 
unmodified His6-LanA-SPN23F is 9180.11 Da. Since the core peptide contains 
eight serine and threonine residues, a mass loss of 144.16 Da is expected for the 
completely modified peptide. A peak of 9031.72 Da (figure 4A) was identified, 
which closely matches the theoretical mass of eight times dehydrated His6-LanA-
SPN23F, i.e., 9035.95 Da, indicating complete dehydration. 
In order to obtain a more precise insight in the degree of dehydration, 
His6-LanA-SPN23F was submitted to trypsin digestion. Peptide fractions were 
separated using RP-HPLC and analyzed by MALDI-TOF MS. A peak of 2147.77 Da 
was identified as a peptide fragment containing the His-tag up to amino acid 
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Lys19 (Gly2-Lys19) of the leader sequence (theoretical mass: 2146.90 Da, see 
also table 3). A second peak of 2061.28 Da was identified corresponding to 
amino acids Lys20-Arg38 of the leader peptide (theoretical mass: 2060.07 Da). 
In addition, two peaks of 4881.14 Da and 4864.47 Da were observed (figure 4C) 
that correspond to a seven and eight times dehydrated peptide including amino 
acid Glu39-Cys85 (the core peptide with a part of the leader peptide, theoretical 
mass: 4878.87 Da and 4860.85 Da, respectively). These results suggest that 
LanM-SPN23F is expressed and active in E. coli mediating the complete 
dehydration of His6-LanA-SPN23F. 
 
Introduction of decarboxylation modification in His6-LanA-SPN23F. 
The three C-terminal amino acids of LanA-SPN23F are Ile-Cys-Cys, which 
matches the consensus sequence of the C-terminal amino acids for the 
recognition by EpiD which is [V/I/L/F/W/Y/(M)]-[A/S/V/T/C/(I/L)]-C (6). EpiD 
belongs to the group of LanD enzymes that are responsible for the formation of 
an S-aminovinyl-D-cysteine (AviCys) amino acid at the C-terminus of some LanA 
peptides. However, no LanD encoding gene was identified in the lantibiotic gene 
cluster of Streptococcus pneumoniae ATCC 700669. GdmD of S. gallinarum 
shows 87% identity with EpiD. In addition, this enzyme was shown to modify a 
nisin variant when heterologously co-expressed in L. lactis (7). Therefore, GdmD 
was chosen to determine if LanA-SPN23F is indeed a substrate of LanD and can 
be modified accordingly. The gene encoding GdmD was cloned in the pETD-lanM 
vector, and co-expressed with His6-LanA-SPN23F and LanM-SPN23F in E. coli 
Bl21(DE3) cells. By SDS-PAGE a unique protein band of around 19 kDa 
corresponding to GdmD (figure 2B, indicated by the arrow) matching the 
molecular mass of 20,646 Da was observed. Cell free extract was passed over an 
IMAC column to extract the His6-tagged peptide, and by Coomassie stained Tris-
tricine SDS-PAGE and Western Blotting (figure 2C and D) the His6-LanA-SPN23F 
could be detected. Next, the purified peptide was subjected to RP-HPLC and 
MALDI-TOF MS. As shown in figure 3, a unique peak around 27 minutes was 
evident on HPLC that was not observed in the empty vector control. 
Decarboxylation by GdmD will result in a mass loss of 46 Da due to the loss of a 
CO2 molecule and two H atoms. The theoretical mass of eight times dehydrated  
  




Figure 3: HPLC chromatograms of the produced LanA-SPN23F monitored at 214 nm. Comparison of 
the control (dotted line) and His6-LanA-SPN23F containing sample (solid line) derived from an E. 
coli strain expressing His6-LanA-SPN23F and LanM-SPN23F (A). Comparison of a control sample 
(dotted line) and a His6-LanA-SPN23F containing sample (solid line) derived from an E. coli strain 
expressing His6-LanA-SPN23F, GdmD and LanM-SPN23F (B).  




Figure 4: MALDI-TOF mass spectra of HPLC fractions containing His6-LanA-SPN23F after co-
expression with LanM-SPN23F (A) or LanM-SPN23F and GdmD (B). The asterisk (*) indicates a 
peak with the mass corresponding to double charged His6-LanA-SPN23F. MALDI-TOF mass spectra 
of trypsin digested peptide fraction, Glu39-Cys85, of His6-LanA-SPN23F after co-expression with 
LanM-SPN23F (C) or LanM-SPN23F and GdmD (D). 
 
 
and decarboxylated His6-LanA-SPN23F is 8989.95 Da. A peak with the mass of 
8968.45 Da (figure 4B) that may correspond to the predicted modified His6-
LanA-SPN23F was observed. In addition, a peak of 9085.61 Da was observed 
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which may correspond to the seven times dehydrated and decarboxylated His6-
LanA-SPN23F. Since the difference between the theoretical mass and the 
observed mass is 20.5 Da the peptides were further analyzed by trypsin 
digestion and mass spectrometry to validate the modifications. Again peptide 
fragments corresponding to the parts of the leader peptide were found, i.e., 
Gly2-Lys19 with a mass of 2148.82 Da (theoretical mass of 2146.90 Da), and 
Lys20-Arg38 with a mass of 2060.92 Da (theoretical mass of 2060.07 Da). 
Importantly, peptides corresponding to amino acids Glu39-Cys85 with masses of 
4817.10 and 4831.35 Da were observed (figure 4D). These correspond to the 
eight and seven times dehydrated and decarboxylated His6-LanA-SPN23F 
(theoretical mass 4814.85 and 4832.87 Da, respectively), showing that His6-
LanA-SPN23F is indeed modified by both LanM-SPN23F and GdmD. 
 
Leader peptide cleavage by peptidase domain LanTc39. Previous 
studies have shown that the isolated and purified peptidase domain of LctT can 
function in vitro to process the leader peptide from LctA and substrate variants to 
release a mature peptide (11). Our studies show that the LanA peptide under 
study can be fully modified with respect to dehydration and terminal cysteine 
modification, but to release an active peptide, the leader peptide needs to be 
removed. Therefore, the peptidase domain of the S. pneumoniae LanT-SPN23F 
was expressed as a His-tagged protein, termed His6-LanTc39. The peptidase C39 
domain of LanT-SPN23F covers the region of Val4-Phe131. Therefore, an 
extended fragment covering Leu1-Lys151 of LanT-SPN23F was cloned in the 
pRSFDuet vector. The protein was expressed in E. coli Bl21(DE3) cells, and 
detectable on SDS-PAGE as a 17 kDa protein (figure 5A) that also stains with a 
Tetra-His antibody (5 prime) in western blotting (figure 5B). To remove the 
leader of His6-LanA-SPN23F it was incubated with His6-LanTc39 and analyzed by 
MALDI-TOF mass spectrometry. The theoretical mass of unmodified and 
processed LanA-SPN23F is 3583.47 Da. However, no peaks were identified that 
could relate to the presence of processed, neither unmodified or modified, LanA-
SPN23F. 
  




Figure 5: Coomassie stained SDS-PAGE comparing cells of E. coli expressing empty vector or His6-
LanTc39 (A). Western blot developed with a Tetra-His antibody (5 prime) showing the presence of 
His-tagged LanTc39 at a molecular mass of about 17 kDa (B). (The gel and blot figures are 





This study, examined the heterologous expression of a putative lantibiotic 
encoded in the genome of Streptococcus pneumoniae ATCC 700669. The gene 
was described previously and shown to be part of an autonomously mobile 
genetic entity (ICE), ICESp23FST81 (17). ICEs are transmitted between bacteria 
through conjugative transfer in a circularized form and insert into, and excise 
from, host DNA via site-specific recombination (17, 21). Via heterologous co-
expression with the corresponding synthetase gene, the lanthipeptide could be 
detected. Unfortunately, expression appeared not high as purification and 
western blotting was necessary to detect the product. MALDI-TOF mass 
spectrometry analysis indicates that the peptide is fully dehydrated, namely eight 
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times, when produced in E. coli. This suggests that heterologously expressed 
LanM-SPN23F is active in E. coli. In addition, when adding GdmD to the 
expression system a fully dehydrated and decarboxylated His6-LanA-SPN23F 
could be detected, suggesting LanA-SPN23F indeed is a substrate for a LanD 
enzyme although no such gene was found in the putative gene cluster. These 
results add to the construction of a generic class II lantibiotic system in E. coli. 
However, an active lantibiotic is obtained only after leader peptide cleavage. To 
realize this goal, the C39 peptidase domain of the LanT-SPN23F transporter was 
cloned and expressed. His6-LanTc39 was readily obtained but co-incubation with 
His6-LanA-SPN23F did not lead to the emerge of mature LanA-SPN23F peptides. 
This is, however, a preliminary finding. Since processing is a necessity before the 
biological function of LanA-SPN23F can be established, bioactivity of the 
heterologously produced LanA-SPN23F could not be demonstrated. 
LanA-SPN23F is predicted by BAGEL3 and Croucher et. al. (17) to be a 
lantibiotic similar to lichenicidin A1 and mersacidin. Figure 1A shows a conserved 
region between lichenicidin A1, mersacidin, haladuracin A1 and LanA-SPN23F 
peptides. This region in lichenicidin A1 and mersacidin is associated with the 
third thioether ring that is thought to be most important for activity, inhibiting 
the peptidoglycan transglycosylation reaction as previously shown for mersacidin 
(17, 22). Such a lanthionine ring could also be formed in LanA-SPN23F. Trypsin 
digestion of the peptide occurs after lysine or arginine residue, except when the 
amino acid is followed by a proline. For that reason His6-LanA-SPN23F should be 
digested into five fragments, Gly2-Lys19, Lys20-Arg38, Glu39-Arg55, Ser56-
Arg69 and Gly70-Cys85. However, only three fragments were found by MALDI-
TOF mass spectrometry. The first two fragments, Gly2-Lys19 and Lys20-Arg38, 
comprising the His-tag and a part of the leader peptide. The remaining three 
fragments are not found but instead one large fragment, Glu39-Cys85, was 
detected. Since the presence of a (methyl)lanthionine bond should protect the 
peptide against enzyme digestion, these data suggest that at least two 
(methyl)lanthionine rings were formed in the peptide. More detailed studies need 
to be performed to resolve the exact ring structure formed by LanM-SPN23F in 
His6-LanA-SPN23F. In addition, bioactivity of LanA-SPN23F could give indication 
if the (methyl)lanthionine rings are correctly formed. Unfortunately, leader 
cleavage was unsuccessful and therefore antimicrobial activity of LanA-SPN23F 
could not be determined. 
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Summarizing, these data demonstrate that E. coli can be used for the 
production of class II lantibiotics as exemplified by the expression and post-
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Summary and concluding remarks 
 
Lantibiotics, lanthionine-containing ribosomally produced peptides, possess 
antimicrobial activity and some even display activity towards drug resistant 
pathogens, like methicillin-resistant Staphylococcus aureus (MRSA) or 
vancomycin-resistant enterococci (VRE) (1-3). In addition, lanthipeptides can 
possess morphogenetic (4), antiviral (5) or anti-allodynic (6) activity. The 
presence of the thioether bridge and other post translational modifications 
provide lanthipeptides with a higher protection against proteolytic degradation. 
This makes lantibiotics and lanthipeptides interesting targets for the use as 
therapeutic agents. However, there are also several challenges that need to be 
overcome. Many lantibiotics are liable to degradation by enzymes present in the 
gastrointestinal tract, therefore, applications of lantibiotics has been limited to 
topical applications only. In addition, lantibiotics are often not sufficiently stable 
over the full pH range. Nisin, for example, looses activity above pH 7 since under 
basic conditions oxidation of the (methyl)lanthionine bridges occurs resulting in a 
loss of the antimicrobial activity (7). 
The use of lanthipeptide biosynthesis enzymes in bioengineering to 
introduce (methyl)lanthionine residues or additional modifications in peptides is 
of particular interest as it provides a means to generate an even greater diversity 
of lanthipeptides and a potential methodology to tackle the aforementioned 
challenges. Therefore, this thesis focused on creating a generic system for the 
production of class II lantibiotics/lanthipeptides. Unlike class I lanthipeptides, 
which have an elongated structure, class II lanthipeptides have a more globular 
structure and require the activity of an integrated dehydratase/cyclase enzyme 
for post-translational modification. Therefore, the intended production system 
will contain a known class II lantibiotic LanM modification enzyme and possibly 
the associated transporter (figure 1). 
 
Initially, in our studies the Gram-positive host strain Lactococcus lactis 
NZ9000 was explored as a production host employing the modification enzymes 
(LtnM1 or LtnM2) and transporter (LtnT) of lacticin 3147. Lacticin 3147 is a two- 
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component lantibiotic of wich the LtnA1 peptide is considered an typical example 
of a class II lanthipeptide. Co-expression of LtnA1, LtnM1 and LtnT or LtnA2, 
LtnM2 and LtnT led to the production of modified, processed and active lacticin 
3147 (chapter 3). In addition, Kuipers et al. (8) showed that LtnM2 and LtnT are 
able to modify and transport non-lantibiotic peptides fused behind the LtnA2 
leader peptide, namely angiotensin variants which suggested a relaxed substrate 
specificity for LtnM2. This drove further exploration of the substrate specificities 
of LtnM1 and LtnM2 as well as generic aspects of the production system. The 
respective enzymes where co-expressed with substrate variants (chapter 4). 
Although, Cys-less peptide variants of LtnA1 and LtnA2 where produced to some 
extent when co-expressed with LtnT/LtnM2, production levels were very low 
which interfered with the reproducibility. In addition, most peptide variants 
generated could not be detected. These results suggest some degree of 
substrate specificity of the LtnM enzymes, but the in general low production of 
peptide variants makes this system less suitable for a generic production system. 
In this regard, the gene cluster of lacticin 3147 already indicates substrate 
specificity, as it encodes two separate dedicated modification enzymes specific 




Figure 1: Schematic representation of the intended generic production systems. Expressing a 
known modification enzyme (LanM), possibly a lanthipeptide transporter (LanT) and the 
lanthipeptide substrate (LanA) in a Gram-positive host strain such as L. lactis (top). In this system, 
the product is secreted in an unmatured form. Alternatively, a Gram-negative host strain like E. 
coli (bottom) expresses only the LanM and LanA and the product accumulates intracellularly. After 
induced expression and production, the peptide needs to be extracted and purified, where up 
leader cleavage by a LanP domain, or alternative protease should result in the release of the 
matured lanthipeptide.   
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The lacticin 3147 transporter used in the production system also exhibited 
some degree of substrate specificity. Transport of unmodified peptides is possible 
but not favorable (chapter 2), Cys-less peptides are transported to some extent, 
but when the core peptides were swapped, production was completely abolished 
(chapter 4). Class II lantibiotic transporters, like LtnT, belong to the ABC 
transporter maturation and secretion (AMS) protein family, meaning they remove 
the leader peptide during transport thus secreting the matured form of the 
lantibiotic. However, in a generic production system the production of a mature 
and active uncharacterized lantibiotic is not desired since it might display 
bioactivity towards the production host. Removing the N-terminal C39 peptidase 
domain of LtnT or mutating the catalytic cysteine in this peptidase domain 
resulted in a non-functioning LtnT (chapter 2). This suggests that an active 
peptidase domain is required for transport, confirming earlier studies for NukT, 
the transporter of nukacin ISK-1 (9). As an alternative means, one can envision 
the secretion of the non-maturated lanthipeptide, for instance by replacing the 
double glycine motif of the leader peptide with a factor Xa proteases site. This 
would result in the production of the inactive peptide that next might be 
converted into the active form upon processing by the factor Xa protease. 
Indeed, NisB/NisC and NisT accept the presence of a factor Xa site in nisin and 
pre-nisin can be activated by the post-secretion treatment with factor Xa (10). 
However, by replacing the double glycine motif or placing the factor Xa between 
the double glycine motif and the core peptide of LtnA1, peptide production was 
completely eliminated (chapter 4). Although the exact reason of this defect was 
not further analyzed, it appears that such modifications prevent transport. 
 
To circumvent the low production levels and the export problems, the 
Gram-negative host strain Escherichia coli was examined as a potential generic 
production system for intracellular lanthipeptides. Heterologous expression of 
lanthipeptides in E. coli has been shown before for nukacin ISK-1, nisin, 
prochlorosins and haloduracin (11, 12). The anticipated production system was 
based on either the modification enzymes MutM or LtnM2 and these enzymes 
were co-expressed with the corresponding his-tagged substrate peptide (chapter 
5). In these cases fully dehydrated preMutA and preLtnA2 could be isolated from 
the cytosolic fraction of E. coli cells. Although, fully dehydrated peptides were 
detected also incomplete dehydrated intermediates were identified, suggesting 
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that the heterologous expression in E. coli is possible but not optimal. 
Interestingly, MutM displayed a relaxed substrate specificity towards various core 
peptides of LtnA1, LtnA2 and even the class I lanthipeptide nisin when fused 
behind the MutA leader peptide. Although dehydration took place, the extent of 
dehydration varies from full to under dehydration. While LtnM2 in conjunction 
with LtnT seemed to display a higher degree of substrate specificity when 
expressed in L. lactis, the intracellular expression in E. coli appeared to be 
equipped with a less stringent substrate specificity. This study only examined the 
dehydration and did not establish whether the correct thioether bridges were 
formed. In this respect, for none of the heterologously expressed lanthipeptides, 
antimicrobial activity could be demonstrated since the peptides were produced as 
precursor peptides. For future research it will be interesting to introduce a 
protease site in the substrate peptide so the peptide can be matured in vitro. 
Although, introduction of the factor Xa protease site in LtnA1 in the Gram-
positive host production system (chapter 4) resulted in production loss, it 
exhibited promising results in a NisB/NisC/NisT expression system (10). In 
addition, a study by Patton et al. (13) showed that mutating the double glycine 
motif of the lacticin 481 leader peptide did not result in loss of LctM activity. 
Introduction of the factor Xa protease site could be a promising addition for the 
production system in the heterologous expression host E. coli. 
 
The results gathered in chapter 2 to 5 suggest that the modification 
enzymes of class II lantibiotics are highly specific. When mutations are made in 
the substrate peptides, in most cases the production level dropped or production 
was even completely abolished. In addition, incomplete modification occurred 
and the reproducibility was low. Due to this presumed substrate specificity it 
turned out to be difficult to set up a generic production system in L. lactis. In 
contrast, heterologous expression in E. coli of lanthipeptides with their 
corresponding enzymes has been shown before (chapter 5, (11, 12)) and 
provides an alternative for a generic production system. To examine this 
possibility, a putative class II lantibiotic gene cluster in Streptococcus 
pneumoniae ATCC 700669 was identified with BAGEL3. The genes encoding the 
peptide and the biosynthesis enzyme were heterologously expressed in E. coli 
(chapter 6). The core peptide of LanA-SPN23F contains eight serine and 
threonine residues, and MALDI-TOF mass spectrometry analysis of the 
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heterologously produced peptide indeed indicate seven to eight times 
dehydration events. In addition, an extra modification, namely the 
decarboxylation of the carboxyl-terminus by GdmD, could be introduced. GdmD 
was found to be active in E. coli and able to modify the heterologously expressed 
LanA-SPN23F. In order to obtain the active peptide an attempt was made to 
cleave the leader peptide by heterologously expressing the N-terminal C39 
peptidase domain of the corresponding LanT in E. coli. Although, the peptidase 
domain was expressed, cleavage activity could not be established. Nevertheless, 
the use of such a peptidase domain should be further considered as a means to 
process heterologously produced class II lanthipeptides. As Furgerson Ihnken et 
al. (14) demonstrated in vitro activity of the lacticin 481 LtnT C39 peptidase 
domain by cleaving the lacticin 481 leader peptide and rendering a mature 
lacticin 481. 
 
Overall, the use of E. coli as a generic production system for class II 
lanthipeptides shows a number of promising features but the system should be 
further examined on its promiscuity. For future research on the production of 
novel lantibiotics identified in metagenomes, the heterologous expression of the 
required part of a given gene cluster seems, however, a more reliable approach. 
This would then concern expression of the substrate peptide together with their 
natural modification enzyme. The availability of commercial DNA synthesis at 
lower prices and improved quality of large DNA fragments might convert this 
approach even into a high throughput methodology. This will be a necessity for 
the metagenome-wide identification of novel antimicrobials. This system could be 
complemented by the addition of extra modification enzymes when required. For 
instance, the decarboxylase GdmD showed a less stringent substrate specificity 
in this study. Finally, the active peptide needs to be produced. This requires an 
efficient means of post-production processing. The use of the isolated peptidase 
domain of the LanT transporter might provide such an enzyme but further work 
is needed to define its substrate specificity. Also, introduction of a protease 
cleavage site is a possible solution so in vitro the lanthipeptide can be converted 
into an active mature form. Only when all these requirements are met, it 
becomes feasible to explore metagenomes for unknown lanthipeptides as 
potential new antimicrobials. 
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Table 1: Summary of detected peptides in this thesis, by means of MALDI-TOF mass spectrometry, 
in supernatant of L. lactis NZ9000 or cell free extract of E. coli co-expressing transporter and/or 
modification enzymes in combination with the indicated substrate variants. 
Lactococcus lactis host 
 
 LtnT LtnM1/LtnT LtnM2/LtnT  
 
Wild type peptides 
 











LtnA1-A2 X X X   
LtnA2-A1 X X X   
 
Cysteine less peptides 
 
LtnA1(C-less) 0x Dha/Dhb X N/A 
 
 
LtnA2(C-less) X N/A X   
LtnA1-A2(C-less) X X N/A   






Factor Xa containing peptides 
 
LtnA1-xa1 X X N/A   
LtnA1-xa2 X X N/A   
Escherichia coli host 
 




Wild type peptides 
His6-LtnA2 
0-8x 
Dha/Dhb N/A N/A N/A 
His6-MutA N/A 
0-4x 
Dha/Dhb N/A N/A 
His6-LanA-Spn23F N/A N/A 
7, 8x 
Dha/Dhb 






Dha/Dhb N/A N/A N/A 
His6-Mut-LtnA1 N/A 
2-4x 
Dha/Dhb N/A N/A 
His6-Mut-NisA N/A 
1, 4x 
Dha/Dhb N/A N/A 
His6-Mut-ltnA2 N/A 
2, 7-8x 
Dha/Dhb N/A N/A 
1x Dha/Dhb amount of dehydrations detected for the peptide by MALDI-TOF MS 
X no peptide detected by MALDI-TOF MS 
N/A not applicable/not determined 
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Samenvatting en concluderende opmerkingen 
 
Infectieziekten, veroorzaakt door pathogene micro-organismen, worden 
over het algemeen behandeld door middel van antibiotica. Maar helaas zijn er 
tegenwoordig steeds meer antibioticaresistente bacteriën die niet meer 
behandeld kunnen worden met traditionele antibiotica. Daarom is het 
noodzakelijk om nieuwe soorten antibiotica te ontwikkelen om de resistentie te 
omzeilen. Lantibiotica zouden in aanmerking kunnen komen als een nieuw soort 
antibiotica. Het hier beschreven onderzoek richt zich daarom op de productie van 
lantibiotica. 
Lanthipeptiden zijn een groep van lanthionine bevattende ribosomaal 
geproduceerde peptiden, wanneer deze peptide antimicrobiële activiteit bezitten 
worden ze lantibiotica genoemd. Deze peptiden kunnen activiteit vertonen tegen 
antibioticaresistente pathogene micro-organismen, zoals methicilline-resistente 
Staphylococcus aureus (MRSA) en vancomycine-resistente enterococci (VRE) (1-
3). Lanthipeptiden kunnen ook morfogenetische (4), antivirale (5) of anti-
allodynische (6) activiteit bezitten. De aanwezigheid van de kenmerkende thio-
etherbruggen en andere post-translationale modificaties zorgen ervoor dat de 
lanthipeptiden beter beschermd zijn tegen proteolytische afbraak. Deze 
eigenschap maken lantibiotica en lanthipeptiden zeer interessant voor het 
gebruik als therapeutische stoffen. 
Echter bezitten lantibiotica ook een aantal niet-gewenste eigenschappen 
die eerst overwonnen moeten worden alvorens medische toepassingen mogelijk 
zijn. Zo kunnen lantibiotica gevoelig zijn voor afbraak door enzymen die 
aanwezig zijn in het maagdarmkanaal. Daardoor is het gebruik van deze 
peptiden beperkt tot toepassingen op oppervlaktes zoals de huid, waarbij ze zijn 
verwerkt in een zalf. Daarnaast zijn lantibiotica vaak niet stabiel bij 
veranderende pH waarden. Nisine, een lantibioticum, verliest bijvoorbeeld zijn 
antimicrobiële activiteit wanneer de pH stijgt, omdat onder alkalische condities 
oxidatie van de (methyl)lanthionine verbindingen plaats kan vinden (7). 
Het gebruik van de biosynthese enzymen van lanthipeptiden in 
bioengineering, om zo (methyl)lanthionine verbindingen of aanvullende  
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modificaties in peptiden aan te brengen, zou een mogelijke methode kunnen zijn 
om een nog grotere verscheidenheid aan lanthipeptiden te creëren. Met een 
grotere diversiteit aan lanthipeptiden kunnen ook nieuwe lantibiotica ontwikkeld 
worden die eventueel de bovengenoemde problemen aanpakken. Het onderzoek 
beschreven in dit proefschrift is daarom gericht op de ontwikkeling van een 
generiek systeem voor de productie van klasse II lantibiotica/lanthipeptiden. In 
tegenstelling tot klasse I lantibiotica, welke langgerekte structuren vormen, 
bezitten klasse II lantibiotica een meer globulaire (bolvormige) structuur. In 
klasse II lantibiotica worden de karakteristieke modificaties niet aangebracht 
door twee aparte enzymen maar door één enkele enzym dat zowel dehydratase 
als cyclase activiteit bezit. Het beoogde productiesysteem zal bestaan uit een 
bekend klasse II lantibiotica modificatie-enzym, LanM, en eventueel het 




Figuur 1: Schematische weergave van de beoogde generieke productiesystemen. Expressie van 
een bekend modificatie enzym (LanM), eventueel de transporter (LanT) en het substraat (LanA) in 
een Grampositieve stam zoals Lactococcus lactis (boven). In dit systeem wordt het product 
uitgescheiden als niet actief pre-lantibiotica. Als alternatief, expressie van het modificatie enzym in 
een Gramnegatieve gastheer zoals Escherichia coli (onder). Hier worden alleen het LanM enzym en 
LanA substraat tot expressie gebracht, en zal het product intracellulair ophopen. Na geïnduceerde 
expressie en productie van het peptide zal deze geëxtraheerd en gezuiverd worden. Daarna word 
het leader peptide verwijderd doormiddel van een LanP domein of een protease. Dit laatste zal 
resulteren in het vrijkomen van het mature lanthipeptide. 
 
 
De Grampositieve Lactococcus lactis NZ9000 stam is in eerste instantie 
geanalyseerd als mogelijke productie stam door in dit organisme de modificatie 
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enzymen (LtnM1 of LtnM2) en transporter (LtnT) van lacticine 3147 tot expressie 
te brengen. Lacticine 3147 is een twee-componenten lantibioticum, en bestaat 
uit twee peptiden die samen een actief lantibioticum vormen. Van de twee 
peptiden lijkt het LtnA1 peptide het meest op een klasse II lantibioticum. Co-
expressie van de combinatie LtnA1, LtnM1 en LtnT of LtnA2, LtnM2 en LtnT 
resulteerde in gemodificeerd en actief lacticine 3147 (hoofdstuk 3). Kuipers et al. 
(8) liet al eerder zien dat LtnM2 en LtnT niet-lantibioticum peptiden, zoals 
angiotensine varianten, kunnen modificeren en transporteren. Dit suggereert dat 
LtnM2 een brede substraat specificiteit bezit. Zodoende is er voor gekozen om de 
substraat specificiteit van LtnM1 en LtnM2 en hun generieke toepassing in het 
productiesysteem verder te onderzoeken. LtnM1 en LtnM2 werden tot expressie 
gebracht samen met verschillende substraat varianten (hoofdstuk 4). Hierbij zijn 
onder meer de cysteïne residuen vervangen door alanine residuen om te 
voorkomen dat er thio-etherbruggen gevormd kunnen worden. Nadat een aantal 
Cys-loze peptide varianten van LtnA1 en LtnA2 werden geproduceerd wanneer ze 
tot co-expressie waren gebracht met LtnT/LtnM2, bleek dat het productie niveau 
over het algemeen dusdanig laag was dat dit de reproduceerbaarheid van het 
resultaat belemmerde. Tevens konden de meeste peptide varianten niet worden 
gedetecteerd. De gevonden resultaten suggereren dat de LtnM enzymen toch 
enige substraat specificiteit bezitten. De organisatie van het lacticine 3147 
genencluster geeft zelf al een indicatie dat er sprake is van substraat specificiteit. 
Het genencluster bevat namelijk twee genen die coderen voor twee aparte 
gespecialiseerde modificatie enzymen voor de twee lacticine 3147 peptiden. Er 
lijkt dus sprake van specialisatie. Echter, het feit dat over het algemeen de 
productie van de peptide varianten laag was maakt dit systeem minder geschikt 
als een generiek productiesysteem. 
 
Ook de lacticine 3147 transporter die gebruikt is in het productiesysteem 
lijkt een zekere mate van substraat specificiteit te tonen. Transport van het niet-
gemodificeerde peptide is mogelijk maar lijkt inefficiënt (hoofdstuk 2). De Cys-
loze peptiden worden maar deels getransporteerd en wanneer de kernpeptiden 
achter de leader peptiden worden verwisseld stopt de productie (hoofdstuk 4). 
Klasse II lantibiotica transporters, zoals LtnT, behoren tot de familie van 
de ABC transporter maturatie en secretie (ABC transporter maturation and 
secretion (AMS)) eiwitten. Deze eiwitten verwijderen het leader peptide van het 
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lantibioticum tijdens het transport over het membraan en scheiden zo het 
mature lantibioticum uit. Deze eigenschap, om het mature en actieve niet-
gekarakteriseerde lantibioticum te produceren, is in het generieke 
productiesysteem niet gewenst. Het zou eventueel kunnen dat het 
geproduceerde lantibioticum bio-activiteit vertoont tegen de productie stam. Om 
de productie van actieve lantibiotica tegen te gaan is er getracht de peptidase 
activiteit van de LtnT transporter te verwijderen. Het verwijderen van de N-
terminale C39 peptidase domein of het muteren van het katalytische cysteïne 
residue van dit domein resulteerde in een niet werkend LtnT (hoofdstuk 2). Deze 
resultaten suggereren dat LtnT een actief peptidase domein nodig heeft om het 
transport van het lantibioticum te realiseren. Mogelijk zijn beide processen 
gekoppeld. Eerdere studies voor NukT, het transporteiwit van nukacine ISK-1, 
gaf vergelijkbare resultaten (9). 
Een alternatieve methode voor het uitscheiden van het niet-mature 
lanthipeptide is het vervangen van het dubbele glycine motief van het leader 
peptide met bijvoorbeeld een specifieke factor Xa protease sequentie. Het 
geproduceerde peptide zou dan in een vervolgstap, door middel van het factor 
Xa protease, omgezet kunnen worden naar zijn actieve vorm. De enzymen NisB 
en NisC accepteren de factor Xa sequentie in pre-nisine dat vervolgens kan 
worden omgezet naar het actieve nisine door middel van de behandeling met 
factor Xa (10). Echter na het vervangen van het dubbele glycine motief of het 
plaatsen van de factor Xa sequentie tussen het dubbele glycine motief en het 
kernpeptide van LtnA1, werd de productie volledig geëlimineerd (hoofdstuk 4). 
Alhoewel de exacte reden van dit defect niet verder geanalyseerd is, geeft het 
wel aan dit soort modificaties een negatief effect hebben op de productie en 
mogelijk het transport van de peptiden. 
 
Vanwege de lage productie niveaus en de problemen met uitscheiding in L. 
lactis, is de Gramnegatieve gastheer Escherichia coli geanalyseerd als potentieel 
generiek productiesysteem voor intracellulaire lanthipeptiden. Heterologe 
expressie van lanthipeptiden in E. coli is al aangetoond voor nukacine ISK-1, 
nisine, prochlorosinen en haloduracine (11, 12). In dit geval was het 
productiesysteem gebaseerd op het modificatie enzym MutM of LtnM2, waarna 
deze enzymen tot expressie zijn gebracht met hun overeenkomstige 
hexahistidine-gelabelde substraat peptide (hoofdstuk 5). Volledig 
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gedehydrateerd preMutA en preLtnA2 konden geïsoleerd worden uit de 
cytosolische fractie van E. coli cellen. Daarnaast werden ook incompleet 
gedehydrateerde tussenvormen geïdentificeerd. Dit suggereert dat de heterologe 
expressie in E. coli mogelijk is maar nog niet optimaal. Het enzym MutM liet een 
ogenschijnlijke bredere substraat specificiteit zien. Verschillende kernpeptiden 
van bijvoorbeeld LtnA1, LtnA2 en zelfs de klasse I lanthipeptide nisine werden 
gedehydrateerd wanneer deze gefuseerd waren achter het MutA leader peptide. 
Hoewel dehydratatie plaats vond varieerde de dehydratie van volledig tot 
onvolledig. In het L. lactis systeem gaf LtnM2 in combinatie met LtnT 
ogenschijnlijk een hogere mate van substraat specificiteit in vergelijking tot de 
lagere substraat specificiteit in het intracellulaire E. coli systeem. Mogelijk speelt 
de substraatspecificiteit van het transporteiwit hierin een rol. 
 
In deze studie is alleen dehydratie aangetoond en is niet onderzocht of de 
correcte thio-etherbruggen worden gevormd. Omdat de peptiden als prepeptiden 
geproduceerd werden met het E. coli systeem, kon de antimicrobiële activiteit 
voor de heteroloog geproduceerde lanthipeptiden niet bepaald worden. Voor 
toekomstig onderzoek is het daarom van belang om een protease 
herkenningssequentie te introduceren in het prepeptide zodat in vitro het mature 
peptide gegenereerd kan worden. Ondanks dat de introductie van de factor Xa 
protease sequentie in het Grampositieve klasse II lanthipeptide productiesysteem 
(hoofdstuk 4) resulteerde in verlies van productie liet een studie met het 
NisB/NisC/NisT expressiesysteem met een overeenkomstige benadering goede 
resultaten zien (10). Tevens is eerder gevonden dat mutaties in de dubbele 
glycine motief van lacticine 481 niet interfereren met de werking van het 
modificatie enzym LctM (13). Al met al kan de introductie van de factor Xa 
protease sequentie een veelbelovende toevoeging in het heterologe E. coli 
productiesysteem zijn. Een alternatief is het gebruik van het protease domein 
van de transporter dat, indien actief, toegepast kan worden om het prepeptide 
op een juiste wijze om te zetten naar het mature lanthipeptide. 
 
De resultaten in hoofdstuk 2 tot en met 5 suggereren dat de modificatie 
enzymen van klasse II lantibiotica een hoge specificiteit bezitten. Wanneer er 
mutaties gemaakt worden in de substraat peptiden daalt in veel van de gevallen 
het productie niveau of stopt de productie zelfs compleet. Daarbij vindt veelal 
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onvolledige modificatie plaats en bleek de reproduceerbaarheid laag. Door deze 
veronderstelde substraatspecificiteit bleek het moeilijk te zijn om een generiek 
productiesysteem in L. lactis op te zetten. Daarentegen is de heterologe 
expressie van lanthipeptiden en bijbehorende enzymen in E. coli mogelijk 
(hoofdstuk 5, (11, 12)). Om dit verder te onderzoeken is een mogelijke klasse II 
lantibioticum genencluster met behulp van BAGEL3 geïdentificeerd in 
Streptococcus pneumoniae ATCC 700669. Vervolgens zijn de genen coderend 
voor het biosynthese enzym en het substraat heteroloog tot expressie gebracht 
in E. coli (hoofdstuk 6). Het kernpeptide van LanA-SPN23F bevat acht serine en 
threonine residuen die eventueel gemodificeerd kunnen worden door LanM-
SPN23F. MALDI-TOF massaspectrometrie analyse van het heteroloog 
geproduceerde peptide toonde inderdaad aan dat het peptide zeven tot acht keer 
werd gedehydrateerd. Daarnaast is een extra modificatie toegevoegd, namelijk 
de decarboxylatie van het carboxyl-einde van het peptide door GdmD. GdmD 
bleek actief in E. coli en kon het heteroloog tot expressie gebrachte LanA-SPN23F 
decarboxyleren. 
Om actief peptide te verkrijgen werd een poging gedaan om het leader 
peptide te verwijderen door middel van het heteroloog tot expressie gebrachte 
N-terminale C39 peptidase domein van LanT-SPN23F. Hoewel dit domein tot 
expressie kon worden gebracht in E. coli kon er geen activiteit worden 
vastgesteld. Niettemin is de toepassing van dergelijke peptidase domeinen een 
interessante methode om heteroloog geproduceerde klasse II lanthipeptiden te 
activeren. Zo lieten Furgerson Ihnken e.a. (14) in vitro activiteit van het lacticine 
481 LtnT C39 peptidase domein zien, waarbij het mature lacticine 481 werd 
gevormd na afsplitsing van het lacticine 481 leader peptide. 
 
Kortom, het gebruik van E. coli als generiek productiesysteem voor klasse 
II lanthipeptiden toont een aantal veelbelovende eigenschappen. Echter het 
systeem moet verder onderzocht worden op brede toepassing. Voor toekomstig 
onderzoek lijkt de meest betrouwbare methode voor de succesvolle productie 
van niet eerder gekarakteriseerde lantibiotica, de heterologe expressie van het 
gewenste gedeelte van een genencluster. Dit zou dan de expressie van het 
substraat peptide tezamen met het bijbehorende natuurlijke modificatie enzym 
betreffen. Door de toenemende beschikbaarheid van commerciële DNA-synthese 
tegen lage prijzen met een betere kwaliteit van grote DNA-fragmenten kan men 
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deze aanpak zelfs omzetten in een high throughput methode. Dit is noodzakelijk 
voor metagenoom-brede identificatie van nieuwe antimicrobiële stoffen. Dit 
productiesysteem kan wanneer nodig worden aangevuld met extra modificatie 
enzymen. Het decarboxylase GdmD laat in deze studie een minder stringente 
substraatspecificiteit zien en is daarom een mogelijke kandidaat om toe te 
voegen aan het productiesysteem. Uiteindelijk zal een actief peptide moeten 
worden geproduceerd. Dit houd in dat er een efficiënte manier voor de vorming 
van het actieve lanthipeptide moet worden ontwikkeld. Het gebruik van een 
geïsoleerd peptidase domein van LanT transporters zou een manier kunnen zijn, 
maar verder onderzoek is nodig om de toepasbaarheid en de substraat 
specificiteit te bepalen. Alleen wanneer aan al deze eisen wordt voldaan zal het 
mogelijk worden om metagenomen te verkennen voor onbekende lanthipeptiden 
met potentiële antimicrobiële werking. 
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Tabel 1: Samenvatting van de in dit proefschrift gedetecteerde peptiden middels MALDI-TOF 
massaspectrometrie in het supernatant van L. lactis NZ9000 of het cel-vrij extract van E. coli in 
welke de transporter en/of de modificatie-enzymen in combinatie met het aangegeven substraat 
varianten tot co-expressie zijn gebracht. 
Lactococcus lactis gastheer 
 















LtnA1-A2 X X X   
LtnA2-A1 X X X   
 
Cysteine loze peptiden 
 
LtnA1(C-loos) 0x Dha/Dhb X N/A 
 
 
LtnA2(C-loos) X N/A X   
LtnA1-A2(C-loos) X X N/A   






Factor Xa bevattende peptiden 
 
LtnA1-xa1 X X N/A   
LtnA1-xa2 X X N/A   
Escherichia coli gastheer 
 







Dha/Dhb N/A N/A N/A 
His6-MutA N/A 
0-4x 
Dha/Dhb N/A N/A 
His6-LanA-Spn23F N/A N/A 
7, 8x 
Dha/Dhb 






Dha/Dhb N/A N/A N/A 
His6-Mut-LtnA1 N/A 
2-4x 
Dha/Dhb N/A N/A 
His6-Mut-NisA N/A 
1, 4x 
Dha/Dhb N/A N/A 
His6-Mut-ltnA2 N/A 
2, 7-8x 
Dha/Dhb N/A N/A 
1x Dha/Dhb hoeveelheid dehydraties gedetecteerd in het peptide door MALDI-TOF MS 
X geen peptide gedetecteerd middels MALDI-TOF MS 
N/A niet van toepassing/niet bepaald 
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